



TAHOE FOREST HOSPITAL DISTRICT

# 2020-05-28 Regular Meeting of the Board of Directors

Thursday, May 28, 2020 at 4:00pm

Pursuant to Section 3 of Executive Order N-29-20, issued by Governor Newsom on March 17, 2020, the Regular Meeting of the Tahoe Forest Hospital District Board of Directors for May 28, 2020 will be conducted telephonically through Zoom.

Please be advised that pursuant to the Executive Order, and to ensure the health and safety of the public by limiting human contact that could spread the COVID-19 virus, the Eskridge Conference Room will not be open for the meeting.

Board Members will be participating telephonically and will not be physically present in the Eskridge Conference Room.

If you would like to speak on an agenda item, you can access the meeting remotely:  
<https://tfhd.zoom.us/j/96686963087>

If you prefer to use your phone, you may call in using the following numbers: (346) 248 7799 or (301) 715 8592, Meeting ID: 966 8696 3087

## Meeting Book - 2020-05-28 Regular Meeting of the Board of Directors

---

### AGENDA

2020-05-28 Regular Meeting of the Board of Directors\_FINAL  
Agenda.pdf Page 4

---

### ITEMS 1 - 11 See Agenda

---

### 12. ACKNOWLEDGMENTS

12.1. May 2020 Employee of the Month.pdf Page 7

12.2. TFHS Celebrates National Nurses Week 2020.pdf Page 8

12.3. National Hospital Week - May 10-16, 2020

---

### 13. MEDICAL STAFF EXECUTIVE COMMITTEE

13.1. Level 3 Trauma Update

No related materials.

13.2.a. 05.21.2020 Open Session Consent Board Meeting Agenda Item  
Cover Sheet.pdf Page 9

13.2.b. Diagnostic Imaging Policies.pdf Page 10

13.2.c. TFH IVCH Pharmacy 2020 Annual P&P List.pdf Page 14

13.2.d. Late Career Provider, MSCP-1701\_Revised 5.5.20.pdf Page 16

13.2.e. Tahoe Forest Health System Formulary 2020.pdf Page 19

13.2.f. Scanning Advance Directives-POLSTS into EHR, DHIM-2001.pdf Page 56

---

### 14. CONSENT CALENDAR

14.1. Approval of Meeting Minutes

14.1.1. 2020-04-23 Special Meeting of the Board of  
Directors\_DRAFT Minutes.pdf Page 61

14.1.2. 2020-04-23 Regular Meeting of the Board of  
Directors\_DRAFT Minutes.pdf Page 63

14.2. Financial Report

14.2.1. Financial Report - April 2020.pdf Page 68

14.3. Approve President & Chief Executive Officer Job  
Description

14.3.1. President CEO Job Description.pdf Page 81

---

### 15. ITEMS FOR BOARD DISCUSSION

15.1. COVID-19 Update

No related materials.

---

### 16. ITEMS FOR BOARD ACTION

16.1.a. BOD Project Summary - Exit and Security Doors & Central  
Supply Storage.pdf Page 84

16.1.b. Exit and Security Doors & Central Supply Storage Staff Page 85

Recommendation - May 2020.pdf

**16.2. President & CEO Employment Agreement**

Agreement will be distributed prior to the meeting.

16.3. Resolution 2020-05 General Election Services.pdf

Page 86

16.4. Delay of Fiscal Year 2021 Budget

---

ITEMS 17 - 22: See Agenda

---

23. ADJOURN



# REGULAR MEETING OF THE BOARD OF DIRECTORS AGENDA

Thursday, May 28, 2020 at 4:00 p.m.

Pursuant to Section 3 of Executive Order N-29-20, issued by Governor Newsom on March 17, 2020, the Regular Meeting of the Tahoe Forest Hospital District Board of Directors for May 28, 2020 will be conducted telephonically through Zoom. Please be advised that pursuant to the Executive Order, and to ensure the health and safety of the public by limiting human contact that could spread the COVID-19 virus, the Eskridge Conference Room will not be open for the meeting. Board Members will be participating telephonically and will not be physically present in the Eskridge Conference Room.

**If you would like to speak on an agenda item, you can access the meeting remotely:**

Please use this web link: <https://tfhd.zoom.us/j/96686963087>

**Or join by phone:**

If you prefer to use your phone, you may call in using the numbers below.

(346) 248 7799 or (301) 715 8592

Meeting ID: 966 8696 3087

Public comment will also be accepted by email to [mrochefort@tfhd.com](mailto:mrochefort@tfhd.com). Please list the item number you wish to comment on and submit your written comments 24 hours prior to the start of the meeting.

Oral public comments will be subject to the three minute time limitation (approximately 350 words). Written comments will be distributed to the board prior to the meeting but not read at the meeting.

## **1. CALL TO ORDER**

## **2. ROLL CALL**

## **3. DELETIONS/CORRECTIONS TO THE POSTED AGENDA**

## **4. INPUT AUDIENCE**

This is an opportunity for members of the public to comment on any closed session item appearing before the Board on this agenda. Please state your name for the record. Comments are limited to three minutes. Written comments should be submitted to the Clerk of the Board 24 hours prior to the meeting to allow for distribution.

## **5. CLOSED SESSION**

### **5.1. Hearing (Health & Safety Code § 32155)◆**

*Subject Matter: Annual Home Health & Hospice Quality Report*

*Number of items: One (1)*

### **5.2. Hearing (Health & Safety Code § 32155)◆**

*Subject Matter: Third Quarter Fiscal Year 2020 Quality Dashboard Report*

*Number of items: One (1)*

### **5.3. Hearing (Health & Safety Code § 32155)**

*Subject Matter: Quality Assurance Report*

*Number of items: One (1)*

**5.4. Approval of Closed Session Minutes** ◆

04/23/2020 – Special Meeting, 04/23/2020 – Regular Meeting

**5.5. TIMED ITEM – 5:30PM - Hearing (Health & Safety Code § 32155)** ◆

*Subject Matter: Medical Staff Credentials*

**APPROXIMATELY 6:00 P.M.**

**6. DINNER BREAK**

**7. OPEN SESSION – CALL TO ORDER**

**8. REPORT OF ACTIONS TAKEN IN CLOSED SESSION**

**9. DELETIONS/CORRECTIONS TO THE POSTED AGENDA**

**10. INPUT – AUDIENCE**

This is an opportunity for members of the public to address the Board on items which are not on the agenda. Please state your name for the record. Comments are limited to three minutes. Written comments should be submitted to the Board Clerk 24 hours prior to the meeting to allow for distribution. Under Government Code Section 54954.2 – Brown Act, the Board cannot take action on any item not on the agenda. The Board Chair may choose to acknowledge the comment or, where appropriate, briefly answer a question, refer the matter to staff, or set the item for discussion at a future meeting.

**11. INPUT FROM EMPLOYEE ASSOCIATIONS**

This is an opportunity for members of the Employee Associations to address the Board on items which are not on the agenda. Please state your name for the record. Comments are limited to three minutes.

**12. ACKNOWLEDGMENTS**

**12.1.** May 2020 Employee of the Month..... ATTACHMENT

**12.2.** Nurses Week - May 6-12, 2020 ..... ATTACHMENT

**12.3.** National Hospital Week - May 10-16, 2020

**13. MEDICAL STAFF EXECUTIVE COMMITTEE** ◆

**13.1.** Level 3 Trauma Update

**13.2.** Medical Executive Committee (MEC) Meeting Consent Agenda..... ATTACHMENT

*MEC recommends the following for approval by the Board of Directors:*

Policies without content changes

- *Diagnostic Imaging*
- *TFH/IVCH Pharmacy 2020 Annual Policies & Procedures List*

Policies with content changes

- *Late Career Provider, MSCP-1701*
- *Tahoe Forest Health System Formulary 2020*
- *Scanning Advance Directives/POLSTS into the Electronic Health Record, DHIM-2001*

**14. CONSENT CALENDAR** ◆

These items are expected to be routine and non-controversial. They will be acted upon by the Board without discussion. Any Board Member, staff member or interested party may request an item to be removed from the Consent Calendar for discussion prior to voting on the Consent Calendar.

**14.1. Approval of Minutes of Meetings**

**14.1.1.** 04/23/2020 – Special Meeting ..... ATTACHMENT

- 14.1.2. 04/23/2020 – Regular Meeting ..... ATTACHMENT
- 14.2. **Financial Reports**
  - 14.2.1. Financial Report – April 2020 ..... ATTACHMENT
- 14.3. **Approve President & Chief Executive Officer Job Description**
  - 14.3.1. President & CEO Job Description ..... ATTACHMENT

**15. ITEMS FOR BOARD DISCUSSION**

**15.1. COVID-19 Update**

The Board of Directors will receive an update on hospital and clinic operations related to COVID-19.

**16. ITEMS FOR BOARD ACTION**

**16.1. Contract for Exit and Security Door and Central Supply Storage Project ..... ATTACHMENT**

The Board of Directors will review and consider award of a contract for the Exit and Security Doors and Central Supply Storage Project to J.M. Streamline, Inc. dba Streamline Construction for \$359,750.00.

**16.2. President & CEO Employment Agreement with Harry Weis ..... ATTACHMENT\***

The Board of Directors will review and consider approval of the President & Chief Executive Officer Employment Agreement with Harry Weis.

**16.3. Resolution 2020-05 ..... ATTACHMENT**

The Board of Directors will review and consider approval of a resolution determining to consolidate the hospital district general election with the statewide general election and authorizing the canvass of returns by the respective Boards of Supervisors of Placer and Nevada Counties, California.

**16.4. Delay of Fiscal Year 2021 Budget**

The Board of Directors will review and consider delaying the fiscal year 2021 budget.

**17. DISCUSSION OF CONSENT CALENDAR ITEMS PULLED, IF NECESSARY**

**18. BOARD COMMITTEE REPORTS**

**19. BOARD MEMBERS REPORTS/CLOSING REMARKS**

**20. CLOSED SESSION CONTINUED, IF NECESSARY**

**21. OPEN SESSION**

**22. REPORT OF ACTIONS TAKEN IN CLOSED SESSION, IF NECESSARY**

**23. ADJOURN**

*The next regularly scheduled meeting of the Board of Directors of Tahoe Forest Hospital District is June 25, 2020 at Tahoe Forest Hospital, 10121 Pine Avenue, Truckee, CA, 96161. A copy of the board meeting agenda is posted on the District's web site ([www.tfhd.com](http://www.tfhd.com)) at least 72 hours prior to the meeting or 24 hours prior to a Special Board Meeting.*

\*Denotes material (or a portion thereof) may be distributed later.

Note: It is the policy of Tahoe Forest Hospital District to not discriminate in admissions, provisions of services, hiring, training and employment practices on the basis of color, national origin, sex, religion, age or disability including AIDS and related conditions. Equal Opportunity Employer. The telephonic meeting location is accessible to people with disabilities. Every reasonable effort will be made to accommodate participation of the disabled in all of the District's public meetings. If particular accommodations for the disabled are needed or a reasonable modification of the teleconference procedures are necessary (i.e., disability-related aids or other services), please contact the Executive Assistant at 582-3481 at least 24 hours in advance of the meeting.



## MAY 2020 EMPLOYEE OF THE MONTH

### DOLORES CORONA

#### FINANCIAL CUSTOMER SERVICE REPRESENTATIVE – ACCESS CENTER

We are honored to announce Dolores Corona as our May 2020 Employee of the Month! Dolores has been with the Tahoe Forest Health System since September of 2018. Here are some of the great things Dolores' colleagues have to say about her:

“Dolores demonstrates all core values every day. She is great on the phone with all patients and their family members. She listens to the problem, offers a solution and follows through until the matter is resolved. Dolores is always eager to help her team members in any way she can, especially training new team members. She is very flexible with her schedule; she often volunteers to work extra. Dolores is always willing to help other departments with special projects. It truly is a pleasure to work with her.” Dolores is also a Values Advocate and a Peer Supporter. Thank you, Dolores, for your excellent work and your commitment to our values!

**Please join us in congratulating all of our terrific nominees!**

**Stacey Tedsen  
Samantha Smith  
Juanita Martinez  
Lauren Caprio  
Joshua Fetbrandt  
Eva Lopez  
Maria Zarate**



**FOR IMMEDIATE RELEASE**

April 29, 2020

Contact: Paige Nebeker Thomason

Director of Marketing and Communications, TFHS

[pthomason@tfhd.com](mailto:pthomason@tfhd.com)

530.582.6290

## **Tahoe Forest Health System Celebrates National Nurses Week**

***May 6 – 12, 2020***

[www.tfhd.com](http://www.tfhd.com)

***(Tahoe/Truckee, Calif.)*** – Tahoe Forest Health System proudly celebrates all nurses in our community during National Nurses Week, May 6-12.

Nurses play a vital role in health care every day, performing the most essential health care tasks in various medical settings. The nursing profession offers many roles—from staff nurse, educator, nurse practitioner, to nurse researcher – in which each strive to serve with passion for their profession and a strong commitment to patient care and safety.

National Nurses Week is observed on May 6-12 every year, since 1994, to recognize the invaluable contributions of nurses and the nursing profession that impact the health and well-being of our communities.

Tahoe Forest Health System observes National Nurses Week by honoring and thanking all nurses for their commitment and service in keeping our community healthy.

#####

### ***About Tahoe Forest Health System***

*Tahoe Forest Health System, which includes Tahoe Forest Hospital in Truckee, CA, and Incline Village Community Hospital in Incline Village, NV, offers 24-hour emergency care, primary and specialty health care clinics including Tahoe Forest Orthopedics and Sports Medicine, Commission on Cancer (COC) accredited cancer center, the Gene Upshaw Memorial Tahoe Forest Cancer Center, the Joseph Family Center for Women and Newborn Care and the Tahoe Forest Primary Care Clinic with same-day appointments. With a strong focus on high quality patient care, community collaboration, clinical excellence and innovation, Tahoe Forest Health System is a UC Davis Rural Center of Excellence. For a complete list of physician specialties and services, visit [www.tfhd.com](http://www.tfhd.com).*



## AGENDA ITEM COVER SHEET

<b>ITEM</b>	Medical Executive Committee Consent Agenda
<b>RESPONSIBLE PARTY</b>	Greg Tirdel, MD, Chief of Staff
<b>ACTION REQUESTED?</b>	For Board Action
<p><b>BACKGROUND:</b> During the May 21, 2020 Medical Executive Committee meeting, the committee made the following open session consent agenda item recommendations to the Board of Directors at the May 28, 2020 meeting.</p>	
<p><b>SUMMARY/OBJECTIVES:</b> Approval of the following consent agenda items:</p> <p><u>Policies Without Content Changes</u></p> <ul style="list-style-type: none"> <li>• Diagnostic Imaging</li> <li>• TFH/IVCH Pharmacy 2020 Annual P&amp;P List</li> </ul> <p><u>Policies With Content Changes</u></p> <ul style="list-style-type: none"> <li>• Late Career Provider, MSCP-1701</li> <li>• Tahoe Forest Health System Formulary 2020</li> <li>• HIM-2010 Scanning Advance Directive &amp; Polst</li> </ul>	
<p><b>SUGGESTED DISCUSSION POINTS:</b></p> <ul style="list-style-type: none"> <li>• None</li> </ul>	
<p><b>SUGGESTED MOTION/ALTERNATIVES:</b> Move to approve Medical Executive Committee Consent Agenda as presented.</p>	
<p><b>LIST OF ATTACHMENTS:</b></p> <p><u>Policies Without Content Changes</u></p> <ul style="list-style-type: none"> <li>• Diagnostic Imaging</li> <li>• TFH/IVCH Pharmacy 2020 Annual P&amp;P List</li> </ul> <p><u>Policies With Content Changes</u></p> <ul style="list-style-type: none"> <li>• Late Career Provider, MSCP-1701</li> <li>• Tahoe Forest Health System Formulary 2020</li> <li>• HIM-2010 Scanning Advance Directive &amp; Polst</li> </ul>	

## Diagnostic Imaging

Policy/Stat Id	Title	Department	Last Approved
6860705	"Abd Doppler Study-Portal Venous System, DUS-10"	Ultrasound - DUS	9/9/2019
6860703	"Abd Limited Scan, DUS-12"	Ultrasound - DUS	9/9/2019
6860706	"Abdominal Ultrasound, DUS-13"	Ultrasound - DUS	9/9/2019
6860552	"Absence of Explicit Orders, DNUC-28"	Nuclear Medicine - DNUC	9/9/2019
6860579	"Administration of Definity (Pharmaceutical Contrast Agent), DUS-2"	Ultrasound - DUS	9/9/2019
6860635	"ALARA, DNUC-111"	Nuclear Medicine - DNUC	9/9/2019
6860737	"Alternate Source of Diagnostic Services, DNUC-13"	Nuclear Medicine - DNUC	9/9/2019
6860708	"Aorta Scan, DUS-14"	Ultrasound - DUS	9/9/2019
6860707	"Appendix: Male or Children, DUS-15"	Ultrasound - DUS	9/9/2019
6860578	"Approval of Additional Radiologists, DXR-48"	X-Ray - DXR	9/9/2019
6860746	"Auxiliary Personnel Training, DNUC-48"	Nuclear Medicine - DNUC	9/9/2019
6860748	"Availability of Nuclear Medicine Testing, DNUC-25"	Nuclear Medicine - DNUC	9/9/2019
7790410	"Biopsy Follow Up Procedures, DMAM-1"	Mammography - DMAM	4/17/2020
6860701	"Biopsy Procedure, DUS-17"	Ultrasound - DUS	9/9/2019
6860586	"Bladder Ultrasound, DUS-18"	Ultrasound - DUS	9/9/2019
6860738	"Bone Marrow Scan, DNUC-73"	Nuclear Medicine - DNUC	9/9/2019
6860752	"Bone SPECT, DNUC-1601"	Nuclear Medicine - DNUC	9/9/2019
6860744	"Brain Scan, DNUC-90"	Nuclear Medicine - DNUC	9/9/2019
6860750	"Breast Imaging, DNUC-101"	Nuclear Medicine - DNUC	9/9/2019
6860709	"Breast Ultrasound, DUS-19"	Ultrasound - DUS	9/9/2019
6860544	"C-Arm Spacer Cone Exemption Use CA, DXR-28"	X-Ray - DXR	9/9/2019
6000349	"C-Spine Trauma Procedure, DXR-23"	X-Ray - DXR	8/27/2019
6860747	"Calibration of Dose Calibrator, DNUC-141"	Nuclear Medicine - DNUC	9/9/2019
6860754	"Camera-Computer Maintenance, DNUC-147"	Nuclear Medicine - DNUC	9/9/2019
6860749	"Captopril Renal, DNUC-96"	Nuclear Medicine - DNUC	9/9/2019
6860627	"Cardiac Stress Testing w/Myoview or Cardiolite, DNUC-64"	Nuclear Medicine - DNUC	9/9/2019
6860626	"Cardiac Stress Testing with Lexiscan (Regadenoson), DNUC-64A"	Nuclear Medicine - DNUC	9/9/2019
6860686	"Care of the Critically Ill, DNUC-53"	Nuclear Medicine - DNUC	9/9/2019
7789797	"Care of the Critically Ill, DXR-25"	X-Ray - DXR	3/10/2020
6860696	"Carotid Examination, DUS-20"	Ultrasound - DUS	9/9/2019
6860685	"CEA Scan, DNUC-102"	Nuclear Medicine - DNUC	9/9/2019
6860690	"Cerebral Blood Flow, DNUC-89"	Nuclear Medicine - DNUC	9/9/2019
6860694	"Certifying Bodies Educational Requirements, DNUC-44"	Nuclear Medicine - DNUC	9/9/2019
6860711	"Cidex OPA Disinfection, DUS-21"	Ultrasound - DUS	9/9/2019
6860681	"Cisternogram, DNUC-91"	Nuclear Medicine - DNUC	9/9/2019
7637315	Coagulation Guidelines for Invasive Radiology Procedures	Interventional Radiology - DINT	2/10/2020
6860710	"Complete Obstetrical Ultrasound, DUS-22"	Ultrasound - DUS	9/9/2019
7789805	"Computed Tomography Safety & Reporting, DINT-1801"	Interventional Radiology - DINT	3/10/2020
7789787	"Conscious Sedation Pre-Exam Medication, DXR-10"	X-Ray - DXR	3/10/2020
7021315	"Consumer Complaint, DMAM-5"	Mammography - DMAM	10/3/2019
7789793	"Contamination Control and Decontamination Procedures, DNUC-133"	Nuclear Medicine - DNUC	3/10/2020
6860736	"Continuing Education, DMAM-2"	Mammography - DMAM	9/9/2019
6423067	"Contrast – IV Injection in Radiology, DXR-6"	X-Ray - DXR	8/27/2019
7789803	"Contrast – IV Screening GFR, DINT-7"	Interventional Radiology - DINT	3/10/2020
7789804	"Contrast – IV Screening GFR, DXR-7"	X-Ray - DXR	3/10/2020
7789790	"Contrast – Medium Infiltration, DXR-8"	X-Ray - DXR	3/10/2020
6860761	"Contrast – Storage - IV, DXR-2"	X-Ray - DXR	9/9/2019
6860755	"Contrast – Warmer Temperature, DXR-1"	X-Ray - DXR	9/9/2019
6860733	"Contrast Injections - Personnel Qualifications, DXR-5"	X-Ray - DXR	9/9/2019
6860683	"Control of Radiation Exposure to Female Nuclear Medicine Personnel During Pregnancy, DNUC-119"	Nuclear Medicine - DNUC	9/9/2019
6860684	"Control of Radiation Exposure to Patients During Pregnancy, DNUC-115"	Nuclear Medicine - DNUC	9/9/2019
7032140	"Critical Results Reporting Radiology, DXR-66"	X-Ray - DXR	10/8/2019
6860682	"Current Requirements for Technologist Certification, DNUC-42"	Nuclear Medicine - DNUC	9/9/2019
6860676	"Cystogram Renal Reflux Study, DNUC-99"	Nuclear Medicine - DNUC	9/9/2019
6860669	"Daily Radiation Safety Surveys, DNUC-131"	Nuclear Medicine - DNUC	9/9/2019
7789785	"Department Cleaning Procedure, DXR-30"	X-Ray - DXR	3/10/2020
6860689	"Department Manager Orientation Procedures, DNUC-47"	Nuclear Medicine - DNUC	9/9/2019
6860675	"DI Monitoring and Certifying, DNUC-148"	Nuclear Medicine - DNUC	9/9/2019
7790549	"Diagnostic Mammogram Work Up, DMAM-1801"	Mammography - DMAM	4/17/2020
6860679	"Dose Calibrator Constancy Test, DNUC-142"	Nuclear Medicine - DNUC	9/9/2019
6860581	"Dose Calibrator Linearity Test, DNUC-143"	Nuclear Medicine - DNUC	9/9/2019
6860672	"Dose Preparation Procedure, DNUC-130"	Nuclear Medicine - DNUC	9/9/2019
6860677	"Duties of Medical Director/Advisor, DNUC-43"	Nuclear Medicine - DNUC	9/9/2019
6860687	"Emergencies and/or Equipment Related Questions, DNUC-3"	Nuclear Medicine - DNUC	9/9/2019
6860730	"Equipment QA Ultrasound, DUS-8"	Ultrasound - DUS	9/9/2019
6860545	"Equipment, DMAM-7"	Mammography - DMAM	9/9/2019
7726779	"ER Discrepancy, DXR-27"	X-Ray - DXR	3/10/2020
6860632	"Exam Indications not Requiring Prior Approval, DNUC-34"	Nuclear Medicine - DNUC	9/9/2019
6860731	"Exams Performed Outside the Department, C-Arm Non-Surgical, DXR-13"	X-Ray - DXR	9/9/2019
6860631	"External Radiation Accident, DNUC-136"	Nuclear Medicine - DNUC	9/9/2019
6860704	"Extracranial Carotid and Vertebral Arteries, DUS-23"	Ultrasound - DUS	9/9/2019
7789809	"Film Badges, DXR-35"	X-Ray - DXR	3/10/2020
7789791	"Film Copy & Check Out Policy, DXR-58"	X-Ray - DXR	3/10/2020
7790563	"Film Records, DMAM-8"	Mammography - DMAM	4/17/2020
6860680	"First Pass-Cardiac Blood Pool Study, DNUC-68"	Nuclear Medicine - DNUC	9/9/2019
6860665	"Gallium Scan, DNUC-103"	Nuclear Medicine - DNUC	9/9/2019
6860668	"Gamma Camera Uniformity Flood, DNUC-140"	Nuclear Medicine - DNUC	9/9/2019

6860563	"Gastric Emptying 1, 2 and 4 Hour Protocol, DNUC-1602"	Nuclear Medicine - DNUC	9/9/2019
6860673	"Gastric Emptying Solid and or Liquid, DNUC-86"	Nuclear Medicine - DNUC	9/9/2019
6860674	"Gastric Reflux Scan, DNUC-81"	Nuclear Medicine - DNUC	9/9/2019
6860678	"Gastrointestinal Bleeding, DNUC-85"	Nuclear Medicine - DNUC	9/9/2019
7056713	"Hearing Protection During MRI Exams, DMRI-1901"	Magnetic Resonance Imaging - DMRI	10/10/2019
7332290	"HEPATOBIILIARY (for Sphincter of Oddi Dysfunction), DNUC-84A"	Nuclear Medicine - DNUC	1/15/2020
7332289	"Hepatobiliary Scan, DNUC-84"	Nuclear Medicine - DNUC	1/15/2020
6860757	"Hours of Operation, DXR-44"	X-Ray - DXR	9/9/2019
6860715	"Hysterosonogram, DUS-24"	Ultrasound - DUS	9/9/2019
6860671	"Identification of Undesirable Side Affects, DNUC-58"	Nuclear Medicine - DNUC	9/9/2019
6860728	"Infection Control for Isolation Patient in Department, DXR-29"	X-Ray - DXR	9/9/2019
7789807	"Infection Control, DMAM-3"	Mammography - DMAM	3/10/2020
6860657	"Injection Policy for Patients with IVs, DNUC-36"	Nuclear Medicine - DNUC	9/9/2019
6860664	"Inservice and Continuing Education, DNUC-45"	Nuclear Medicine - DNUC	9/9/2019
6860759	"Intravenous Injection of Radiopharmaceuticals, DNUC-35"	Nuclear Medicine - DNUC	9/9/2019
6860662	"Introduction to Nuclear Medicine for Nursing Personnel, DNUC-49"	Nuclear Medicine - DNUC	9/9/2019
6860670	"Iodine 123-MIBG, DNUC-107"	Nuclear Medicine - DNUC	9/9/2019
6860743	"Isotope Drug Administration, DNUC-32"	Nuclear Medicine - DNUC	9/9/2019
6860745	"IVCH – Radiographic Equipment Daily QC, DXR-18"	X-Ray - DXR	9/9/2019
6860753	"Kit Preparation According to Manufacturer, DNUC-88"	Nuclear Medicine - DNUC	9/9/2019
7789799	"Labeling of Radiographs, DXR-21"	X-Ray - DXR	3/10/2020
6860542	"Lead Apron Inspection and Inventory, DXR-39"	X-Ray - DXR	9/9/2019
6860660	"LeVeen Shunt Scan, DNUC-80"	Nuclear Medicine - DNUC	9/9/2019
7789794	"Licensure, DMAM-9"	Mammography - DMAM	3/10/2020
6860712	"Limited/Follow-Up Obstetrical Ultrasound, DUS-25"	Ultrasound - DUS	9/9/2019
6860666	"Liver Hemangioma Study, DNUC-83"	Nuclear Medicine - DNUC	9/9/2019
6860663	"Liver Spleen Scan, DNUC-82"	Nuclear Medicine - DNUC	9/9/2019
6860654	"Location Hours of Operation, DNUC-4"	Nuclear Medicine - DNUC	9/9/2019
6860655	"Lung Aerosol Scan, DNUC-74"	Nuclear Medicine - DNUC	9/9/2019
6860659	"Lung Perfusion Scan, DNUC-75"	Nuclear Medicine - DNUC	9/9/2019
6860667	"Lymphoscintigraphy, DNUC-104"	Nuclear Medicine - DNUC	9/9/2019
7789796	"Mammography Orders, DMAM-10"	Mammography - DMAM	3/10/2020
7792490	"Mammography/DI Request, DMAM-21"	Mammography - DMAM	4/17/2020
7072065	Management of Contrast Reactions in Radiology	X-Ray - DXR	10/15/2019
6860653	"Meckels Diverticulum Scan, DNUC-87"	Nuclear Medicine - DNUC	9/9/2019
6860549	"Medical Physicist Responsibilities, DMAM-4"	Mammography - DMAM	9/9/2019
6860642	"Medical Records, DNUC-10"	Nuclear Medicine - DNUC	9/9/2019
6860553	"Medical Staff Credentials for the Use of Imaging Equipment, DXR-52"	X-Ray - DXR	9/9/2019
7071760	Minimizing Radiation Exposure for Pediatric Patients DXR-1901	X-Ray - DXR	10/15/2019
6860648	"Misadministration of Doses, DNUC-59"	Nuclear Medicine - DNUC	9/9/2019
6860561	"MPI Heart Study (Myocardial Perfusion), DNUC-65"	Nuclear Medicine - DNUC	9/9/2019
6649679	"MQSA-EQUIP Procedure, DMAM-1802"	Mammography - DMAM	8/27/2019
7656604	"MRI Contrast Administration, DMRI-2001"	Magnetic Resonance Imaging - DMRI	2/19/2020
7071806	"MRI Contrast Injection Policy, DMRI-1"	Magnetic Resonance Imaging - DMRI	10/15/2019
6860740	"MRI Ferromagnetic Objects, DMRI-2"	Magnetic Resonance Imaging - DMRI	9/9/2019
7022744	MRI Medical Director (MRMD) and MRI Safety Officer (MRSO) Responsibilities DMRI-1905	Magnetic Resonance Imaging - DMRI	10/7/2019
6860729	"MRI Patient and Visitor Safety, DMRI-5"	Magnetic Resonance Imaging - DMRI	9/9/2019
7030770	"MRI Policy Code Blue, DMRI-3"	Magnetic Resonance Imaging - DMRI	10/7/2019
7003564	"MRI Policy Quench Evacuation, DMRI-4"	Magnetic Resonance Imaging - DMRI	10/7/2019
7030958	MRI Safety Education DMRI-1906	Magnetic Resonance Imaging - DMRI	10/7/2019
7004025	MRI Thermal Burns DMRI-1902	Magnetic Resonance Imaging - DMRI	10/3/2019
7004040	MRI Zone Restrictions-DMRI 1903	Magnetic Resonance Imaging - DMRI	10/3/2019
7332291	"Multi-Gated Acquisition of the Heart (MUGA), DNUC-66"	Nuclear Medicine - DNUC	1/15/2020
6860651	"Multi-Limited Bone Scan, DNUC-72"	Nuclear Medicine - DNUC	9/9/2019
6860661	"Myocardial Infarct Study Hot PYP Study, DNUC-67"	Nuclear Medicine - DNUC	9/9/2019
7792430	"Needle Localization, DMAM-11"	Mammography - DMAM	4/17/2020
6860727	"Neonatal Head, DUS-26"	Ultrasound - DUS	9/9/2019
6860658	"Neuroendocrine Tumor Somatostatin, DNUC-105"	Nuclear Medicine - DNUC	9/9/2019
7789786	"Night Shift Department Closure, DXR-60"	X-Ray - DXR	3/10/2020
6860564	"NM List of Approved Procedures and Radiopharmaceutical Doses, DNUC-38"	Nuclear Medicine - DNUC	9/9/2019
6860639	"NM Scope of Services General Information Dept Objectives, DNUC – 14"	Nuclear Medicine - DNUC	9/9/2019
7789789	"Non-Radiology Staff Room Use, DXR-12"	X-Ray - DXR	3/10/2020
6860583	"Nuclear Medicine Receiving Form, DNUC-127"	Nuclear Medicine - DNUC	9/9/2019
6860623	"Nuclear Medicine Standards, DNUC-120"	Nuclear Medicine - DNUC	9/9/2019
6860652	"Occupational Radiation Exposure, DNUC-16"	Nuclear Medicine - DNUC	9/9/2019
6860569	"Oncoscint-IN-111, DNUC-106"	Nuclear Medicine - DNUC	9/9/2019
6860580	"Opening Packages Containing Radioactive Materials, DNUC-124"	Nuclear Medicine - DNUC	9/9/2019
6860647	"Ordering and Accepting Delivery of Radioactive Material, DNUC-125"	Nuclear Medicine - DNUC	9/9/2019
6860645	"Ordering of Procedures, DNUC-27"	Nuclear Medicine - DNUC	9/9/2019
6860567	"Orientation of New Employees, DNUC - 46"	Nuclear Medicine - DNUC	9/9/2019
6860758	"Orientation–Radiologic Technologist–Equipment–Supplies, DXR-15"	X-Ray - DXR	9/9/2019
6860624	"Parathyroid Scan, DNUC-79"	Nuclear Medicine - DNUC	9/9/2019
7789788	"Patient Care Within the Radiology Department, DXR-3"	X-Ray - DXR	3/10/2020
6860585	"Patient Consent, DNUC-54"	Nuclear Medicine - DNUC	9/9/2019
6860571	"Patient Rights to Refuse Examination, DNUC-57"	Nuclear Medicine - DNUC	9/9/2019
6860629	"Pediatric Radiopharmaceutical Doses, DNUC-39"	Nuclear Medicine - DNUC	9/9/2019
6860716	"Pelvic Ultrasound-Transabdominal, DUS-27"	Ultrasound - DUS	9/9/2019
7789798	"Performance of Diagnostic Imaging Services, DXR-56"	X-Ray - DXR	3/10/2020
6860717	"Peripheral Venous Upper Extremity Ultrasound, DUS-29"	Ultrasound - DUS	9/9/2019
6860713	"Peripheral Venous Lower Extremity Ultrasound, DUS-28"	Ultrasound - DUS	9/9/2019

6860646	"Personnel Monitoring for External Radiation Exposure, DNUC - 114"	Nuclear Medicine - DNUC	9/9/2019
6860548	"Personnel Qualifications, DXR-53"	X-Ray - DXR	9/9/2019
6860541	"PET/CT Scan Protocol for Tahoe Forest Cancer Center, DNUC-150"	Nuclear Medicine - DNUC	9/9/2019
6860697	"PET/CT Scans for Patients with Elevated Serum Blood Glucose, DNUC-151"	Nuclear Medicine - DNUC	9/9/2019
6860637	"PET/CT Screening Form, DNUC-152"	Nuclear Medicine - DNUC	9/9/2019
6860560	"Pharmaceutical Stress Testing, DNUC-63"	Nuclear Medicine - DNUC	9/9/2019
6860734	"Physician Orders, DMAM-12"	Mammography - DMAM	9/9/2019
6860587	"Physician Policy Guidelines, DMAM-18"	Mammography - DMAM	9/9/2019
7792730	"Positioning and Views, DMAM-13"	Mammography - DMAM	4/17/2020
6860741	"Post Mortem Imaging Procedure, DXR-23"	X-Ray - DXR	9/9/2019
6860643	"Potentially Hazardous Procedures, DNUC - 29"	Nuclear Medicine - DNUC	9/9/2019
7789806	"Pregnancy - Patient Screening, DXR-34"	X-Ray - DXR	3/10/2020
7789808	"Pregnancy - Employee-Technologist, DXR-33"	X-Ray - DXR	3/10/2020
6860633	"Pregnant Patients, DNUC-116"	Nuclear Medicine - DNUC	9/9/2019
6860650	"Priority for Services, DNUC-26"	Nuclear Medicine - DNUC	9/9/2019
6860656	"Proficiency Evaluation of Technical Personnel, DNUC-30"	Nuclear Medicine - DNUC	9/9/2019
6860751	"Protocol Setup, DNUC-62"	Nuclear Medicine - DNUC	9/9/2019
6860644	"Quality Assurance Monitoring Plan, DNUC-23"	Nuclear Medicine - DNUC	9/9/2019
6860634	"Quality Assurance Plan, DNUC-21"	Nuclear Medicine - DNUC	9/9/2019
7789800	"Quality Control Weekly Protocol, DMAM-19"	Mammography - DMAM	3/10/2020
6860640	"Quality Review, DNUC-9"	Nuclear Medicine - DNUC	9/9/2019
6860636	"Quantitative Lung Scan, DNUC-76"	Nuclear Medicine - DNUC	9/9/2019
6860620	"Radiation Accident Response, DNUC-135"	Nuclear Medicine - DNUC	9/9/2019
6860572	"Radiation Accidents Preparedness, DNUC-134"	Nuclear Medicine - DNUC	9/9/2019
6860573	"Radiation Physicist Services, DXR-38"	X-Ray - DXR	9/9/2019
6860641	"Radiation Protection Program, DNUC - 121"	Nuclear Medicine - DNUC	9/9/2019
6860618	"Radiation Safety Committee, DNUC-122"	Nuclear Medicine - DNUC	9/9/2019
6860617	"Radiation Safety Compliance Officer Job Description, DNUC-41"	Nuclear Medicine - DNUC	9/9/2019
6860695	"Radiation Safety Program in the ""Hot"" Laboratory Area, DNUC-129"	Nuclear Medicine - DNUC	9/9/2019
6860555	"Radiation Safety, DNUC-113"	Nuclear Medicine - DNUC	9/9/2019
6860557	"Radiation Safety, DXR-36"	X-Ray - DXR	9/9/2019
6860625	"Radioactive Material Containers, DNUC-128"	Nuclear Medicine - DNUC	9/9/2019
6860616	"Radioactive Material Reception - Inspection, DNUC-126"	Nuclear Medicine - DNUC	9/9/2019
6860615	"Radioactive Waste Disposal, DNUC-149"	Nuclear Medicine - DNUC	9/9/2019
6860649	"Radioactive Waste Disposal, DNUC-17"	Nuclear Medicine - DNUC	9/9/2019
7942072	"Radiologist Peer Review Policy, DXR-61"	Interventional Radiology - DINT	4/17/2020
6860739	"Radiologist Specific Responsibilities, DMAM-20"	Mammography - DMAM	9/9/2019
7789795	"Radiologist's Signature of Results, DXR-55"	X-Ray - DXR	3/10/2020
7942616	"Radiology Scope of Service, DXR-42"	X-Ray - DXR	4/17/2020
6860584	"Radionuclide Doses, DNUC-37"	Nuclear Medicine - DNUC	9/9/2019
6860621	"Radiopharmaceutical Prep/Disposal Facility, DNUC-18"	Nuclear Medicine - DNUC	9/9/2019
6860702	"Record Location, DNUC-1"	Nuclear Medicine - DNUC	9/9/2019
6860558	"Record Retention Radiology, DXR-57"	X-Ray - DXR	9/9/2019
6860619	"Renal Baseline Renogram, DNUC-95"	Nuclear Medicine - DNUC	9/9/2019
6860550	"Renal GFR, DNUC-94"	Nuclear Medicine - DNUC	9/9/2019
6860700	"Renal Scan or Renogram with Lasix, DNUC-97"	Nuclear Medicine - DNUC	9/9/2019
6860688	"Renal Tubular Function (DMSA), DNUC-98"	Nuclear Medicine - DNUC	9/9/2019
6860720	"Renal Ultrasound, DUS-30"	Ultrasound - DUS	9/9/2019
6860543	"Repeat Analysis Program, DXR-1802"	X-Ray - DXR	9/9/2019
7022874	Reporting of MRI Accidents DMRI-1904	Magnetic Resonance Imaging - DMRI	10/7/2019
6860742	"Request for Repair of Equipment, DUS-36"	Ultrasound - DUS	9/9/2019
6649675	"Responsibility Road Map, DMAM-14"	Mammography - DMAM	8/27/2019
6860638	"Review Prior to Administration of Radionuclides, DNUC-33"	Nuclear Medicine - DNUC	9/9/2019
6860699	"Routine Care to Avoid Contamination, DNUC-123"	Nuclear Medicine - DNUC	9/9/2019
6860726	"Safety Maintenance of Transducer (2), DUS-31"	Ultrasound - DUS	9/9/2019
6860691	"Safety Precautions and Procedures, DNUC-60"	Nuclear Medicine - DNUC	9/9/2019
6860559	"Scheduling Procedures, DNUC-8"	Nuclear Medicine - DNUC	9/9/2019
7789792	"Scheduling Targeted Biopsies, DINT-1"	Interventional Radiology - DINT	3/10/2020
6860723	"Scrotum, DUS-32"	Ultrasound - DUS	9/9/2019
6860575	"Sealed Sources, DNUC-20"	Nuclear Medicine - DNUC	9/9/2019
7560123	"Sentinel Lymph Node Lymphoscintigraphy, DNUC-108"	Nuclear Medicine - DNUC	2/10/2020
6860693	"Shunt Evaluation, DNUC-92"	Nuclear Medicine - DNUC	9/9/2019
6860714	"Small Parts Scan, DUS-33"	Ultrasound - DUS	9/9/2019
6860577	"Sources, Storage and Disposal of Radioactive Waste, DNUC-19"	Nuclear Medicine - DNUC	9/9/2019
6860576	"Specimen Procedure, DMAM-15"	Mammography - DMAM	9/9/2019
6649664	"Standard Responsible Personnel, DMAM-16"	Mammography - DMAM	8/27/2019
6860556	"Statement of General Principles, DNUC-112"	Nuclear Medicine - DNUC	9/9/2019
6860760	"Statement of General Safety Principles, DXR-31"	X-Ray - DXR	9/9/2019
6860582	"Stress ECG, DNUC-61"	Nuclear Medicine - DNUC	9/9/2019
6860722	"Stress Echo Protocol, DUS-3"	Ultrasound - DUS	9/9/2019
7789801	"Surgery Procedure for Obtaining Technologist Support, DXR-11"	X-Ray - DXR	3/10/2020
6860698	"Survey Meter Daily Consistency and Battery Check, DNUC-146"	Nuclear Medicine - DNUC	9/9/2019
6860551	"Survey Meter Reference Test, DNUC-145"	Nuclear Medicine - DNUC	9/9/2019
6860718	"Tahoe Forest Ultrasound Procedure Order Policy, DUS-7"	Ultrasound - DUS	9/9/2019
7789802	"Technologists Responsibilities, DMAM-17"	Mammography - DMAM	3/10/2020
6860724	"TEE Probe, DUS-5"	Ultrasound - DUS	9/9/2019
7726766	"Telerradiology Discrepancy, DXR-26"	X-Ray - DXR	3/10/2020
6860565	"Testicular Scan, DNUC-100"	Nuclear Medicine - DNUC	9/9/2019
6860539	"TFH-Scope of Service Organizational Description, DXR-41"	X-Ray - DXR	9/9/2019
6860719	"Thoracentesis with Ultrasound Guidance, DUS-34"	Ultrasound - DUS	9/9/2019

6860562	"Three Phase Bone Scan, DNUC-71"	Nuclear Medicine - DNUC	9/9/2019
6860630	"Thyroid Scan Only – No Uptake, DNUC-78"	Nuclear Medicine - DNUC	9/9/2019
6860721	"Thyroid Ultrasound, DUS-35"	Ultraound - DUS	9/9/2019
6860756	"Thyroid Uptake and/or Scan, DNUC-77"	Nuclear Medicine - DNUC	9/9/2019
6860628	"Transcription of Reports, DXR-54"	X-Ray - DXR	9/9/2019
6860570	"Transporting Patients with Foley Catheters, DNUC-52"	Nuclear Medicine - DNUC	9/9/2019
6860614	"Turnover on Results, DMAM-23"	Mammography - DMAM	9/9/2019
6860540	"Use of Contrast Media During Lactation, DXR-1801"	X-Ray - DXR	9/9/2019
6860568	"WBC 99mTc or IN-111 Scans, DNUC-109"	Nuclear Medicine - DNUC	9/9/2019
6860622	"Weekly Quality Control – Fluoro Room & C-Arm, DXR-19"	X-Ray - DXR	9/9/2019
7789784	"Well Counter Daily Quality Control Check, DNUC-144"	Nuclear Medicine - DNUC	3/10/2020
6860554	"Whole Body Bone Scan, DNUC-70"	Nuclear Medicine - DNUC	9/9/2019

**TFH/IVCH Pharmacy 2020 Annual P&P List**

Title	Last Approved	Next Review	Has Attachments	Reviewed	Edits
Adverse Drug Reaction Reporting, APH-25	5/8/2019	5/7/2020	No	1/29/2020	
Alteplase Emergency Room Pyxis Override, APH-1405	5/8/2019	5/7/2020	Yes	1/29/2020	Minor verbiage, no intent change
Aminoglycoside Protocol, DPH-2	5/8/2019	5/7/2020	Yes	1/29/2020	Minor verbiage, addition of pregnancy exception and references
Anticoagulation Protocol, APH-1401	5/8/2019	5/7/2020	No	1/29/2020	Minor verbiage, no intent change
Antimicrobial Stewardship Program, APH-1403	5/8/2019	5/7/2020	No	2/12/2020	ECC process delineated
Automated Dispensing Cabinet (ADM), APH-47	5/8/2019	5/7/2020	No	1/29/2020	Minor verbiage, no intent change
Automatic Stop Orders, APH-41	5/8/2019	5/7/2020	No	1/30/2020	
Bedside Medications, APH-26	5/8/2019	5/7/2020	No	1/30/2020	
Bio-Terrorism Pharmaceutical Cache, DPH-6	5/8/2019	5/7/2020	No	1/30/2020	
Blood Derivatives, DPH-7	5/8/2019	5/7/2020	No	1/30/2020	Minor verbiage, no intent change
Bowel Management Program, APH-40	5/8/2019	5/7/2020	No	1/30/2020	
Budget, DPH-1	5/8/2019	5/7/2020	No	1/30/2020	
Cancer Center Hypersensitivity/Anaphylaxis Pharmacist Protocol, APH-1802	5/8/2019	5/7/2020	Yes	1/30/2020	
Chemotherapy: Non-FDA Approved, APH-6	5/8/2019	5/7/2020	No	1/30/2020	
Clarification of Medication Orders, APH-27	5/8/2019	5/7/2020	No	1/30/2020	
Communication Plan, DPH-9	5/8/2019	5/7/2020	No	1/30/2020	Rename Pharmacy communication, minor verbiage, no intent change
Compounding, APH-16	8/21/2019	8/20/2020	No	1/30/2020	
Consultant Pharmacist Services Provider Requirements, APH-73	5/8/2019	5/7/2020	No	1/30/2020	
Continuous Subcutaneous Insulin Infusion (Home Insulin Pump), APH-1804	5/8/2019	5/7/2020	Yes	1/30/2020	
Controlled Substances, APH-2	7/17/2019	7/16/2020	No	1/30/2020	
Disposal of Expired Drugs, APH-42	5/8/2019	5/7/2020	No	1/30/2020	
Drug Information, APH-119	5/8/2019	5/7/2020	No	1/30/2020	
Drug Procurement/Inventory Control, DPH-13	5/8/2019	5/7/2020	No	1/30/2020	
Drug Samples, APH-7	5/8/2019	5/7/2020	No	1/30/2020	
Drug Shortages, APH-8	5/8/2019	5/7/2020	No	1/30/2020	
Drug Utilization Evaluation, DPH-14	5/8/2019	5/7/2020	No	1/30/2020	
Drug-Drug, Drug-Food Interaction Screening, DPH-15	5/8/2019	5/7/2020	No	1/30/2020	
Duplicate Medication Orders, APH-1407	5/8/2019	5/7/2020	No	1/30/2020	
Emergency Medications-Crash Carts, APH-9	7/17/2019	7/16/2020	No	1/30/2020	
Emergency Preparedness, DPH-16	5/8/2019	5/7/2020	No	1/30/2020	
Emergency Room Discharge Prescriptions, APH-10	5/8/2019	5/7/2020	No	1/30/2020	
Extemporaneous Packaging, DPH-18	5/8/2019	5/7/2020	No	1/30/2020	
Extravasation Management Chemotherapy Agents, APH-3	5/8/2019	5/7/2020	No	1/30/2020	
FDA Medication Black Box Warning, APH-116	5/8/2019	5/7/2020	No	1/30/2020	
FentaNYL Patch Protocol, DPH-42	5/8/2019	5/7/2020	No	1/30/2020	
Floor Stock, APH-11	5/8/2019	5/7/2020	No	1/30/2020	
Food Drug Interaction Education, DPH-19	5/8/2019	5/7/2020	No	1/30/2020	Minor verbiage, no intent change
Formulary, APH-12	5/8/2019	5/7/2020	No	1/30/2020	
Hazardous Materials Records (MSDS), DPH-20	5/8/2019	5/7/2020	Yes	1/30/2020	
Hazardous Substances Safe Handling and Preparation, APH-13	5/8/2019	5/7/2020	Yes	1/30/2020	
High Alert Medications, APH-15	8/13/2019	8/12/2020	No	1/30/2020	
Hospital Organization, DPH-21	5/8/2019	5/7/2020	No	1/30/2020	
Hospital Pharmacy Delivery Process, APH-2002				3/3/2020	New policy
Hours of Operation/After Hours, APH-14	7/17/2019	7/16/2020	No	1/30/2020	Rename Pharmacy Hours, minor verbiage, no intent change, add reference Emergency Room Discharge Prescriptions, APH-10
Hospital Pharmacy Operations During the Temporary Absence of the Pharmacist, DPH 2001	1/22/2020	1/22/2021	No	1/30/2020	
Impairment or Theft, DPH-1901	10/23/2019	10/22/2020	Yes	1/30/2020	
Informed Consent Investigational Drugs, APH-17	10/23/2019	10/22/2020	No	1/30/2020	
Intravenous Medication Therapy - Multispecialty Clinics, APH-117	5/8/2019	5/7/2020	No	1/3/2020	TTMG Revision after COVID 19 done and privileges
Intravenous to Oral Therapy Conversion Protocol, DPH-41	5/8/2019	5/7/2020	No	1/30/2020	

Investigational Drugs, APH-18	5/8/2019	5/7/2020	No	1/30/2020	
Irrigation Solution Expiration, APH-19	5/8/2019	5/7/2020	No	1/30/2020	
<b>IV Drug Administration Guidelines, APH-20</b>	5/8/2019	5/7/2020	No	1/30/2020	Review, addition of Nicardipine
IVCH Authorized Personnel, APH-51	5/8/2019	5/7/2020	No	1/30/2020	
IVCH Bulk Medications, DPH-50	5/8/2019	5/7/2020	No	Retire	
Labeling Standards, APH-21	5/8/2019	5/7/2020	No	1/30/2020	
Licensure and Professional Standards, DPH-10	5/8/2019	5/7/2020	No	1/30/2020	No intent change, addition of Nevada requirements
<b>Malignant Hyperthermia Carts-Crisis Guidelines, APH-22</b>	5/8/2019	5/7/2020	No	2/10/2020	Removal of Heparinized saline for arterial lines
Medical Waste Nursing, Pharmacy, and EVS, APH-30	5/8/2019	5/7/2020	No	1/30/2020	Minor verbiage, no intent change, nicotine patch removal
Medical Waste, DPH-24	5/8/2019	5/7/2020	No	1/30/2020	
Medication Administration, APH-23	1/9/2020	1/8/2021	No	1/30/2020	
Medication Error Reduction Plan, APH-34	5/8/2019	5/7/2020	No	1/30/2020	
Medication Error Reporting, APH-24	10/23/2019	10/22/2020	No	1/30/2020	
Medication Expiration Dates SDV and MDV, APH-28	5/8/2019	5/7/2020	No	1/30/2020	
Medication Order Verification, DPH-25	5/8/2019	5/7/2020	No	1/30/2020	
Medication Recall/ External Alerts, DPH-26	7/17/2019	7/16/2020	No	2/3/2020	
Medication Security, APH-35	5/8/2019	5/7/2020	No	2/3/2020	
Medication Storage, APH-48	5/8/2019	5/7/2020	Yes	2/3/2020	
Methotrexate in Ectopic Pregnancy, APH-58	5/8/2019	5/7/2020	No	2/3/2020	
Off Label Medication Dose, Use, APH-37	5/8/2019	5/7/2020	No	2/3/2020	
Oncology Pharmacy Services, APH-1801	5/8/2019	5/7/2020	No	2/3/2020	
Oral Adherence Program, APH-1803	5/8/2019	5/7/2020	No	2/3/2020	
Order Sets, APH-43	5/8/2019	5/7/2020	No	2/3/2020	
Outpatient RN Anticoagulation Protocol, APH-1701	10/23/2019	10/22/2020	No	2/3/2020	
Parenteral Nutrition Protocol, APH-36	7/18/2019	7/17/2020	No	2/3/2020	
Patient Drug Profiles, APH-39	5/8/2019	5/7/2020	No	2/3/2020	
Patient's Own Medication, APH-1	5/8/2019	5/7/2020	No	2/3/2020	
Pediatric Dosing Guidelines, DPH-4	5/8/2019	5/7/2020	No	2/3/2020	
Pharmacy and Therapeutics Committee, APH-38	5/8/2019	5/7/2020	No	2/3/2020	
Pharmacy Electrolyte Replacement Protocol, DPH-43	5/8/2019	5/7/2020	No	2/3/2020	
Pharmacy Liquid Auto-Substitution, APH-1601	5/8/2019	5/7/2020	No	2/3/2020	
Pharmacy Organization, DPH-11	5/8/2019	5/7/2020	No	2/3/2020	
Pharmacy Policy Review Process, APH-46	7/17/2019	7/16/2020	No	2/3/2020	
Pharmacy Purchase Records, DPH-34	5/8/2019	5/7/2020	No	2/3/2020	
Pharmacy Quality Improvement Plan, DPH-30	5/8/2019	5/7/2020	No	2/6/2020	
Pharmacy Renal Dosing Protocol, DPH-17	5/8/2019	5/7/2020	No	2/6/2020	Minor verbiage, no intent change.
Pharmacy Security, DPH-31	5/8/2019	5/7/2020	No	2/6/2020	
Poison Control, DPH-33	5/8/2019	5/7/2020	No	2/6/2020	
Potassium Chloride Admin, APH-29	5/8/2019	5/7/2020	No	2/6/2020	
Prescribing Ordering General Practices, APH-44	8/12/2019	8/11/2020	No	2/6/2020	minor verbiage, no intent change
Reconciliation of Medications, APH-31	5/8/2019	5/7/2020	No	2/6/2020	
Self Medication Administration, APH-32	5/8/2019	5/7/2020	No	2/6/2020	
Temporary Segregated Compounding Area, DPH-40	5/8/2019	5/7/2020	No	Retire	
Tenecteplase Emergency Room Automated Dispensing Machine Override, APH-1406	5/8/2019	5/7/2020	Yes	2/6/2020	Minor verbiage, no intent change.
<b>Therapeutic Substitution, DPH-35</b>	11/21/2019	11/20/2020	No	2/19/2020	Major, Zenpep and Biosimilars
Unit Inspections, DPH-38	10/23/2019	10/22/2020	No	2/6/2020	
Use of Abbreviations, APH-4	5/8/2019	5/7/2020	No	2/6/2020	
Vancomycin Pharmacy Protocol, DPH-39	5/8/2019	5/7/2020	No	2/6/2020	
Warming Medications/Solutions, APH-50	5/8/2019	5/7/2020	No	2/6/2020	

# Late Career Provider, MSCP-1701

## PURPOSE:

- A. Clinical excellence is a complex composite of performance in many domains, including, among others, cognitive ability, technical proficiency, communication skills, professional judgment, productivity, and stamina. As individuals age, the natural aging process may have the potential to adversely affect the capacity of practitioners to carry out their clinical responsibilities. Given this reality, it is imperative from the point of view of patient safety as well as physician well-being, to establish a process by which late career clinicians' performance and capacities can be fairly and accurately evaluated. The purpose of this policy is to establish this evaluation process.
- B. *Key elements of this policy are to assure high quality care for patients, to be supportive of the practitioner and to address issues that the individual may not recognize.*
- C. *The Medical Staff of Tahoe Forest Hospital System and its clinics adopts this policy in order to:*
  - 1. Provide patients with medical care of high quality and safety and protect them from harm
  - 2. Identify issues that may be pertinent to the health and clinical practice of medical staff members
  - 3. Support members of the medical staff
  - 4. Apply evaluation criteria objectively, respectfully, and confidentially

## POLICY:

Any practitioner aged 70 or older who applies for initial appointment to the Medical Staff will complete, as part of the application process, a physical and mental health evaluation to screen for possible issues that may affect his/her capacity to competently perform the clinical privileges requested. Physicians who are currently on the medical staff who are 70 or older will be required to complete these assessments every 2 years, starting from the member's next scheduled reappointment.

## PROCEDURE:

- A. Components of the ~~assessment~~ assessment: Any practitioner who wishes to apply for initial appointment and is age 70 or will reach the age of 70 within the next six (6) months, must complete this process. For any practitioner who has reached the age of 70 or will reach the age of 70 before his or her next scheduled reappointment to the Medical Staff, the Medical Staff Services Department will notify the practitioner of the assessment and screenings required by this policy. These are as follows:
  - 1. The physician will be required to undergo a screening evaluation at U.C. San Diego PACE ~~Aging Physician Assessment (PAPA)~~ Late Career Health Screening (LCHS). ~~PAPA-LCHS~~ is a physical and mental health screening intended for late career physicians who have reached a certain age, but otherwise have no known impairment or competency problems. ~~PAPA-LCHS~~ is designed to detect the presence of physical or mental health problems affecting a physician's ability to practice. Components of ~~PAPA-LCHS~~ include:
    - a. Review of self-reported health questionnaire
    - b. A comprehensive physical examination
    - c. MicroCog™ Cognitive screening examination
    - d. Psychological screening
    - e. Dexterity test (for proceduralists only)
  - 2. The cost of the initial examination for current Medical Staff members will be paid by Tahoe Forest Hospital District (TFHD). Travel expenses will be paid as per the TFHD Travel Policy. For initial applicants, the costs will be borne by the applicant.
  - 3. For initial applicants, obtaining an evaluation and submitting documentation of the results



shall be a prerequisite to deeming an initial application for appointment to the Medical Staff complete for processing. Failure to render the application complete within a reasonable period of time, or by such deadline as may be specified, shall be grounds for determining the application incomplete with no action being taken on the application, as provided in the Medical Staff Bylaws.

4. A current member of the Medical Staff who has reached the age of 70 or will reach the age of 70 before his/her next scheduled reappointment shall obtain the required evaluation at least four (4) months prior to the expiration of his/her reappointment. Failure to comply within this time frame will be considered a withdrawal of his/her application with no action being taken on the reappointment application.

B. Notification to the practitioner will include:

1. For physicians currently holding medical staff membership and privileges, the practitioner who has reached the age of 70 or will reach the age of 70 before his/her next scheduled reappointment, will be notified six months prior to the expiration of their next reappointment of the date on which the results of the health screening are due to the Medical Staff Services Department.
  - a. A Letter of Intent for Assessment of Practitioner Health.
  - b. The PACE [Aging Physician Assessment \(PAPA\)Late Career Health Screening \(LCHS\)](#) Enrollment Form.
  - c. A copy of this policy.
  - d. A copy of the current clinical privileges held (or privileges requested) by the practitioner.
  - e. An Authorization Form, to be signed and returned by the practitioner, allowing the results of the evaluation to be disclosed to appropriate representatives of the Medical Staff for purposes consistent with this Policy.

C. Review of assessments

1. The completed [PAPA-LCHS](#) report will be submitted to the Medical Staff Services Department.
2. This information, which will be treated as highly confidential, will be reviewed by the Chief of Staff and the Chief Medical Officer and the Chief of the Department as deemed appropriate. If further evaluation is recommended, and assistance is needed in obtaining an appropriate referral, the Well-Being Committee may be consulted. Additional evaluation and consultations may be sought regarding the interpretation of the results as needed. Costs of any additional evaluations will be borne by the practitioner. However, TFHD and the Medical Staff may reimburse you for some of your out-of-pocket expenses.

D. Outcomes of review

1. If the [PAPA-LCHS](#) report does not identify potential patient care concerns in relation to the expected level of performance in exercising the clinical privileges at issue, the report will be filed in a confidential [envelope-file](#) maintained by the Medical Staff Services Department as part of the Credentials File, and the remainder of the Credentials File that is accessible for routine reappointment credentialing and peer review purposes will only reflect that the assessment and screening process has been completed with no significant concerns identified. The initial appointment process will then proceed as specified in the Medical Staff Bylaws. Current members of the Medical Staff will be notified that their screening obligation has been discharged.
2. If the [PAPA-LCHS](#) report identifies the need for further evaluation, the Chief of Staff and the Chief Medical Officer, and the Chief of the Department, as deemed appropriate, will decide how to proceed. The options [shall-may](#) include, [one or all of the following](#):
  - a. Consulting with the relevant department chair and/or the Medical Executive Committee. If it appears that an accommodation will be necessary, the practitioner may choose to voluntarily adjust their practice; otherwise, the Corrective Action provisions of the Medical Staff Bylaws may be invoked.
  - b. If the evaluation was obtained in connection with an initial application for appointment, the review process shall include the Medical Staff officials and committees that have credentialing responsibilities under the Medical Staff Bylaws.
  - c. The Well Being Committee may be consulted if assistance is needed in obtaining

- an appropriate referral or other resources.
3. All of these functions will be performed in a way that is respectful and supportive of the practitioner, while being consistent with the Medical Staff's overarching responsibility for maintaining the Medical Staff's professional standards and protecting the interests of patients. If the practitioner is determined to have a condition for which reasonable accommodations might be made in order to protect the interests of patients while allowing the practitioner to hold some or all of the clinical privileges requested or in effect, this issue will be explored at the practitioner's request.
  4. Throughout this process the intent of each step is to protect patient safety, provide support to the practitioner and assist in any resulting changes in practice patterns or transitions. This process is also available to individual practitioners, who, on their own, express concerns. Inquiries by such practitioners should be directed to the Chief of Staff or designee.

## References:

- A. Stanford University Medical Center Late Career Practitioner Policy
- B. UC San Diego ~~Physician Assessment and Clinical Education (PACE)~~ Late Career Health Screening (LCHS) Program
- C. CME Report 5-A-15, Assuring Safe and Effective Care for Patients by Senior/Late Career Physicians, Council on Medical Education. American Medical Association
- D. Smart DR. Physician Characteristics and Distribution in the US. American Medical Association. 2015 Ed.
- E. Burroughs MD, MBA, FACHE, FACPE, Jonathan H., Hogan, Esq., James B., and Richter, Esq., Jennifer H., "The Aging Physician: Balancing Safety, Respect, and Compliance," Med Staff New, March 2013. (citing Powell, Douglas H., Profiles in Cognitive Aging, *Harvard University Press, Press*, December 1994)
- F. Norcross, MD, Ching, MFT, Sieber, PhD. Toward a More Accountable Profession: The Case of the Aging Physician. Medical Board of California Action Report, Jan 2006
- G. Pitkanen. "Doctor's Health and Fitness to Practice: Performance Problems in Doctors and Cognitive Impairments." *Occup Med*, 2008
- H. Waljee, MD, MPH, Greenfield, MD, Dimick MD, MPH, Birkmeyer, MD, "Surgeon Age and Operative Mortality in the United States," Annals, Annals of Surgery, Vol 244, No. 3, September 2006
- I. Choudhry NK, Fletcher RH, Soumerai SB. Systematic review: the relationship between clinical experience and quality of health care. *Ann Intern Med*. 2005; 142:260-273
- J. AMA Code of Medical Ethics Opinion 9.0305- Physician Health and Wellness. <http://www.ama-assn.org/ama/pib/physician/resources/medical-ethics/code-medical-ethics/opinion90305.page#>
- K. Assessing Late Career Practitioners: Policies and Procedures for Age Based Screening. A Guideline for California Public Protection & Physician Health/ 2015. <http://www.cppph.org/cppph/wp-content/uploads/2015/07/assessing-late-career-practitioners-adopted-by-cppph-changes-6-10-151.pdf>

## Tahoe Forest Health System Formulary 2020

P	Medication	ID
Y	ABATACEPT (WITH MALTOSE) 250 MG INTRAVENOUS SOLUTION	95440
Y	ABATACEPT IVPB	1000307
Y	ACETAMINOPHEN 1,000 MG/100 ML (10 MG/ML) INTRAVENOUS SOLUTION	193180
Y	ACETAMINOPHEN 120 MG RECTAL SUPPOSITORY	103
Y	ACETAMINOPHEN 160 MG/5 ML (5 ML) ORAL SUSPENSION	183753
Y	ACETAMINOPHEN 325 MG RECTAL SUPPOSITORY	104
Y	ACETAMINOPHEN 325 MG TABLET	101
Y	ACETAMINOPHEN 500 MG TABLET	102
Y	ACETAMINOPHEN 650 MG RECTAL SUPPOSITORY	105
Y	ACETAMINOPHEN 80 MG RECTAL SUPPOSITORY	81906
Y	ACETAMINOPHEN ORAL LIQUID IMS TEMPLATE	1000657
Y	ACETAZOLAMIDE 125 MG TABLET	112
Y	ACETAZOLAMIDE 250 MG TABLET	113
Y	ACETAZOLAMIDE 500 MG SOLUTION FOR INJECTION	114
Y	ACETIC ACID-ALUMINUM ACETATE 2 % EAR DROPS	8965
Y	ACETYLCOLINE CHLORIDE 1 % (10 MG/ML) INTRAOCULAR KIT	81263
Y	ACETYLCYSTEINE 100 MG/KG IN D5W 1000 ML IVPB	1000095
Y	ACETYLCYSTEINE 150 MG/KG IN D5W 200 ML IVPB	1000093
Y	ACETYLCYSTEINE 200 MG/ML (20 %) INTRAVENOUS SOLUTION	92528
Y	ACETYLCYSTEINE 200 MG/ML (20 %) SOLUTION	123
Y	ACETYLCYSTEINE 50 MG/KG IN D5W 500 ML IVPB	1000094
Y	ACTIVATED CHARCOAL 25 GRAM ORAL SUSPENSION	84983
Y	ACTIVATED CHARCOAL-SORBITOL 50 GRAM/240 ML ORAL SUSPENSION	93321
Y	ACYCLOVIR 200 MG CAPSULE	8969
Y	ACYCLOVIR 800 MG TABLET	8972
Y	ACYCLOVIR IN 100 ML IVPB DISPENSABLE	1001344
Y	ACYCLOVIR IN 150 ML IVPB DISPENSABLE	1001345
Y	ACYCLOVIR IN 250 ML IVPB DISPENSABLE	1001346
Y	ACYCLOVIR IVPB IMS TEMPLATE	1001347
Y	ACYCLOVIR PEDIATRIC SYRINGE	177321
Y	ACYCLOVIR PO IMS TEMPLATE	1001395
Y	ACYCLOVIR SODIUM 50 MG/ML INTRAVENOUS SOLUTION	23128
Y	ADENOSINE 3 MG/ML INTRAVENOUS SOLUTION	8975
Y	ADO-TRASTUZUMAB EMTANSINE 100 MG INTRAVENOUS SOLUTION	204464
Y	ADO-TRASTUZUMAB EMTANSINE IVPB	301254
Y	ADULT TPN - TFH	1001442
Y	ALBUMIN, HUMAN 25 % INTRAVENOUS SOLUTION	8981
Y	ALBUTEROL NEB SOLUTION IMS TEMPLATE	1000848
Y	ALBUTEROL SULFATE 2.5 MG/3 ML (0.083 %) SOLUTION FOR NEBULIZATION	250
Y	ALBUTEROL SULFATE CONCENTRATE 2.5 MG/0.5 ML SOLUTION FOR NEBULIZATION	93139
Y	ALBUTEROL SULFATE CONTINUOUS INHALATION SOLUTION	300506
Y	ALBUTEROL SULFATE HFA 90 MCG/ACTUATION AEROSOL INHALER	40196
Y	ALFUZOSIN ER 10 MG TABLET,EXTENDED RELEASE 24 HR	89055
Y	ALLOPURINOL 100 MG TABLET	310
Y	ALLOPURINOL 300 MG TABLET	311
Y	ALPHA-1-PROTEINASE INHIBITOR (HUMAN) 1,000 MG INTRAVENOUS SOLUTION	82309
Y	ALPRAZOLAM 0.25 MG TABLET	324
Y	ALPROSTADIL 20 MCG/ML NEONATAL INFUSION - TFH	1001474

Y	ALPROSTADIL 500 MCG/ML INJECTION SOLUTION	9001
Y	ALPROSTADIL PEDIATRIC INFUSION	1000961
Y	ALTEPLASE 2 MG INTRA-CATHETER SOLUTION	82551
Y	ALTEPLASE 50 MG INTRAVENOUS SOLUTION	79456
Y	ALUMINUM-MAG HYDROXIDE-SIMETHICONE 200 MG-200 MG-20 MG/5 ML ORAL SUSP	38285
Y	AMANTADINE HCL 100 MG CAPSULE	364
Y	AMIKACIN 1,000 MG/4 ML INJECTION SOLUTION	190982
Y	AMIKACIN 500 MG IVPB	1000170
Y	AMIKACIN CONSULT TO PHARMACY	168287
Y	AMIKACIN EXTENDED INTERVAL IVPB	1000836
Y	AMIKACIN INJECTION IMS TEMPLATE	1000902
Y	AMINO ACIDS 5 % WITH LYLES AND CALCIUM IN D20W INTRAVENOUS SOLUTION	77097
Y	AMINOCAPROIC ACID 250 MG/ML INTRAVENOUS SOLUTION	403
Y	AMINOCAPROIC ACID INFUSION	1001076
Y	AMINOCAPROIC ACID IVPB	1000422
Y	AMINOPHYLLINE 250 MG/10 ML INTRAVENOUS SOLUTION	88540
Y	AMINOPHYLLINE IV INFUSION	1000796
Y	AMINOPHYLLINE IVPB	1000797
Y	AMIODARONE 200 MG TABLET	9066
Y	AMIODARONE 50 MG/ML INTRAVENOUS SOLUTION	9065
Y	AMIODARONE BOLUS IMS TEMPLATE	1000937
Y	AMIODARONE INFUSION IMS TEMPLATE	1000936
Y	AMIODARONE IV BOLUS	200000
Y	AMIODARONE IV DRIP	200001
Y	AMITRIPTYLINE 10 MG TABLET	432
Y	AMITRIPTYLINE 25 MG TABLET	435
Y	AMITRIPTYLINE 50 MG TABLET	436
Y	AMLODIPINE 5 MG TABLET	79041
Y	AMMONIUM LACTATE 12 % TOPICAL CREAM	17997
Y	AMOXICILLIN 125 MG/5 ML ORAL SUSPENSION	453
Y	AMOXICILLIN 250 MG CAPSULE	450
Y	AMOXICILLIN 250 MG/5 ML ORAL SUSPENSION	454
Y	AMOXICILLIN 400 MG/5 ML ORAL SUSPENSION	25246
Y	AMOXICILLIN 400 MG-POTASSIUM CLAVULANATE 57 MG/5 ML ORAL SUSPENSION	33230
Y	AMOXICILLIN 500 MG CAPSULE	451
Y	AMOXICILLIN 500 MG-POTASSIUM CLAVULANATE 125 MG TABLET	33227
Y	AMOXICILLIN 600 MG-POTASSIUM CLAVULANATE 42.9 MG/5 ML ORAL SUSPENSION	31177
Y	AMOXICILLIN 875 MG-POTASSIUM CLAVULANATE 125 MG TABLET	33228
Y	AMPHOTERICIN B 50 MG SOLUTION FOR INJECTION	464
Y	AMPHOTERICIN B IVPB	1000168
Y	AMPICILLIN 1 GRAM SOLUTION FOR INJECTION	469
Y	AMPICILLIN 10 GRAM SOLUTION FOR INJECTION	470
Y	AMPICILLIN 1000 MG IN 50 ML DISPENSABLE (MBP ADS)	5000047
Y	AMPICILLIN 1000 MG IN 50 ML SODIUM CHLORIDE 0.9% DISPENSABLE (ADV CMX)	5000239
Y	AMPICILLIN 1000 MG IN 50 ML SODIUM CHLORIDE 0.9% DISPENSABLE (CMX)	5000219
Y	AMPICILLIN 2 GRAM SOLUTION FOR INJECTION	472
Y	AMPICILLIN 2000 MG IN 100 ML DISPENSABLE (MBP ADS)	5000048
Y	AMPICILLIN 2000 MG IN 100 ML SODIUM CHLORIDE 0.9% DISPENSABLE (ADV CMX)	5000240
Y	AMPICILLIN 2000 MG IN 100 ML SODIUM CHLORIDE 0.9% DISPENSABLE (CMX)	5000220
Y	AMPICILLIN 250 MG CAPSULE	465

Y	AMPICILLIN 250 MG SOLUTION FOR INJECTION	473
Y	AMPICILLIN 50 ML DISPENSABLE (CUSTOM RX IVPB)	5000225
Y	AMPICILLIN 500 MG CAPSULE	466
Y	AMPICILLIN IVPB IMS TEMPLATE	5000025
Y	AMPICILLIN PEDIATRIC 3 ML SYRINGE	1001466
Y	AMPICILLIN PEDIATRIC IV SYRINGE	200013
Y	AMPICILLIN PEDIATRIC IVPB	1001458
Y	AMPICILLIN-SULBACTAM 1.5 GRAM - AMPICILLIN BASED DOSING	300507
Y	AMPICILLIN-SULBACTAM 1.5 GRAM IN 50 ML DISPENSABLE (ADS)	5000191
Y	AMPICILLIN-SULBACTAM 1.5 GRAM IN 50 ML DISPENSABLE (MBP ADS)	5000049
Y	AMPICILLIN-SULBACTAM 1.5 GRAM IN 50 ML SODIUM CHLORIDE 0.9% DISPENSABLE (CMX)	5000189
Y	AMPICILLIN-SULBACTAM 1.5 GRAM IN 50 ML SODIUM CHLORIDE 0.9% DISPENSABLE (MBP CM)	5000187
Y	AMPICILLIN-SULBACTAM 1.5 GRAM SOLUTION FOR INJECTION	32470
Y	AMPICILLIN-SULBACTAM 100 ML DISPENSABLE (CUSTOM RX IVPB)	5000194
Y	AMPICILLIN-SULBACTAM 3 GRAM IN 100 ML DISPENSABLE (ADS)	5000192
Y	AMPICILLIN-SULBACTAM 3 GRAM IN 100 ML DISPENSABLE (MBP ADS)	5000050
Y	AMPICILLIN-SULBACTAM 3 GRAM IN 100 ML SODIUM CHLORIDE 0.9% DISPENSABLE (CMX)	5000190
Y	AMPICILLIN-SULBACTAM 3 GRAM IN 100 ML SODIUM CHLORIDE 0.9% DISPENSABLE (MBP CM)	5000188
Y	AMPICILLIN-SULBACTAM 3 GRAM SOLUTION FOR INJECTION	32471
Y	AMPICILLIN-SULBACTAM 50 ML DISPENSABLE (CUSTOM RX IVPB)	5000193
Y	AMPICILLIN-SULBACTAM IVPB IMS TEMPLATE	5000026
Y	AMPICILLIN-SULBACTAM PEDIATRIC IVPB	1001470
Y	ANASTROZOLE 1 MG TABLET	77198
Y	ANTIBIOTIC CONSULT TO PHARMACY	301133
Y	APIXABAN 5 MG TABLET	203370
Y	APREPITANT 130 MG/18 ML INTRAVENOUS EMULSION	224147
Y	ARGATROBAN 50 MG/50 ML (1 MG/ML) IN SODIUM CHLORIDE (ISO-OSMOTIC) IV	196312
Y	ARIPIPRAZOLE 10 MG TABLET	86966
Y	ASCORBIC ACID (VITAMIN C) 500 MG TABLET	664
Y	ASPIRIN 25 MG-DIPYRIDAMOLE 200 MG CAPSULE,EXT.RELEASE 12 HR MULTIPHASE	77234
Y	ASPIRIN 300 MG RECTAL SUPPOSITORY	693
Y	ASPIRIN 325 MG TABLET,DELAYED RELEASE	13654
Y	ASPIRIN 325 MG TABLET	681
Y	ASPIRIN 81 MG CHEWABLE TABLET	680
Y	ASPIRIN 81 MG TABLET,DELAYED RELEASE	14113
Y	ASPIRIN-ACETAMINOPHEN-CAFFEINE 250 MG-250 MG-65 MG TABLET	82707
Y	ATENOLOL 25 MG TABLET	717
Y	ATENOLOL 50 MG TABLET	718
Y	ATEZOLIZUMAB 1,200 MG/20 ML (60 MG/ML) INTRAVENOUS SOLUTION	218713
Y	ATEZOLIZUMAB IVPB	1001370
Y	ATORVASTATIN 20 MG TABLET	77412
Y	ATROPINE 0.1 MG/ML INJECTION SYRINGE	730
Y	ATROPINE 0.4 MG/ML INJECTION SOLUTION	731
Y	ATROPINE 1 % EYE DROPS	736
Y	ATROPINE INJECTION IMS TEMPLATE	1001157
Y	AZACITIDINE 100 MG SOLUTION FOR INJECTION	92970
Y	AZACITIDINE 25 MG/ML SUBCUT SUSPENSION	1000319
Y	AZACITIDINE IVPB	1000320
Y	AZATHIOPRINE 50 MG TABLET	9183
Y	AZITHROMYCIN 100 MG/5 ML ORAL SUSPENSION	81540

Y	AZITHROMYCIN 200 MG/5 ML ORAL SUSPENSION	82066
Y	AZITHROMYCIN 250 MG TABLET	20943
Y	AZITHROMYCIN 500 MG IN 250 ML DISPENSABLE (ADS)	5000265
Y	AZITHROMYCIN 500 MG IN 250 ML DISPENSABLE (ADV ADS)	5000051
Y	AZITHROMYCIN 500 MG IN 250 ML SODIUM CHLORIDE 0.9% DISPENSABLE (ADV CMX)	5000247
Y	AZITHROMYCIN 500 MG INTRAVENOUS SOLUTION	21063
Y	AZITHROMYCIN DISPENSABLE (CUSTOM RX IVPB)	168603
Y	AZITHROMYCIN IVPB (DO NOT USE)	168602
Y	AZITHROMYCIN IVPB IMS TEMPLATE	5000027
Y	AZITHROMYCIN PEDIATRIC IV SYRINGE	177313
Y	AZITHROMYCIN PEDIATRIC IVPB	1001460
Y	AZTREONAM 1 GRAM SOLUTION FOR INJECTION	81970
Y	AZTREONAM 1000 MG IN 50 ML DEXTROSE ISO-OSMOTIC IVPB (PREMIX)	77021
Y	AZTREONAM 1000 MG IN 50 ML DISPENSABLE (ADS)	5000184
Y	AZTREONAM 1000 MG IN 50 ML DISPENSABLE (MBP ADS)	5000052
Y	AZTREONAM 1000 MG IN 50 ML SODIUM CHLORIDE 0.9% DISPENSABLE (CMX)	5000181
Y	AZTREONAM 1000 MG IN 50 ML SODIUM CHLORIDE 0.9% DISPENSABLE (MBP CMX)	5000179
Y	AZTREONAM 2 GRAM SOLUTION FOR INJECTION	80585
Y	AZTREONAM 2000 MG IN 100 ML DISPENSABLE (MBP ADS)	5000053
Y	AZTREONAM 2000 MG IN 50 ML DEXTROSE ISO-OSMOTIC IVPB (PREMIX)	82550
Y	AZTREONAM 2000 MG IN 50 ML DISPENSABLE (ADS)	5000185
Y	AZTREONAM 2000 MG IN 50 ML DISPENSABLE (MBP ADS)	5000183
Y	AZTREONAM 2000 MG IN 50 ML SODIUM CHLORIDE 0.9% DISPENSABLE (CMX)	5000182
Y	AZTREONAM 2000 MG IN 50 ML SODIUM CHLORIDE 0.9% DISPENSABLE (MBP CMX)	5000180
Y	AZTREONAM DISPENSABLE (CUSTOM RX IVPB)	5000186
Y	AZTREONAM IVPB IMS TEMPLATE	5000028
Y	BACITRACIN 50,000 UNIT INTRAMUSCULAR SOLUTION	851
Y	BACITRACIN 500 UNIT/GRAM EYE OINTMENT	852
Y	BACITRACIN TOPICAL OINTMENT IMS TEMPLATE	1001158
Y	BACITRACIN ZINC 500 UNIT/GRAM TOPICAL OINTMENT	13818
Y	BACITRACIN ZINC 500 UNIT/GRAM TOPICAL PACKET	88212
Y	BACITRACIN-POLYMYXIN B 500 UNIT-10,000 UNIT/GRAM EYE OINTMENT	856
Y	BACITRACIN-POLYMYXIN B 500 UNIT-10,000 UNIT/GRAM TOPICAL PACKET	88234
Y	BACLOFEN 10 MG TABLET	860
Y	BALANCED SALT SOLUTION COMBINATION NO.2 INTRAOCULAR IRRIGATION	37578
Y	BALANCED SALT SOLUTION NON-SURGICAL NO.3 EYE WASH	92561
Y	BARIUM SULFATE 0.1 % (W/V), 0.1 % (W/W) ORAL SUSPENSION	177857
Y	BARIUM SULFATE 105 % (W/V), 58 % (W/W) ORAL SUSPENSION	168037
Y	BARIUM SULFATE 2.1 % (W/V), 2.0 % (W/W) ORAL SUSPENSION	83429
Y	BARIUM SULFATE 60 % (W/V) ORAL SUSPENSION	82471
Y	BARIUM SULFATE 700 MG TABLET	183952
Y	BARIUM SULFATE 96 % (W/W) ORAL POWDER FOR SUSPENSION	179410
Y	BARIUM SULFATE 98 % ORAL POWDER FOR SUSPENSION	168038
Y	BARIUM-METHYLCELLULOSE 24 % ORAL LIQUID	94211
Y	BECLOMETHASONE DIPROPIONATE 40 MCG/ACTUATION AEROSOL INHALER	82576
Y	BELIMUMAB 120 MG INTRAVENOUS SOLUTION	193869
Y	BELIMUMAB 400 MG INTRAVENOUS SOLUTION	193870
Y	BELIMUMAB IVPB	1000839
Y	BELLADONNA ALKALOIDS-OPIUM 16.2 MG-60 MG RECTAL SUPPOSITORY	24731
Y	BENZAEPRI 10 MG TABLET	9220

Y	BENDAMUSTINE (BENDEKA) IVPB	1001352
Y	BENDAMUSTINE 25 MG/ML INTRAVENOUS SOLUTION	216497
Y	BENZOCAINE 15 MG-MENTHOL 2.6 MG LOZENGES	195940
Y	BENZOCAINE 20 % TOPICAL AEROSOL	79663
Y	BENZONATATE 100 MG CAPSULE	988
Y	BENZTROPINE 2 MG TABLET	1000
Y	BENZTROPINE 2 MG/2 ML INJECTION SOLUTION	81468
Y	BETAMETHASONE ACETATE AND SODIUM PHOS 6 MG/ML SUSPENSION FOR INJECTION	79652
Y	BETAMETHASONE DIPROPIONATE 0.05 % TOPICAL OINTMENT	1029
Y	BETAMETHASONE, AUGMENTED 0.05 % TOPICAL CREAM	9175
Y	BEVACIZUMAB 25 MG/ML INTRAVENOUS SOLUTION	89931
Y	BEVACIZUMAB IVPB	169799
Y	BIMATOPROST 0.01 % EYE DROPS	191872
Y	BISACODYL 10 MG RECTAL SUPPOSITORY	1080
Y	BISACODYL 5 MG TABLET,DELAYED RELEASE	13632
Y	BISMUTH SUBSALICYLATE 262 MG/15 ML ORAL SUSPENSION	80560
Y	BISOPROLOL FUMARATE 5 MG TABLET	18288
Y	BLEOMYCIN 15 UNIT SOLUTION FOR INJECTION	9289
Y	BLEOMYCIN 30 UNIT SOLUTION FOR INJECTION	17012
Y	BLEOMYCIN IVPB	169792
Y	BORTEZOMIB 3.5 MG SOLUTION FOR INJECTION	87808
Y	BORTEZOMIB INJECTION SYRINGE	1000871
Y	BORTEZOMIB SUBCUT SYRINGE	1000944
Y	BREAST MILK	300004
Y	BRENTUXIMAB VEDOTIN 50 MG INTRAVENOUS SOLUTION	195988
Y	BRIMONIDINE 0.2 % EYE DROPS	17881
Y	BROMOCRIPTINE 2.5 MG TABLET	9297
Y	BSS WITH ADDITIVES COMPOUND SOLUTION	1001328
Y	BUDESONIDE 0.25 MG/2 ML SUSPENSION FOR NEBULIZATION	81321
Y	BUDESONIDE 0.5 MG/2 ML SUSPENSION FOR NEBULIZATION	81378
Y	BUDESONIDE 90 MCG/ACTUATION BREATH ACTIVATED POWDER INHALER	167495
Y	BUDESONIDE DR - ER 3 MG CAPSULE,DELAYED,EXTENDED RELEASE	82000
Y	BUMETANIDE 0.25 MG/ML INJECTION SOLUTION	9308
Y	BUMETANIDE 1 MG TABLET	9310
Y	BUPIVACAINE (PF) 0.25 % (2.5 MG/ML) INJECTION SOLUTION	87866
Y	BUPIVACAINE (PF) 0.5 % (5 MG/ML) INJECTION SOLUTION	87867
Y	BUPIVACAINE (PF) 0.75 % (7.5 MG/ML) IN 8.25 % DEXTROSE INJECTION	9316
Y	BUPIVACAINE (PF) 0.75 % (7.5 MG/ML) INJECTION SOLUTION	1224
Y	BUPIVACAINE LIPOSOMAL DILUTION (ANESTHESIA INTRA-OP)	1001507
Y	BUPIVACAINE LIPOSOME(PF) 1.3 %(13.3 MG/ML) SUSPENSION FOR INFILTRATION	196823
Y	BUPIVACAINE-EPINEPHRINE (PF) 0.25 %-1:200,000 INJECTION SOLUTION	87865
Y	BUPIVACAINE-EPINEPHRINE (PF) 0.5 %-1:200,000 INJECTION SOLUTION	87863
Y	BUPRENORPHINE HCL 0.3 MG/ML INJECTION SOLUTION	94666
Y	BUPRENORPHINE HCL 8 MG SUBLINGUAL TABLET	87437
Y	BUPROPION HCL 100 MG TABLET	9321
Y	BUPROPION HCL 75 MG TABLET	9322
Y	BUPROPION HCL SR 100 MG TABLET,12 HR SUSTAINED-RELEASE	18385
Y	BUPROPION HCL SR 150 MG TABLET,12 HR SUSTAINED-RELEASE	18386
Y	BUPROPION HCL XL 150 MG 24 HR TABLET, EXTENDED RELEASE	88619
Y	BUSPIRONE 10 MG TABLET	9323

Y	BUTALBITAL-ACETAMINOPHEN-CAFFEINE 50 MG-325 MG-40 MG TABLET	8958
Y	CABAZITAXEL 10 MG/ML (FIRST DILUTION) INTRAVENOUS SOLUTION	191027
Y	CABAZITAXEL IVPB	1000751
Y	CALCITONIN (SALMON) 200 UNIT/ACTUATION NASAL SPRAY	80202
Y	CALCITONIN (SALMON) 200 UNIT/ML INJECTION SOLUTION	83048
Y	CALCITRIOL 0.25 MCG CAPSULE	9350
Y	CALCIUM ACETATE(PHOSPHATE BINDERS) 667 MG TABLET	79005
Y	CALCIUM ACETATE-ALUMINUM 952 MG-1,347 MG TOPICAL POWDER IN PACKET	199620
Y	CALCIUM CARBONATE 200 MG CALCIUM (500 MG) CHEWABLE TABLET	224476
Y	CALCIUM CARBONATE 500 MG (1,250 MG)-VITAMIN D3 200 UNIT TABLET	19483
Y	CALCIUM CHLORIDE 100 MG/ML (10 %) INTRAVENOUS SYRINGE	85730
Y	CALCIUM CITRATE 315 MG-VITAMIN D3 250 UNIT TABLET	181152
Y	CALCIUM GLUCONATE 100 MG/ML (10 %) INTRAVENOUS SOLUTION	1312
Y	CALCIUM GLUCONATE IVPB	1000803
Y	CALCIUM REPLACEMENT REMINDER	301614
Y	CALFACTANT 35 MG/ML IN 0.9% SODIUM CHLORIDE INTRATRACHEAL SUSPENSION	76930
Y	CANDESARTAN 8 MG TABLET	82607
Y	CAPSAICIN 0.025 % TOPICAL CREAM	1350
Y	CAPTOPRIL 12.5 MG TABLET	9401
Y	CARBAMAZEPINE 200 MG TABLET	1357
Y	CARBAMAZEPINE ER 200 MG TABLET,EXTENDED RELEASE,12 HR	80285
Y	CARBAMIDE PEROXIDE 6.5 % EAR DROPS	1359
Y	CARBIDOPA 10 MG-LEVODOPA 100 MG TABLET	9406
Y	CARBIDOPA 25 MG-LEVODOPA 100 MG TABLET	9407
Y	CARBIDOPA 25 MG-LEVODOPA 250 MG TABLET	9408
Y	CARBIDOPA ER 50 MG-LEVODOPA 200 MG TABLET,EXTENDED RELEASE	26371
Y	CARBOPLATIN 10 MG/ML INTRAVENOUS SOLUTION	39267
Y	CARBOPLATIN IVPB - TFH (NOT FOR MERCY USE)	1001668
Y	CARBOPLATIN IVPB	177295
Y	CARBOPROST TROMETHAMINE 250 MCG/ML INTRAMUSCULAR SOLUTION	82963
Y	CARBOXYMETHYLCELLULOSE SODIUM 0.5 % EYE DROPS IN A DROPPERETTE	86912
Y	CARFILZOMIB (KYPROLIS) IVPB	1000948
Y	CARFILZOMIB 30 MG INTRAVENOUS SOLUTION	219120
Y	CARFILZOMIB 60 MG INTRAVENOUS SOLUTION	201098
car	CARISOPRODOL 350 MG TABLET	1395
Y	CARVEDILOL 12.5 MG TABLET	77424
Y	CARVEDILOL 3.125 MG TABLET	79317
Y	CEFAZOLIN 1 GRAM SOLUTION FOR INJECTION	1445
Y	CEFAZOLIN 10 GRAM/50 ML SOLUTION FOR INJECTION	1446
Y	CEFAZOLIN 100 ML DISPENSABLE (CUSTOM RX IVPB)	5000082
Y	CEFAZOLIN 1000 MG IN 10 ML STERILE WATER DISPENSABLE (CMX SYRINGE)	5000093
Y	CEFAZOLIN 1000 MG IN 50 ML DEXTROSE ISO-OSMOTIC IVPB (PREMIX)	25365
Y	CEFAZOLIN 1000 MG IN 50 ML DISPENSABLE (ADS)	5000088
Y	CEFAZOLIN 1000 MG IN 50 ML DISPENSABLE (ADV ADS)	5000054
Y	CEFAZOLIN 1000 MG IN 50 ML DISPENSABLE (MBP ADS)	5000087
Y	CEFAZOLIN 1000 MG IN 50 ML SODIUM CHLORIDE 0.9% DISPENSABLE (ADV CMX)	5000241
Y	CEFAZOLIN 1000 MG IN 50 ML SODIUM CHLORIDE 0.9% DISPENSABLE (CMX)	5000090
Y	CEFAZOLIN 1000 MG IN 50 ML SODIUM CHLORIDE 0.9% DISPENSABLE (MBP CMX)	5000089
Y	CEFAZOLIN 2000 MG IN 100 ML DEXTROSE 5% IVPB (PREMIX)	94027
Y	CEFAZOLIN 2000 MG IN 100 ML DEXTROSE ISO-OSMOTIC IVPB (PREMIX)	216159



Y	CEFAZOLIN 2000 MG IN 100 ML SODIUM CHLORIDE 0.9% IVPB (PREMIX)	94007
Y	CEFAZOLIN 2000 MG IN 20 ML STERILE WATER DISPENSABLE (CMX SYRINGE)	5000091
Y	CEFAZOLIN 2000 MG IN 50 ML DEXTROSE 5% IVPB (PREMIX)	219151
Y	CEFAZOLIN 2000 MG IN 50 ML DEXTROSE ISO-OSMOTIC IVPB (PREMIX)	198641
Y	CEFAZOLIN 2000 MG IN 50 ML SODIUM CHLORIDE 0.9% DISPENSABLE (CMX)	5000256
Y	CEFAZOLIN 2000 MG IN 50 ML SODIUM CHLORIDE 0.9% IVPB (PREMIX)	216129
Y	CEFAZOLIN 3000 MG IN 30 ML STERILE WATER DISPENSABLE (CMX SYRINGE)	5000092
Y	CEFAZOLIN 50 ML DISPENSABLE (CUSTOM RX IVPB)	5000094
Y	CEFAZOLIN 500 MG IN 50 ML DISPENSABLE (ADS)	5000085
Y	CEFAZOLIN 500 MG IN 50 ML DISPENSABLE (MBP ADS)	5000055
Y	CEFAZOLIN 500 MG IN 50 ML SODIUM CHLORIDE 0.9% DISPENSABLE (CMX)	5000086
Y	CEFAZOLIN 500 MG IN 50 ML SODIUM CHLORIDE 0.9% DISPENSABLE (MBP CMX)	5000084
Y	CEFAZOLIN IVPB IMS TEMPLATE	5000029
Y	CEFAZOLIN PEDIATRIC IVPB	1001461
Y	CEFDINIR 250 MG/5 ML ORAL SUSPENSION	93557
Y	CEFDINIR 300 MG CAPSULE	82406
Y	CEFEPIME 1 GRAM SOLUTION FOR INJECTION	77523
Y	CEFEPIME 1000 MG IN 50 ML DEXTROSE 5% IVPB (PREMIX)	190324
Y	CEFEPIME 1000 MG IN 50 ML DEXTROSE ISO-OSMOTIC IVPB (PREMIX)	179847
Y	CEFEPIME 1000 MG IN 50 ML DISPENSABLE (ADS)	5000133
Y	CEFEPIME 1000 MG IN 50 ML DISPENSABLE (ADV ADS)	5000056
Y	CEFEPIME 1000 MG IN 50 ML DISPENSABLE (MBP ADS)	5000131
Y	CEFEPIME 1000 MG IN 50 ML SODIUM CHLORIDE 0.9% DISPENSABLE (CMX)	5000129
Y	CEFEPIME 1000 MG IN 50 ML SODIUM CHLORIDE 0.9% DISPENSABLE (MBP CMX)	5000127
Y	CEFEPIME 2 GRAM SOLUTION FOR INJECTION	78195
Y	CEFEPIME 2000 MG IN 100 ML DEXTROSE ISO-OSMOTIC IVPB (PREMIX)	179848
Y	CEFEPIME 2000 MG IN 50 ML DEXTROSE 5% IVPB (PREMIX)	190325
Y	CEFEPIME 2000 MG IN 50 ML DISPENSABLE (ADS)	5000134
Y	CEFEPIME 2000 MG IN 50 ML DISPENSABLE (ADV ADS)	5000057
Y	CEFEPIME 2000 MG IN 50 ML DISPENSABLE (MBP ADS)	5000132
Y	CEFEPIME 2000 MG IN 50 ML SODIUM CHLORIDE 0.9% DISPENSABLE (CMX)	5000130
Y	CEFEPIME 2000 MG IN 50 ML SODIUM CHLORIDE 0.9% DISPENSABLE (MBP CMX)	5000128
Y	CEFEPIME DISPENSABLE (CUSTOM RX IVPB)	5000135
Y	CEFEPIME IVPB IMS TEMPLATE	5000030
Y	CEFOXITIN 1 GRAM INTRAVENOUS SOLUTION	9461
Y	CEFOXITIN 10 GRAM INTRAVENOUS SOLUTION	9462
Y	CEFOXITIN 1000 MG IN 50 ML DEXTROSE ISO-OSMOTIC IVPB (PREMIX)	95905
Y	CEFOXITIN 1000 MG IN 50 ML DISPENSABLE (ADS)	5000099
Y	CEFOXITIN 1000 MG IN 50 ML DISPENSABLE (MBP ADS)	5000058
Y	CEFOXITIN 1000 MG IN 50 ML SODIUM CHLORIDE 0.9% DISPENSABLE (CMX)	5000096
Y	CEFOXITIN 1000 MG IN 50 ML SODIUM CHLORIDE 0.9% DISPENSABLE (MBP CMX)	5000095
Y	CEFOXITIN 2 GRAM INTRAVENOUS SOLUTION	9463
Y	CEFOXITIN 2000 MG IN 50 ML DEXTROSE ISO-OSMOTIC IVPB (PREMIX)	95906
Y	CEFOXITIN 2000 MG IN 50 ML DISPENSABLE (ADS)	5000100
Y	CEFOXITIN 2000 MG IN 50 ML DISPENSABLE (MBP ADS)	5000059
Y	CEFOXITIN 2000 MG IN 50 ML SODIUM CHLORIDE 0.9% DISPENSABLE (CMX)	5000098
Y	CEFOXITIN 2000 MG IN 50 ML SODIUM CHLORIDE 0.9% DISPENSABLE (MBP CMX)	5000097
Y	CEFOXITIN DISPENSABLE (CUSTOM RX IVPB)	5000101
Y	CEFOXITIN IVPB IMS TEMPLATE	5000032
Y	CEFOXITIN PEDIATRIC IVPB	1001462

Y	CEFTAZIDIME 1 GRAM SOLUTION FOR INJECTION	82033
Y	CEFTAZIDIME 1000 MG IN 50 ML DEXTROSE 5% IVPB (PREMIX)	195745
Y	CEFTAZIDIME 1000 MG IN 50 ML DEXTROSE ISO-OSMOTIC IVPB (PREMIX)	93439
Y	CEFTAZIDIME 1000 MG IN 50 ML DISPENSABLE (MBP ADS)	5000156
Y	CEFTAZIDIME 1000 MG IN 50 ML SODIUM CHLORIDE 0.9% DISPENSABLE (ADV CMX)	5000251
Y	CEFTAZIDIME 2 GRAM SOLUTION FOR INJECTION	78299
Y	CEFTAZIDIME 2000 MG IN 50 ML DEXTROSE 5% IVPB (PREMIX)	195746
Y	CEFTAZIDIME 2000 MG IN 50 ML DEXTROSE ISO-OSMOTIC IVPB (PREMIX)	93440
Y	CEFTAZIDIME 2000 MG IN 50 ML DISPENSABLE (MBP ADS)	5000157
Y	CEFTAZIDIME 2000 MG IN 50 ML SODIUM CHLORIDE 0.9% DISPENSABLE (ADV CMX)	5000250
Y	CEFTAZIDIME DISPENSABLE (CUSTOM RX IVPB)	5000160
Y	CEFTAZIDIME IVPB IMS TEMPLATE	5000033
Y	CEFTRIAXONE 1 GRAM SOLUTION FOR INJECTION	79742
Y	CEFTRIAXONE 10 GRAM SOLUTION FOR INJECTION	9491
Y	CEFTRIAXONE 1000 MG IN 50 ML DEXTROSE ISO-OSMOTIC IVPB (PREMIX)	9492
Y	CEFTRIAXONE 1000 MG IN 50 ML DISPENSABLE (ADS)	5000116
Y	CEFTRIAXONE 1000 MG IN 50 ML DISPENSABLE (ADV ADS)	5000060
Y	CEFTRIAXONE 1000 MG IN 50 ML DISPENSABLE (MBP ADS)	5000112
Y	CEFTRIAXONE 1000 MG IN 50 ML SODIUM CHLORIDE 0.9% DISPENSABLE (ADV CMX)	5000236
Y	CEFTRIAXONE 1000 MG IN 50 ML SODIUM CHLORIDE 0.9% DISPENSABLE (CMX)	5000108
Y	CEFTRIAXONE 1000 MG IN 50 ML SODIUM CHLORIDE 0.9% DISPENSABLE (MBP CMX)	5000104
Y	CEFTRIAXONE 2 GRAM SOLUTION FOR INJECTION	82936
Y	CEFTRIAXONE 2000 MG IN 50 ML DEXTROSE ISO-OSMOTIC IVPB (PREMIX)	9493
Y	CEFTRIAXONE 2000 MG IN 50 ML DISPENSABLE (ADS)	5000117
Y	CEFTRIAXONE 2000 MG IN 50 ML DISPENSABLE (ADV ADS)	5000061
Y	CEFTRIAXONE 2000 MG IN 50 ML DISPENSABLE (MBP ADS)	5000113
Y	CEFTRIAXONE 2000 MG IN 50 ML SODIUM CHLORIDE 0.9% DISPENSABLE (ADV CMX)	5000237
Y	CEFTRIAXONE 2000 MG IN 50 ML SODIUM CHLORIDE 0.9% DISPENSABLE (CMX)	5000109
Y	CEFTRIAXONE 2000 MG IN 50 ML SODIUM CHLORIDE 0.9% DISPENSABLE (MBP CMX)	5000105
Y	CEFTRIAXONE 250 MG IN 50 ML DISPENSABLE (ADS)	5000114
Y	CEFTRIAXONE 250 MG IN 50 ML DISPENSABLE (MBP ADS)	5000110
Y	CEFTRIAXONE 250 MG IN 50 ML SODIUM CHLORIDE 0.9% DISPENSABLE (CMX)	5000106
Y	CEFTRIAXONE 250 MG IN 50 ML SODIUM CHLORIDE 0.9% DISPENSABLE (MBP CMX)	5000102
Y	CEFTRIAXONE 250 MG SOLUTION FOR INJECTION	9489
Y	CEFTRIAXONE 500 MG IN 50 ML DISPENSABLE (ADS)	5000115
Y	CEFTRIAXONE 500 MG IN 50 ML DISPENSABLE (MBP ADS)	5000111
Y	CEFTRIAXONE 500 MG IN 50 ML SODIUM CHLORIDE 0.9% DISPENSABLE (CMX)	5000107
Y	CEFTRIAXONE 500 MG IN 50 ML SODIUM CHLORIDE 0.9% DISPENSABLE (MBP CMX)	5000103
Y	CEFTRIAXONE 500 MG SOLUTION FOR INJECTION	9490
Y	CEFTRIAXONE DISPENSABLE (CUSTOM RX IVPB)	5000118
Y	CEFTRIAXONE IVPB IMS TEMPLATE	5000034
Y	CEFTRIAXONE PEDIATRIC IV SYRINGE	168279
Y	CEFTRIAXONE PEDIATRIC IVPB	1001459
Y	CEFUROXIME 1 MG/0.1 ML OPHTHALMIC INJECTION	301800
Y	CELECOXIB 100 MG CAPSULE	82263
Y	CELLULOSE, OXIDIZED 2" X 3" MISC	85802
Y	CELLULOSE, OXIDIZED 4" X 8" PADS	86200
Y	CEPHALEXIN 125 MG/5 ML ORAL SUSPENSION	9501
Y	CEPHALEXIN 250 MG CAPSULE	9499
Y	CEPHALEXIN 250 MG/5 ML ORAL SUSPENSION	9502

Y	CEPHALEXIN 500 MG CAPSULE	9500
Y	CETIRIZINE 10 MG TABLET	77730
Y	CETUXIMAB 100 MG/50 ML INTRAVENOUS SOLUTION	180440
Y	CETUXIMAB 200 MG/100 ML INTRAVENOUS SOLUTION	180441
Y	CETUXIMAB IVPB	1000363
Y	CHLORAMPHENICOL IVPB	1000428
Y	CHLORDIAZEPOXIDE 25 MG CAPSULE	1623
Y	CHLORHEXIDINE GLUCONATE 0.12 % MOUTHWASH	9516
Y	CHLOROPROCAINE (PF) 30 MG/ML (3 %) INJECTION SOLUTION	1635
Y	CHLOROTHIAZIDE SODIUM 500 MG INTRAVENOUS SOLUTION	81318
Y	CHLORPROMAZINE 25 MG TABLET	1656
Y	CHLORPROMAZINE 25 MG/ML INJECTION SOLUTION	1649
Y	CHLORTHALIDONE 50 MG TABLET	1662
Y	CHOLECALCIFEROL (VITAMIN D3) 25 MCG (1,000 UNIT) TABLET	130098
Y	CHOLESTYRAMINE-ASPARTAME 4 GRAM ORAL POWDER FOR SUSP IN A PACKET	88489
Y	CIPROFLOXACIN 0.2 %-HYDROCORTISONE 1 % EAR DROPS,SUSPENSION	80449
Y	CIPROFLOXACIN 0.3 % EYE DROPS	9610
Y	CISPLATIN 1 MG/ML INTRAVENOUS SOLUTION	9612
Y	CISPLATIN IVPB	200004
Y	CISPLATIN WITH MANNITOL IVPB	169797
Y	CITALOPRAM 20 MG TABLET	21062
Y	CLADRIBINE 10 MG/10 ML INTRAVENOUS SOLUTION	9615
Y	CLINDAMYCIN 150 MG/ML INJECTION SOLUTION	1743
Y	CLINDAMYCIN 300 MG IN 50 ML DEXTROSE 5% IVPB (PREMIX)	9625
Y	CLINDAMYCIN 300 MG IN 50 ML DISPENSABLE (ADV ADS)	5000064
Y	CLINDAMYCIN 300 MG IN 50 ML SODIUM CHLORIDE 0.9% DISPENSABLE (ADV CMX)	5000243
Y	CLINDAMYCIN 300 MG IN 50 ML SODIUM CHLORIDE 0.9% IVPB (PREMIX)	222740
Y	CLINDAMYCIN 600 MG IN 50 ML DEXTROSE 5% IVPB (PREMIX)	9626
Y	CLINDAMYCIN 600 MG IN 50 ML DISPENSABLE (ADV ADS)	5000065
Y	CLINDAMYCIN 600 MG IN 50 ML SODIUM CHLORIDE 0.9% DISPENSABLE (ADV CMX)	5000244
Y	CLINDAMYCIN 600 MG IN 50 ML SODIUM CHLORIDE 0.9% IVPB (PREMIX)	222741
Y	CLINDAMYCIN 900 MG IN 50 ML DEXTROSE 5% IVPB (PREMIX)	9627
Y	CLINDAMYCIN 900 MG IN 50 ML DISPENSABLE (ADV ADS)	5000066
Y	CLINDAMYCIN 900 MG IN 50 ML SODIUM CHLORIDE 0.9% DISPENSABLE (ADV CMX)	5000245
Y	CLINDAMYCIN 900 MG IN 50 ML SODIUM CHLORIDE 0.9% IVPB (PREMIX)	222742
Y	CLINDAMYCIN DISPENSABLE (CUSTOM RX IVPB)	5000200
Y	CLINDAMYCIN HCL 150 MG CAPSULE	1740
Y	CLINDAMYCIN IV IMS TEMPLATE	1000935
Y	CLINDAMYCIN PEDIATRIC IVPB	1001463
Y	CLONAZEPAM 1 MG TABLET	9638
Y	CLONIDINE (PF) 1,000 MCG/10 ML (100 MCG/ML) EPIDURAL SOLUTION	179964
Y	CLONIDINE 0.1 MG/24 HR WEEKLY TRANSDERMAL PATCH	77526
Y	CLONIDINE HCL 0.1 MG TABLET	1755
Y	CLOPIDOGREL 75 MG TABLET	78966
Y	CLOTRIMAZOLE 1 % TOPICAL CREAM	1767
Y	CLOTRIMAZOLE 1 % VAGINAL CREAM	1769
Y	CLOTRIMAZOLE 10 MG TROCHE	9644
Y	CLOTRIMAZOLE-BETAMETHASONE 1 %-0.05 % TOPICAL CREAM	29424
Y	CLOTRIMAZOLE-NYSTATIN-HYDROCORTISONE CREAM	1001473
Y	COCAINE 4 % TOPICAL SOLUTION	1792

Y	COLCHICINE 0.6 MG TABLET	1821
Y	COLLAGENASE CLOSTRIDIUM HISTOLYTICUM 0.9 MG SOLUTION FOR INJECTION	184286
Y	COLLAGENASE CLOSTRIDIUM HISTOLYTICUM 250 UNIT/GRAM TOPICAL OINTMENT	81927
Y	CONJUGATED ESTROGENS 0.3 MG TABLET	82934
Y	CONJUGATED ESTROGENS 0.625 MG TABLET	80884
Y	CONJUGATED ESTROGENS 0.625 MG/GRAM VAGINAL CREAM	80522
Y	CONJUGATED ESTROGENS 25 MG SOLUTION FOR INJECTION	82923
Y	COSYNTROPIN 0.25 MG SOLUTION FOR INJECTION	78840
Y	CUSTOM EPIDURAL	1001457
Y	CUSTOM IV FLUID	168313
Y	CYANOCOBALAMIN (VIT B-12) 1,000 MCG TABLET	2009
Y	CYCLOBENZAPRINE 10 MG TABLET	2017
Y	CYCLOPENTOLATE 1 % EYE DROPS	2025
Y	CYCLOPHOSPHAMIDE 1 GRAM INTRAVENOUS SOLUTION	28918
Y	CYCLOPHOSPHAMIDE 2 GRAM INTRAVENOUS SOLUTION	28922
Y	CYCLOPHOSPHAMIDE 500 MG INTRAVENOUS SOLUTION	28921
Y	CYCLOPHOSPHAMIDE IVPB	169800
Y	CYTARABINE (PF) 2 GRAM/20 ML (100 MG/ML) INJECTION SOLUTION	20156
Y	CYTARABINE HIGH DOSE IVPB	1001141
Y	CYTARABINE IV INFUSION	168282
Y	CYTARABINE IVPB	169249
Y	D5-LR WITH POTASSIUM CHLORIDE 10 MEQ/L	168674
Y	D5-LR WITH POTASSIUM CHLORIDE 30 MEQ/L	168683
Y	D5-LR WITH POTASSIUM CHLORIDE 40 MEQ/L	168684
Y	D5-NS WITH POTASSIUM CHLORIDE 10 MEQ/L	168675
Y	D5-NS WITH POTASSIUM CHLORIDE 30 MEQ/L	168685
Y	D5W WITH KCL 30 MEQ	200012
Y	D5W WITH POTASSIUM CL 10 MEQ/L	168676
Y	D5W WITH POTASSIUM CL 20 MEQ/L	168686
Y	D5W WITH POTASSIUM CL 30 MEQ/L	168687
Y	D5W WITH POTASSIUM CL 40 MEQ/L	168688
Y	DABIGATRAN ETEXILATE 110 MG CAPSULE	216754
Y	DABIGATRAN ETEXILATE 75 MG CAPSULE	192550
Y	DACARBAZINE 200 MG INTRAVENOUS SOLUTION	2091
Y	DACARBAZINE IVPB	169794
Y	DANTROLENE 20 MG INFUSION	1000176
Y	DANTROLENE 20 MG INTRAVENOUS SOLUTION	77793
Y	DAPTOMYCIN 500 MG INTRAVENOUS SOLUTION	89527
Y	DAPTOMYCIN IVPB OR SYRINGE IMS TEMPLATE	1001650
Y	DAPTOMYCIN IVPB	1000079
Y	DAPTOMYCIN RF 50 MG/ML IV ADULT SYRINGE	1001726
Y	DARATUMUMAB 20 MG/ML INTRAVENOUS SOLUTION	216211
Y	DARATUMUMAB IVPB	1001323
Y	DAUNORUBICIN IV SYRINGE	168281
Y	DECITABINE 50 MG INTRAVENOUS SOLUTION	95883
Y	DECITABINE IVPB	1000326
Y	DEFEROXAMINE 500 MG SOLUTION FOR INJECTION	9723
Y	DEFEROXAMINE IVPB	1000890
Y	DENOSUMAB 120 MG/1.7 ML (70 MG/ML) SUBCUTANEOUS SOLUTION	192651
Y	DENOSUMAB 60 MG/ML SUBCUTANEOUS SYRINGE	190284

Y	DESMOPRESSIN 0.1 MG/ML (REFRIGERATE) NASAL SOLUTION	70761
Y	DESMOPRESSIN 4 MCG/ML INJECTION SOLUTION	9748
Y	DESMOPRESSIN IVPB	1000038
Y	DESOGESTREL 0.15 MG-ETHINYL ESTRADIOL 0.03 MG TABLET	77375
Y	DEXAMETHASONE 1 MG TABLET	2324
Y	DEXAMETHASONE 1 MG/ML DROPS (CONCENTRATE)	79206
Y	DEXAMETHASONE 4 MG TABLET	2327
Y	DEXAMETHASONE INJECTION IMS TEMPLATE	1000847
Y	DEXAMETHASONE IVPB IMS TEMPLATE	1001110
Y	DEXAMETHASONE IVPB	1001634
Y	DEXAMETHASONE SODIUM PHOSPHATE (PF) 10 MG/ML INJECTION SOLUTION	167314
Y	DEXAMETHASONE SODIUM PHOSPHATE 0.1 % EYE DROPS	2335
Y	DEXAMETHASONE SODIUM PHOSPHATE 4 MG/ML INJECTION SOLUTION	2332
Y	DEXMEDETOMIDINE 100 MCG/ML INTRAVENOUS SOLUTION	80843
Y	DEXMEDETOMIDINE 4 MCG/ML INFUSION	1001311
Y	DEXMEDETOMIDINE 400 MCG/100 ML (4 MCG/ML) IN 0.9 % SODIUM CHLORIDE IV	205086
Y	DEXMEDETOMIDINE INFUSION IMS TEMPLATE	1001293
Y	DEXRAZOXANE HCL (FOR EXTRAVASATION) 500 MG INTRAVENOUS SOLUTION	223616
Y	DEXRAZOXANE HCL 250 MG INTRAVENOUS SOLUTION	15156
Y	DEXRAZOXANE HCL 500 MG INTRAVENOUS SOLUTION	15157
Y	DEXRAZOXANE IVPB	1000332
Y	DEXRAZOXANE(ZINECARD) IVPB	1000867
Y	DEXTRAN 70-HYPROMELLOSE 0.1 %-0.3 % EYE DROPS	194930
Y	DEXTROMETHORPHAN-GUAIFENESIN 10 MG-100 MG/5 ML IMS TEMPLATE	1000853
Y	DEXTROMETHORPHAN-GUAIFENESIN 10 MG-100 MG/5 ML ORAL SYRUP	15816
Y	DEXTROSE 10 % IN WATER (D10W) INTRAVENOUS SOLUTION	86281
Y	DEXTROSE 10% BOLUS IV	300434
Y	DEXTROSE 25 % IN WATER (D25W) INTRAVENOUS SYRINGE	2361
Y	DEXTROSE 40 % ORAL GEL	78384
Y	DEXTROSE 5 % AND 0.2 % SODIUM CHLORIDE INTRAVENOUS SOLUTION	15863
Y	DEXTROSE 5 % AND 0.45 % SODIUM CHLORIDE INTRAVENOUS SOLUTION	15861
Y	DEXTROSE 5 % AND 0.9 % SODIUM CHLORIDE INTRAVENOUS SOLUTION	15882
Y	DEXTROSE 5 % AND LACTATED RINGERS INTRAVENOUS SOLUTION	9788
Y	DEXTROSE 5 % IN WATER (D5W) INTRAVENOUS PIGGYBACK	95166
Y	DEXTROSE 5 % IN WATER (D5W) INTRAVENOUS SOLUTION	129286
Y	DEXTROSE 5 % IN WATER (D5W) IV PVC FREE	301249
Y	DEXTROSE 5%-NACL 0.45% BOLUS IV	300068
Y	DEXTROSE 50 % IN WATER (D50W) INTRAVENOUS SYRINGE	2365
Y	DEXTROSE 70 % IN WATER (D70W) INTRAVENOUS SOLUTION	2367
Y	DEXTROSE INJECTION IMS TEMPLATE	301425
Y	DIATRIZOATE MEGLUMINE-DIATRIZOATE SODIUM 66 %-10 % ORAL SOLUTION	77945
Y	DIAZEPAM 5 MG TABLET	2405
Y	DICLOFENAC 0.1 % EYE DROPS	80546
Y	DICLOFENAC SODIUM 50 MG TABLET,DELAYED RELEASE	15340
Y	DICLOXACILLIN 250 MG CAPSULE	2414
Y	DICYCLOMINE 20 MG TABLET	2420
Y	DIGOXIN 125 MCG (0.125 MG) TABLET	2444
Y	DIGOXIN 250 MCG/ML (0.25 MG/ML) INJECTION SOLUTION	2442
Y	DIHYDROERGOTAMINE 1 MG/ML INJECTION SOLUTION	9859
Y	DILTIAZEM 1 MG/ML INFUSION (RX IVPB)	1001316

Y	DILTIAZEM 30 MG TABLET	2475
Y	DILTIAZEM 5 MG/ML INTRAVENOUS SOLUTION	9869
Y	DILTIAZEM CD 120 MG CAPSULE,EXTENDED RELEASE 24 HR	29270
Y	DILTIAZEM CD 180 MG CAPSULE,EXTENDED RELEASE 24 HR	29272
Y	DILTIAZEM ER 60 MG CAPSULE,EXTENDED RELEASE 12 HR	14100
Y	DILTIAZEM INFUSION IMS TEMPLATE	1001298
Y	DIMETHYL SULFOXIDE 50 % INTRAVESICAL SOLUTION	179911
Y	DINOPROSTONE ER 10 MG VAGINAL INSERT,CONTROLLED RELEASE	81063
Y	DIPHENHYDRAMINE 12.5 MG/5 ML ORAL ELIXIR	2511
Y	DIPHENHYDRAMINE 12.5 MG/5 ML ORAL LIQUID	12556
Y	DIPHENHYDRAMINE 25 MG TABLET	2513
Y	DIPHENHYDRAMINE 50 MG/ML INJECTION SOLUTION	2508
Y	DIPHENHYDRAMINE INJECTION IMS TEMPLATE BEACON	1001091
Y	DIPHENHYDRAMINE INJECTION IMS TEMPLATE	1001587
Y	DIPHENHYDRAMINE-LIDOCAINE VISCOUS-ANTACID ORAL SUSPENSION COMPOUND	1001476
Y	DIPHENHYDRAMINE-ZINC ACETATE 2 %-0.1 % TOPICAL CREAM	79442
Y	DIPHENOXYLATE-ATROPINE 2.5 MG-0.025 MG TABLET	2516
Y	DIPHTH,PERTUS(AC)TETANUS VAC(PF) (TDAP) IMS TEMPLATE	1000827
Y	DIPHTH,PERTUSSIS(ACEL),TETANUS 2.5 LF UNIT-8 MCG-5 LF/0.5ML IM SYRINGE	94540
Y	DIPHTH,PERTUSSIS(ACELL),TETANUS 2.5 LF UNIT-8 MCG-5 LF/0.5 ML IM SUSP	94541
Y	DIPYRIDAMOLE 25 MG TABLET	2528
Y	DIVALPROEX 125 MG TABLET,DELAYED RELEASE	80913
Y	DIVALPROEX 250 MG TABLET,DELAYED RELEASE	77658
Y	DIVALPROEX ER 250 MG TABLET,EXTENDED RELEASE 24 HR	86975
Y	DIVALPROEX ER 500 MG TABLET,EXTENDED RELEASE 24 HR	80756
Y	DOBUTAMINE 250 MG/20 ML (12.5 MG/ML) INTRAVENOUS SOLUTION	180420
Y	DOBUTAMINE 500 MG/250 ML (2,000 MCG/ML) IN 5 % DEXTROSE IV	15980
Y	DOBUTAMINE INFUSION IMS TEMPLATE	1001297
Y	DOCETAXEL 80 MG/8 ML (10 MG/ML) INTRAVENOUS SOLUTION	193952
Y	DOCETAXEL IVPB (USE 20 MG/ML VIAL)	169807
Y	DOCOSANOL 10 % TOPICAL CREAM	77155
Y	DOCUSATE CALCIUM 240 MG CAPSULE	2565
Y	DOCUSATE SODIUM 100 MG CAPSULE	2566
Y	DOCUSATE SODIUM 50 MG/5 ML ORAL LIQUID	2569
Y	DONEPEZIL 10 MG TABLET	78165
Y	DOPAMINE 200 MG/5 ML (40 MG/ML) INTRAVENOUS SOLUTION	180426
Y	DOPAMINE 800 MG/500 ML (1,600 MCG/ML) IN 5 % DEXTROSE INTRAVENOUS SOLN	180432
Y	DOPAMINE INFUSION IMS TEMPLATE	1001296
Y	DORZOLAMIDE 2 % EYE DROPS	82928
Y	DOXAPRAM 20 MG/ML INTRAVENOUS SOLUTION	2607
Y	DOXAZOSIN 2 MG TABLET	9895
Y	DOXEPIN 25 MG CAPSULE	2611
Y	DOXORUBICIN 2 MG/ML INTRAVENOUS SOLUTION	2616
Y	DOXORUBICIN IVPB	169791
Y	DOXORUBICIN LIPOSOMAL IVPB	1000342
Y	DOXYCYCLINE 100 MG IN 100 ML DISPENSABLE (MBP ADS)	5000068
Y	DOXYCYCLINE 200 MG DISPENSABLE (CUSTOM RX IVPB)	168625
Y	DOXYCYCLINE HYCLATE 100 MG CAPSULE	2623
Y	DOXYCYCLINE HYCLATE 100 MG INTRAVENOUS POWDER FOR SOLUTION	2622
Y	DOXYCYCLINE HYCLATE 100 MG TABLET	2625

Y	DOXYCYCLINE IVPB IMS TEMPLATE	5000036
Y	DOXYLAMINE SUCCINATE 25 MG TABLET	81957
Y	DRONABINOL 2.5 MG CAPSULE	79549
Y	DRONEDARONE 400 MG TABLET	182505
Y	DULOXETINE 20 MG CAPSULE,DELAYED RELEASE	93423
Y	DULOXETINE 30 MG CAPSULE,DELAYED RELEASE	93424
Y	DUTASTERIDE 0.5 MG CAPSULE	86901
Y	EDROPHONIUM CHLORIDE 10 MG/ML INJECTION SOLUTION	9917
Y	ELOTUZUMAB 300 MG INTRAVENOUS SOLUTION	216459
Y	ELOTUZUMAB 400 MG INTRAVENOUS SOLUTION	216460
Y	ELOTUZUMAB IVPB	1001363
Y	EMPTY CONTAINER, PLASTIC BAG 100 ML	89405
Y	EMPTY CONTAINER, STERILE	301838
Y	ENALAPRIL MALEATE 10 MG TABLET	9924
Y	ENALAPRIL MALEATE 2.5 MG TABLET	9925
Y	ENALAPRIL MALEATE 20 MG TABLET	9926
Y	ENALAPRIL MALEATE 5 MG TABLET	9927
Y	ENALAPRILAT 1.25 MG/ML INTRAVENOUS SOLUTION	9929
Y	ENOXAPARIN 100 MG/ML SUBCUTANEOUS SYRINGE	85051
Y	ENOXAPARIN 30 MG/0.3 ML SUBCUTANEOUS SYRINGE	85048
Y	ENOXAPARIN 40 MG/0.4 ML SUBCUTANEOUS SYRINGE	85052
Y	ENOXAPARIN 60 MG/0.6 ML SUBCUTANEOUS SYRINGE	85049
Y	ENOXAPARIN CONSULT TO PHARMACY	168283
Y	ENOXAPARIN IMS TEMPLATE	1001390
Y	EPHEDRINE (PF) 50 MG/10 ML (5 MG/ML) IN 0.9 % SOD.CHLORIDE IV SYRINGE	178480
Y	EPHEDRINE SULFATE 50 MG/ML INJECTION SOLUTION	2833
Y	EPINEPHRINE 0.1 MG/ML INJECTION SYRINGE	2848
Y	EPINEPHRINE 0.3 MG/0.3 ML INJECTION, AUTO-INJECTOR	82015
Y	EPINEPHRINE 1 MG/ML (1 ML) INJECTION SOLUTION	194750
Y	EPINEPHRINE 1 MG/ML INJECTION IMS TEMPLATE	1000914
Y	EPINEPHRINE 1 MG/ML INJECTION SOLUTION	2850
Y	EPINEPHRINE HCL (PF) 1 MG/ML (1 ML) INJECTION SOLUTION	167249
Y	EPINEPHRINE INFUSION IMS TEMPLATE	1001292
Y	EPINEPHRINE INFUSION	1001310
Y	EPIRUBICIN 50 MG/25 ML INTRAVENOUS SOLUTION	178735
Y	EPIRUBICIN IVPB	1000333
Y	EPLERENONE 25 MG TABLET	86804
Y	EPOETIN ALFA 20,000 UNIT/ML INJECTION SOLUTION	79874
Y	EPTIFIBATIDE 0.75 MG/ML INTRAVENOUS SOLUTION	81007
Y	EPTIFIBATIDE 2 MG/ML INTRAVENOUS SOLUTION	77166
Y	ERGOCALCIFEROL (VITAMIN D2) 1,250 MCG (50,000 UNIT) CAPSULE	81876
Y	ERGOCALCIFEROL (VITAMIN D2) 200 MCG/ML (8,000 UNIT/ML) ORAL DROPS	83031
Y	ERIBULIN 1 MG/2 ML (0.5 MG/ML) INTRAVENOUS SOLUTION	301012
Y	ERIBULIN IVPB	1001088
Y	ERTAPENEM 1 GRAM SOLUTION FOR INJECTION	83077
Y	ERTAPENEM 1000 MG IN 50 ML DISPENSABLE (ADV ADS)	5000069
Y	ERTAPENEM 1000 MG IN 50 ML SODIUM CHLORIDE 0.9% DISPENSABLE (ADS)	5000198
Y	ERTAPENEM 1000 MG IN 50 ML SODIUM CHLORIDE 0.9% DISPENSABLE (ADV CMX)	5000238
Y	ERTAPENEM 1000 MG IN 50 ML SODIUM CHLORIDE 0.9% DISPENSABLE (CMX)	5000196
Y	ERTAPENEM 1000 MG IN 50 ML SODIUM CHLORIDE 0.9% DISPENSABLE (MBP ADS)	5000197

Y	ERTAPENEM 1000 MG IN 50 ML SODIUM CHLORIDE 0.9% DISPENSABLE (MBP CMX)	5000195
Y	ERTAPENEM DISPENSABLE (CUSTOM RX IVPB)	5000199
Y	ERTAPENEM IVPB IMS TEMPLATE	5000037
Y	ERYTHROMYCIN 100 ML DISPENSABLE (CUSTOM RX IVPB)	169215
Y	ERYTHROMYCIN 250 ML DISPENSABLE (CUSTOM RX IVPB)	169216
Y	ERYTHROMYCIN 5 MG/GRAM (0.5 %) EYE OINTMENT	2888
Y	ERYTHROMYCIN 500 MG IN 100 ML DISPENSABLE (ADV ADS)	5000070
Y	ERYTHROMYCIN 500 MG IN 100 ML SODIUM CHLORIDE 0.9% DISPENSABLE (ADV CMX)	5000246
Y	ERYTHROMYCIN 500 MG IN 100 ML SODIUM CHLORIDE 0.9% DISPENSABLE (MBP ADS)	5000259
Y	ERYTHROMYCIN ETHYLSUCCINATE 200 MG/5 ML ORAL POWDER FOR SUSPENSION	80736
Y	ERYTHROMYCIN IVPB IMS TEMPLATE	1001117
Y	ERYTHROMYCIN LACTOBIONATE 500 MG INTRAVENOUS SOLUTION	70561
Y	ESCITALOPRAM 10 MG TABLET	86689
Y	ESCITALOPRAM 20 MG TABLET	86690
Y	ESMOLOL 100 MG/10 ML (10 MG/ML) INTRAVENOUS SOLUTION	9957
Y	ESMOLOL 2,500 MG/250 ML (10 MG/ML) IN SODIUM CHLORIDE (ISO-OSMOTIC) IV	78326
Y	ESTRADIOL 0.05 MG/24 HR WEEKLY TRANSDERMAL PATCH	28408
Y	ESTRADIOL 0.5 MG TABLET	12491
Y	ETHACRYNATE SODIUM 50 MG INTRAVENOUS SOLUTION	78005
Y	ETHACRYNATE SODIUM IVPB	1000775
Y	ETHACRYNIC ACID 25 MG TABLET	78392
Y	ETHAMBUTOL 400 MG TABLET	9983
Y	ETHANOL (ETHYL ALCOHOL) 98 % INJECTION SOLUTION	257
Y	ETHYL CHLORIDE 100 % TOPICAL SPRAY	168333
Y	ETOMIDATE 2 MG/ML INTRAVENOUS SOLUTION	20472
Y	ETOPOSIDE 20 MG/ML INTRAVENOUS SOLUTION	10000
Y	ETOPOSIDE IVPB	169798
Y	ETOPOSIDE VINCISTINE AND DOXORUBICIN IV INFUSION	1001017
Y	EZETIMIBE 10 MG TABLET	86887
Y	FACTOR XA,INACTIVATED-ZHZO (RECOMBINANT) 100 MG INTRAVENOUS SOLUTION	225802
Y	FAMCICLOVIR 250 MG TABLET	79839
Y	FAMOTIDINE (PF) 20 MG/2 ML INTRAVENOUS SOLUTION	177144
Y	FAMOTIDINE 20 MG TABLET	10011
Y	FAMOTIDINE 20MG IVPB	168627
Y	FAMOTIDINE INJECTION IMS TEMPLATE BEACON	1001043
Y	FAT EMULSION 20 % INTRAVENOUS	77557
Y	FELODIPINE ER 2.5 MG TABLET,EXTENDED RELEASE 24 HR	27489
Y	FENOFIBRATE NANOCRYSTALLIZED 145 MG TABLET	129642
Y	FENOFIBRATE NANOCRYSTALLIZED 48 MG TABLET	129641
Y	FENTANYL (PF) 2 MCG/ML-BUPIVACAINE 0.125 %-NACL INJECTION SOLUTION	30862
Y	FENTANYL (PF) 2 MCG/ML-BUPIVACAINE 0.125%-NACL PCEA - TFH	301663
Y	FENTANYL (PF) 50 MCG/ML INJECTION SOLUTION	3037
Y	FENTANYL 100 MCG/HR TRANSDERMAL PATCH	27908
Y	FENTANYL 12 MCG/HR TRANSDERMAL PATCH	94562
Y	FENTANYL 25 MCG/HR TRANSDERMAL PATCH	27905
Y	FENTANYL 50 MCG/HR TRANSDERMAL PATCH	27906
Y	FENTANYL 50 MCG/ML INFUSION SO	301672
Y	FENTANYL 50 MCG/ML INFUSION	1001313
Y	FENTANYL 75 MCG/HR TRANSDERMAL PATCH	27907
Y	FENTANYL INFUSION IMS TEMPLATE	1001295



Y	FENTANYL INJECTION IMS TEMPLATE	1000903
Y	FERROUS GLUCONATE 324 MG (37.5 MG IRON) TABLET	195865
Y	FERROUS SULFATE 15 MG IRON (75 MG)/ML ORAL DROPS	180485
Y	FERROUS SULFATE 220 MG (44 MG IRON)/5 ML ORAL ELIXIR	219111
Y	FERROUS SULFATE 325 MG (65 MG IRON) TABLET	3074
Y	FEXOFENADINE 60 MG TABLET	21529
Y	FIDAXOMICIN 200 MG TABLET	194895
Y	FILGRASTIM-SNDZ 300 MCG/0.5 ML INJECTION SYRINGE	213478
Y	FILGRASTIM-SNDZ 480 MCG/0.8 ML INJECTION SYRINGE	213477
Y	FINASTERIDE 5 MG TABLET	82679
Y	FLECAINIDE 100 MG TABLET	10041
Y	FLU VACCINE IM IMS TEMPLATE	1001301
Y	FLUCONAZOLE 10 MG/ML ORAL SUSPENSION	14232
Y	FLUCONAZOLE 100 MG TABLET	10044
Y	FLUCONAZOLE 200 MG/100 ML IN SOD. CHLORIDE (ISO) INTRAVENOUS PIGGYBACK	10049
Y	FLUDARABINE 50 MG/2 ML INTRAVENOUS SOLUTION	41294
Y	FLUDROCORTISONE 0.1 MG TABLET	10054
Y	FLUMAZENIL 0.1 MG/ML INTRAVENOUS SOLUTION	10055
Y	FLUOCINONIDE 0.05 % TOPICAL CREAM	3187
Y	FLUORESCEIN 1 MG EYE STRIPS	79371
Y	FLUOROURACIL 2.5 GRAM/50 ML INTRAVENOUS SOLUTION	179234
Y	FLUOROURACIL 5 GRAM/100 ML INTRAVENOUS SOLUTION	179235
Y	FLUOROURACIL 500 MG/10 ML INTRAVENOUS SOLUTION	179232
Y	FLUOROURACIL INJECTABLE SYRINGE	169803
Y	FLUOROURACIL IV INFUSION	168312
Y	FLUOXETINE 10 MG CAPSULE	10069
Y	FLUOXETINE 20 MG CAPSULE	10070
Y	FLUOXETINE 20 MG/5 ML (4 MG/ML) ORAL SOLUTION	38488
Y	FLUPHENAZINE 5 MG TABLET	3221
Y	FLUTICASONE 100 MCG-SALMETEROL 50 MCG/DOSE BLISTR POWDR FOR INHALATION	82024
Y	FLUTICASONE 250 MCG-SALMETEROL 50 MCG/DOSE BLISTR POWDR FOR INHALATION	77229
Y	FLUTICASONE 500 MCG-SALMETEROL 50 MCG/DOSE BLISTR POWDR FOR INHALATION	80865
Y	FLUTICASONE PROPIONATE 110 MCG/ACTUATION HFA AEROSOL INHALER	82789
Y	FLUTICASONE PROPIONATE 220 MCG/ACTUATION HFA AEROSOL INHALER	81707
Y	FLUTICASONE PROPIONATE 44 MCG/ACTUATION HFA AEROSOL INHALER	80862
Y	FLUTICASONE PROPIONATE 50 MCG/ACTUATION NASAL SPRAY,SUSPENSION	70536
Y	FOLIC ACID 1 MG TABLET	3233
Y	FOLIC ACID 5 MG/ML INJECTION SOLUTION	3232
Y	FOSCARNET 24 MG/ML INTRAVENOUS SOLUTION	10093
Y	FOSCAVIR IVPB	1000436
Y	FOSFOMYCIN TROMETHAMINE 3 GRAM ORAL PACKET	77811
Y	FOSPHENYTOIN 100 MG PE/2 ML INJECTION SOLUTION	178099
Y	FOSPHENYTOIN 500 MG PE/10 ML INJECTION SOLUTION	178100
Y	FOSPHENYTOIN IN 100 ML IVPB LOADING DOSE DISPENSABLE	1001361
Y	FOSPHENYTOIN IN 50 ML IVPB LOADING DOSE DISPENSABLE	1001360
Y	FOSPHENYTOIN IVPB LOADING DOSE IMS TEMPLATE	1001362
Y	FOSPHENYTOIN IVPB LOADING DOSE	169239
Y	FULVESTRANT 250 MG/5 ML INTRAMUSCULAR SYRINGE	84985
Y	FUROSEMIDE 10 MG/ML INJECTION SOLUTION	3291
Y	FUROSEMIDE 10 MG/ML ORAL SOLUTION	3292

Y	FUROSEMIDE 20 MG TABLET	3294
Y	FUROSEMIDE 40 MG TABLET	3295
Y	FUROSEMIDE IV INFUSION	177366
Y	GABAPENTIN 100 MG CAPSULE	18309
Y	GABAPENTIN 300 MG CAPSULE	18308
Y	GABAPENTIN 400 MG CAPSULE	18307
Y	GADOVERSETAMIDE 10 MMOL/20 ML (330.9 MG/ML) INTRAVENOUS SOLUTION	94161
Y	GADOVERSETAMIDE 10 MMOL/20 ML (330.9 MG/ML) INTRAVENOUS SYRINGE	94136
Y	GADOVERSETAMIDE 2.5 MMOL/5 ML (330.9 MG/ML) INTRAVENOUS SOLUTION	94158
Y	GADOVERSETAMIDE 7.5 MMOL/15 ML (330.9 MG/ML) INTRAVENOUS SOLUTION	94160
Y	GADOVERSETAMIDE 7.5 MMOL/15 ML(330.9 MG/ML) INTRAVENOUS SYRINGE	94137
Y	GADOXETATE 0.25 MMOL/ML (181.43 MG/ML) INTRAVENOUS SOLUTION	179665
Y	GANCICLOVIR IVPB	1000437
Y	GELATIN ABSORBABLE MUCOSAL POWDER	78575
Y	GELATIN SPONGE,ABSORBABLE-PORCINE SKIN 12 MM-7 MM TOPICAL SPONGE	81887
Y	GELATIN SPONGE,ABSORBABLE-PORCINE SKIN 50 TOPICAL SPONGE	81361
Y	GEMCITABINE 1 GRAM INTRAVENOUS SOLUTION	80550
Y	GEMCITABINE 1 GRAM/26.3 ML (38 MG/ML) INTRAVENOUS SOLUTION	196826
Y	GEMCITABINE 2 GRAM/52.6 ML (38 MG/ML) INTRAVENOUS SOLUTION	196827
Y	GEMCITABINE 200 MG/5.26 ML (38 MG/ML) INTRAVENOUS SOLUTION	196828
Y	GEMCITABINE IVPB	169819
Y	GEMFIBROZIL 600 MG TABLET	3378
Y	GENTAMICIN (PEDIATRIC) 10 MG/ML INJECTION SO	300501
Y	GENTAMICIN 0.1 % TOPICAL CREAM	3423
Y	GENTAMICIN 0.3 % (3 MG/GRAM) EYE OINTMENT	3427
Y	GENTAMICIN 0.3 % EYE DROPS	3428
Y	GENTAMICIN 100 MG IN 100 ML SODIUM CHLORIDE ISO-OSMOTIC IVPB (PREMIX)	167255
Y	GENTAMICIN 40 MG/ML INJECTION SOLUTION	3426
Y	GENTAMICIN 80 MG IN 100 ML SODIUM CHLORIDE ISO-OSMOTIC IVPB (PREMIX)	167253
Y	GENTAMICIN CONSULT TO PHARMACY	168285
Y	GENTAMICIN EXTENDED INTERVAL (CUSTOM RX IVPB)	1000834
Y	GENTAMICIN EXTENDED INTERVAL IVPB IMS TEMPLATE	5000039
Y	GENTAMICIN PEDIATRIC 3 ML SYRINGE	1001467
Y	GENTAMICIN PEDIATRIC IV SYRINGE	168628
Y	GENTAMICIN SULFATE (PEDIATRIC) (PF) 20 MG/2 ML INJECTION SOLUTION	176446
Y	GENTAMICIN TRADITIONAL DOSE IVPB IMS TEMPLATE	5000038
Y	GENTAMICIN TRADITIONAL DOSING (CUSTOM RX IVPB)	168634
Y	GI COCKTAIL (MAALOX 30ML + LIDOCAINE 2% 10ML) COMPOUND	301561
Y	GLIMEPIRIDE 4 MG TABLET	16357
Y	GLIPIZIDE 5 MG TABLET	10117
Y	GLIPIZIDE ER 2.5 MG TABLET, EXTENDED RELEASE 24 HR	37648
Y	GLIPIZIDE ER 5 MG TABLET, EXTENDED RELEASE 24 HR	37649
Y	GLUCAGON (HUMAN RECOMBINANT) 1 MG/ML SOLUTION FOR INJECTION	191406
Y	GLUCAGON 1 MG INJECTION IMS TEMPLATE	1000884
Y	GLYBURIDE 5 MG TABLET	3489
Y	GLYCERIN (ADULT) RECTAL SUPPOSITORY	15053
Y	GLYCERIN (CHILD) RECTAL SUPPOSITORY	3492
Y	GLYCOPYRROLATE 0.2 MG/ML IMS TEMPLATE	1001364
Y	GLYCOPYRROLATE 0.2 MG/ML INJECTION SOLUTION	3497
Y	GLYCOPYRROLATE 2 MG TABLET	10131

Y	GOSERELIN 10.8 MG SUBCUTANEOUS IMPLANT	78460
Y	GOSERELIN 3.6 MG SUBCUTANEOUS IMPLANT	77749
Y	GUAIFENESIN 100 MG/5 ML ORAL LIQUID	79220
Y	GUAIFENESIN ER 600 MG TABLET, EXTENDED RELEASE 12 HR	209658
Y	GUAIFENESIN EXTENDED RELEASE 600 MG TABLET IMS TEMPLATE	1001159
Y	HAEMOPH B POLYSAC CONJ-MENING (PF) 7.5 MCG/0.5 ML INTRAMUSCULAR SOLN	178095
Y	HAEMOPHILUS B POLYSACCHARID CONJ-TETANUS TOX(PF) 10 MCG/0.5 ML IM SOLN	177957
Y	HALOPERIDOL 1 MG TABLET	3579
Y	HALOPERIDOL 5 MG TABLET	3583
Y	HALOPERIDOL LACTATE 2 MG/ML ORAL CONCENTRATE	3585
Y	HALOPERIDOL LACTATE 5 MG/ML INJECTION SOLUTION	3584
Y	HEPARIN (PORCINE) 1,000 UNIT/ML INJECTION SOLUTION	10176
Y	HEPARIN (PORCINE) 10,000 UNIT/ML INJECTION SOLUTION	10177
Y	HEPARIN (PORCINE) 25,000 UNIT/250 ML IN 0.45 % SODIUM CHLORIDE IV SOLN	15849
Y	HEPARIN (PORCINE) 5,000 UNIT/ML INJECTION SOLUTION	10181
Y	HEPARIN 100 UNIT/ML INFUSION IMS TEMPLATE	1001698
Y	HEPARIN INJECTION IMS TEMPLATE	1000843
Y	HEPARIN, PORCINE (PF) 10 UNIT/ML INTRAVENOUS SYRINGE	19548
Y	HEPARIN, PORCINE (PF) 100 UNIT/ML INTRAVENOUS SYRINGE	17362
Y	HEPATITIS A VACCINE (PF) 1,440 ELISA UNIT/ML INTRAMUSCULAR SYRINGE	168732
Y	HEPATITIS B IMMUNE GLOBULIN > 1,560 UNIT/5 ML INTRAMUSCULAR SOLUTION	168007
Y	HEPATITIS B IMMUNE GLOBULIN IM IMS TEMPLATE	1001430
Y	HEPATITIS B VIRUS VACCINE PEDIATRIC IMS TEMPLATE	1001500
Y	HEPATITIS B VIRUS VACCINE RECOMB (PF) 10 MCG/0.5 ML IM SYRINGE	168401
Y	HEPATITIS B VIRUS VACCINE RECOMB (PF) 20 MCG/ML INTRAMUSCULAR SYRINGE	167799
Y	HETASTARCH 6 % IN 0.9 % SODIUM CHLORIDE INTRAVENOUS SOLUTION	25174
Y	HIGH RISK MEDICATION CONSULT TO PHARMACY	301159
Y	HOMATROPINE 5 % EYE DROPS	3664
Y	HUM PROTHROMBIN CPLX(PCC)4FACT 1,000 UNIT (800-1,240 UNIT) IV SOLUTION	210181
Y	HYDRALAZINE 10 MG TABLET	3698
Y	HYDRALAZINE 100 MG TABLET	3699
Y	HYDRALAZINE 20 MG/ML INJECTION SOLUTION	3697
Y	HYDRALAZINE 25 MG TABLET	3700
Y	HYDROCHLOROTHIAZIDE 25 MG TABLET	3720
Y	HYDROCODONE 10 MG-ACETAMINOPHEN 325 MG TABLET	28384
Y	HYDROCODONE 5 MG-ACETAMINOPHEN 325 MG TABLET	34505
Y	HYDROCODONE 7.5 MG-ACETAMINOPHEN 325 MG TABLET	34544
Y	HYDROCODONE 7.5 MG-ACETAMINOPHEN 325 MG/15 ML ORAL SOLUTION	89859
Y	HYDROCODONE-ACETAMINOPHEN ORAL SOLUTION IMS TEMPLATE	1000846
Y	HYDROCORTISONE 10 MG TABLET	81877
Y	HYDROCORTISONE 2.5 % TOPICAL CREAM WITH PERINEAL APPLICATOR	28824
Y	HYDROCORTISONE 2.5 % TOPICAL CREAM	3727
Y	HYDROCORTISONE ACETATE 25 MG RECTAL SUPPOSITORY	3738
Y	HYDROCORTISONE SOD SUCCINATE (PF) 1,000 MG/8 ML SOLUTION FOR INJECTION	189765
Y	HYDROCORTISONE SOD SUCCINATE (PF) 100 MG/2 ML SOLUTION FOR INJECTION	189764
Y	HYDROCORTISONE SOD SUCCINATE (PF) 250 MG/2 ML SOLUTION FOR INJECTION	189763
Y	HYDROCORTISONE SODIUM SUCCINATE (PF) INJ IMS TEMPLATE	1000723
Y	HYDROCORTISONE-ALOE VERA 1 % TOPICAL CREAM	14190
Y	HYDROMORPHONE (PF) 1 MG/ML IN 0.9 % SODIUM CHLORIDE INTRAVENOUS SOLN	224836
Y	HYDROMORPHONE 0.5 MG/0.5 ML INJECTION SYRINGE	205837

Y	HYDROMORPHONE 1 MG/ML BOLUS FROM PCA SYRINGE	301209
Y	HYDROMORPHONE 1 MG/ML INJECTION SYRINGE	86499
Y	HYDROMORPHONE 1 MG/ML PCA ADULT HIGH TOLERANCE	301583
Y	HYDROMORPHONE 1 MG/ML PCA ADULT LOW TOLERANCE	301581
Y	HYDROMORPHONE 1 MG/ML PCA ADULT MODERATE TOLERANCE	301582
Y	HYDROMORPHONE 1 MG/ML PCA ADULT OPIOID NAÏVE	301580
Y	HYDROMORPHONE 2 MG TABLET	3760
Y	HYDROMORPHONE 2 MG/ML INJECTION SOLUTION	3758
Y	HYDROMORPHONE 50 MG/50 ML IN 0.9 % SODIUM CHLORIDE INJECTION	30795
Y	HYDROMORPHONE INJECTION IMS TEMPLATE	1000840
Y	HYDROXYCHLOROQUINE 200 MG TABLET	10235
Y	HYDROXYUREA 500 MG CAPSULE	10236
Y	HYDROXYZINE HCL 50 MG/ML INTRAMUSCULAR SOLUTION	3770
Y	HYDROXYZINE PAMOATE 25 MG CAPSULE	3777
Y	HYOSCYAMINE 0.125 MG SUBLINGUAL TABLET	17023
Y	HYPROMELLOSE 2.5 % EYE DROPS	38092
Y	IBUPROFEN 100 MG/5 ML ORAL SUSPENSION	10246
Y	IBUPROFEN 200 MG TABLET	3841
Y	IBUPROFEN 600 MG TABLET	3844
Y	IBUPROFEN 800 MG TABLET	3845
Y	IBUTILIDE FUMARATE 0.1 MG/ML INTRAVENOUS SOLUTION	82238
Y	IDARUCIZUMAB 2.5 GRAM/50 ML INTRAVENOUS SOLUTION	215667
Y	IFOSFAMIDE 1 GRAM INTRAVENOUS SOLUTION	10248
Y	IFOSFAMIDE 3 GRAM INTRAVENOUS SOLUTION	10249
Y	IFOSFAMIDE AND MESNA IV INFUSION	169814
Y	IFOSFAMIDE IVPB	1000343
Y	IMIPENEM-CILASTATIN 250 ML DISPENSABLE (CUSTOM RX IVPB)	177373
Y	IMIPENEM-CILASTATIN 500 MG IN 100 ML DISPENSABLE (MBP ADS)	5000260
Y	IMIPENEM-CILASTATIN 500 MG INTRAVENOUS SOLUTION	78056
Y	IMIPENEM-CILISTATIN IVPB IMS TEMPLATE	5000040
Y	IMIPRAMINE 10 MG TABLET	3860
Y	IMIPRAMINE 25 MG TABLET	3861
Y	IMMUNE GLOB G 20 GRAM/200 ML(10%)-GLY-IGA AVE 46 MCG/ML INJECTION SOLN	192864
Y	IMMUNE GLOB,GAMM(IGG) 10 %-PRO-IGA 0 TO 50 MCG/ML INTRAVENOUS SOLUTION	213967
Y	IMMUNE GLOB,GAMMA (IGG) 10 %-GLY-IGA OVER 50 MCG/ML INJECTION SOLUTION	213966
Y	IMMUNE GLOBU G 5 GRAM/50 ML(10 %-GLY-IGA AVE 46 MCG/ML INJECTION SOLN	192862
Y	IMMUNE GLOBULIN FOR IV ADMINISTRATION	301318
Y	INDAPAMIDE 2.5 MG TABLET	3879
Y	INDOMETHACIN 25 MG CAPSULE	3897
Y	INFANT FORMULA	301471
Y	INFLIXIMAB 100 MG INTRAVENOUS SOLUTION	80729
Y	INFLIXIMAB IVPB	1000369
Y	INSULIN 1 UNIT/ML INFUSION (ADULT TITRATION PROTOCOL)	1001561
Y	INSULIN 1 UNIT/ML INFUSION	1000530
Y	INSULIN DRIP (ICU)	168635
Y	INSULIN GLARGINE (U-100) 100 UNIT/ML SUBCUTANEOUS SOLUTION	77487
Y	INSULIN GLARGINE 100 UNITS/ML SO	300062
Y	INSULIN INFUSION (ADULT TITRATION PROTOCOL) IMS TEMPLATE	1001719
Y	INSULIN INFUSION CORRECTION BOLUS	301419
Y	INSULIN INFUSION IMS TEMPLATE	1001718

Y	INSULIN LISPRO (U-100) 100 UNIT/ML SUBCUTANEOUS SOLUTION	82002
Y	INSULIN LISPRO 100 UNIT/ML IMS TEMPLATE	1001337
Y	INSULIN LISPRO 100 UNITS/ML PUMP BASAL INFUSION	301515
Y	INSULIN LISPRO 100 UNITS/ML VARIABLE DOSE	300009
Y	INSULIN NPH ISOPHANE U-100 HUMAN 100 UNIT/ML SUBCUTANEOUS SUSPENSION	80983
Y	INSULIN NPH-REGULAR HUMAN INSULIN 100 UNIT/ML (70-30)SUBCUTANEOUS SUSP	78656
Y	INSULIN REGULAR 100 UNIT/ML PUMP BASAL INFUSION	301514
Y	INSULIN REGULAR 100 UNITS/ML SO	300061
Y	INSULIN REGULAR 100 UNITS/ML VARIABLE DOSE	300005
Y	INSULIN REGULAR ADULT ICU PROTOCOL ONE TIME	301006
Y	INSULIN U-100 REGULAR HUMAN 100 UNIT/ML INJECTION SOLUTION	80719
Y	INTERFERON ALFA-2B IVPB	169816
Y	IODIXANOL 320 MG IODINE/ML INTRAVENOUS SOLUTION	78198
Y	IOHEXOL 180 MG IODINE/ML INTRATHECAL SOLUTION	77784
Y	IOPAMIDOL 61 % INTRATHECAL SOLUTION	95403
Y	IOPAMIDOL 61 % INTRAVENOUS SOLUTION	77711
Y	IOTHALAMATE MEGLUMINE 17.2 % URETHRAL SOLUTION	78254
Y	IOTHALAMATE MEGLUMINE 60 % INJECTION SOLUTION	82181
Y	IOVERSOL 300 MG IODINE/ML INTRAVENOUS SOLUTION	88470
Y	IPILIMUMAB 200 MG/40 ML (5 MG/ML) INTRAVENOUS SOLUTION	194026
Y	IPILIMUMAB 50 MG/10 ML (5 MG/ML) INTRAVENOUS SOLUTION	194025
Y	IPILIMUMAB INFUSION	1000850
Y	IPRATROPIUM 0.5 MG-ALBUTEROL 3 MG (2.5 MG BASE)/3 ML NEBULIZATION SOLN	77459
Y	IPRATROPIUM 20 MCG-ALBUTEROL 100 MCG/ACTUATION MIST FOR INHALATION	211535
Y	IPRATROPIUM BROMIDE 0.02 % SOLUTION FOR INHALATION	12580
Y	IPRATROPIUM BROMIDE 17 MCG/ACTUATION HFA AEROSOL INHALER	94539
Y	IRBESARTAN 150 MG TABLET	81936
Y	IRINOTECAN 100 MG/5 ML INTRAVENOUS SOLUTION	177987
Y	IRINOTECAN 40 MG/2 ML INTRAVENOUS SOLUTION	177988
Y	IRINOTECAN IVPB	169804
Y	IRINOTECAN LIPOSOMAL 4.3 MG/ML INTRAVENOUS	215684
Y	IRON SUCROSE 100 MG IRON/5 ML INTRAVENOUS SOLUTION	80854
Y	IRON SUCROSE IN SODIUM CHLORIDE INFUSION	1000389
Y	IRON SUCROSE IVPB IMS TEMPLATE	1001653
Y	ISONIAZID 300 MG TABLET	4027
Y	ISOSORBIDE DINITRATE 10 MG TABLET	4064
Y	ISOSORBIDE MONONITRATE ER 30 MG TABLET,EXTENDED RELEASE 24 HR	24521
Y	ISOSULFAN BLUE 1 % SUBCUTANEOUS SOLUTION	80781
Y	IV FLUID WITH POTASSIUM	168300
Y	KETAMINE 10 MG/ML INJECTION SOLUTION	81264
Y	KETAMINE 100 MG/ML INJECTION SOLUTION	4237
Y	KETAMINE 2 MG/ML IN DEXTROSE 5% INFUSION (PREMIX)	301875
Y	KETOCONAZOLE 2 % TOPICAL CREAM	10368
Y	KETOCONAZOLE 200 MG TABLET	10369
Y	KETOROLAC 0.5 % EYE DROPS	79475
Y	KETOROLAC 15 MG/ML INJECTION	22472
Y	KETOROLAC 30 MG/ML (1 ML) INJECTION SOLUTION	22473
Y	KETOROLAC 60 MG/2 ML INTRAMUSCULAR SOLUTION	10370
Y	KETOROLAC INJECTION IMS TEMPLATE	170273
Y	LABETALOL 100 MG TABLET	10373

Y	LABELALOL 5 MG/ML INTRAVENOUS SOLUTION	10372
Y	LABELALOL INJECTION IMS TEMPLATE	1000739
Y	LABELALOL IV INFUSION	1000064
Y	LACOSAMIDE 100 MG TABLET	181216
Y	LACTATED RINGERS BOLUS IV	168292
Y	LACTATED RINGERS INTRAVENOUS SOLUTION	4318
Y	LACTATED RINGERS WITH POTASSIUM CHLORIDE 10 MEQ/L	168677
Y	LACTATED RINGERS WITH POTASSIUM CHLORIDE 20 MEQ/L	168689
Y	LACTATED RINGERS WITH POTASSIUM CHLORIDE 30 MEQ/L	168690
Y	LACTATED RINGERS WITH POTASSIUM CHLORIDE 40 MEQ/L	168691
Y	LACTOBACILLUS RHAMNOSUS GG 15 BILLION CELL SPRINKLE CAPSULE	205508
Y	LACTULOSE 10 GRAM/15 ML (15 ML) ORAL SOLUTION	197631
Y	LACTULOSE 10 GRAM/15 ML ORAL SOLUTION	93851
Y	LACTULOSE ORAL SOLUTION IMS TEMPLATE	1000904
Y	LAMOTRIGINE 100 MG TABLET	82659
Y	LAMOTRIGINE 25 MG TABLET	79386
Y	LANOLIN TOPICAL CREAM	37068
Y	LANOLIN TOPICAL IMS TEMPLATE	1000781
Y	LATANOPROST 0.005 % EYE DROPS	77052
Y	LEFLUNOMIDE 20 MG TABLET	23873
Y	LET GEL	300007
Y	LETROZOLE 2.5 MG TABLET	82126
Y	LEUCOVORIN CALCIUM 350 MG SOLUTION FOR INJECTION	4393
Y	LEUCOVORIN IVPB	169802
Y	LEUPROLIDE 22.5 MG (3 MONTH) SUBCUTANEOUS SYRINGE	86720
Y	LEUPROLIDE 3.75 MG (1 MONTH) INTRAMUSCULAR SYRINGE KIT	77466
Y	LEUPROLIDE 7.5 MG (1 MONTH) SUBCUTANEOUS SYRINGE	85015
Y	LEVALBUTEROL 0.63 MG/3 ML SOLUTION FOR NEBULIZATION	77821
Y	LEVALBUTEROL CONCENTRATE 1.25 MG/0.5 ML SOLUTION FOR NEBULIZATION	93411
Y	LEVETIRACETAM 500 MG TABLET	77943
Y	LEVETIRACETAM 500 MG/5 ML INTRAVENOUS SOLUTION	129855
Y	LEVETIRACETAM INFUSION IMS TEMPLATE	1000947
Y	LEVETIRACETAM IVPB	1000065
Y	LEVOCARNITINE 200 MG/ML INTRAVENOUS SOLUTION	20954
Y	LEVOFLOXACIN 25 MG/ML INTRAVENOUS SOLUTION	81918
Y	LEVOFLOXACIN 250 MG/50 ML IN 5 % DEXTROSE INTRAVENOUS PIGGYBACK	87856
Y	LEVOFLOXACIN 500 MG TABLET	82091
Y	LEVOFLOXACIN 500 MG/100 ML IN 5 % DEXTROSE INTRAVENOUS PIGGYBACK	87854
Y	LEVOFLOXACIN 750 MG/150 ML IN 5 % DEXTROSE INTRAVENOUS PIGGYBACK	87855
Y	LEVOFLOXACIN CUSTOM DOSE IVPB	1000862
Y	LEVOFLOXACIN IVPB IMS TEMPLATE	5000387
Y	LEVOFLOXACIN PEDIATRIC IVPB	1001464
Y	LEVOLEUCOVORIN CALCIUM 50 MG INTRAVENOUS POWDER FOR SOLUTION	180029
Y	LEVOLEUCOVORIN IVPB	1000920
Y	LEVONORGESTREL 1.5 MG TABLET	182584
Y	LEVOTHYROXINE 100 MCG INTRAVENOUS POWDER FOR SOLUTION	197553
Y	LEVOTHYROXINE 100 MCG TABLET	4423
Y	LEVOTHYROXINE 112 MCG TABLET	10404
Y	LEVOTHYROXINE 125 MCG TABLET	4424
Y	LEVOTHYROXINE 50 MCG TABLET	4421

Y	LEVOTHYROXINE 75 MCG TABLET	4422
Y	LEVOTHYROXINE 88 MCG TABLET	10403
Y	LIDOCAINE (PF) 10 MG/ML (1 %) INJECTION SOLUTION	95838
Y	LIDOCAINE (PF) 100 MG/5 ML (2 %) INTRAVENOUS SYRINGE	21378
Y	LIDOCAINE (PF) 20 MG/ML (2 %) INJECTION SOLUTION	95839
Y	LIDOCAINE (PF) 4 MG/ML (0.4 %) IN 5 % DEXTROSE INTRAVENOUS SOLUTION	95844
Y	LIDOCAINE (PF) 40 MG/ML (4 %) INJECTION SOLUTION	4455
Y	LIDOCAINE (PF) 5 MG/ML (0.5 %) INJECTION SOLUTION	95841
Y	LIDOCAINE 1 %-EPINEPHRINE 1:100,000 INJECTION SOLUTION	15955
Y	LIDOCAINE 1% INJECTION IMS TEMPLATE	1001714
Y	LIDOCAINE 2 % MUCOSAL JELLY IN APPLICATOR	179718
Y	LIDOCAINE 2% INJECTION IMS TEMPLATE	1001715
Y	LIDOCAINE 20 MG/ML (2 %-)EPINEPHRINE 1:100,000 INJECTION SOLUTION	15954
Y	LIDOCAINE 4 % TOPICAL CREAM	78453
Y	LIDOCAINE 4 %-EPINEPHRINE BITA 1:1,000-TETRACAINE 0.5 % TOP.SOLN(BULK)	203802
Y	LIDOCAINE 5 % TOPICAL OINTMENT	198988
Y	LIDOCAINE 5 % TOPICAL PATCH	80759
Y	LIDOCAINE HCL 10 MG/ML (1 %) INJECTION SOLUTION	4452
Y	LIDOCAINE HCL 2 % MUCOSAL JELLY	4448
Y	LIDOCAINE HCL 2 % MUCOSAL SOLUTION	81336
Y	LIDOCAINE HCL 20 MG/ML (2 %) INJECTION SOLUTION	4454
Y	LIDOCAINE HCL 4 % (40 MG/ML) MUCOSAL SOLUTION	4450
Y	LIDOCAINE PF 1% INJECTION IMS TEMPLATE	1001716
Y	LIDOCAINE PF 2% INJECTION IMS TEMPLATE	1001717
Y	LIDOCAINE-EPINEPHRINE (PF) 1.5 %-1:200,000 INJECTION SOLUTION	15956
Y	LIDOCAINE-PRILOCAINE 2.5 %-2.5 % TOPICAL CREAM	10434
Y	LINEZOLID 600 MG TABLET	80084
Y	LINEZOLID 600 MG/300 ML IMS TEMPLATE	301521
Y	LINEZOLID IN 5% DEXTROSE IN WATER 600 MG/300 ML INTRAVENOUS PIGGYBACK	86283
Y	LIOETHYRONINE 25 MCG TABLET	77939
Y	LIOETHYRONINE 5 MCG TABLET	79163
Y	LIPASE-PROTEASE-AMYLASE 5,000-17,000-27,000 UNIT CAPSULE,DELAYED REL	183389
Y	LISINOPRIL 20 MG TABLET	4526
Y	LISINOPRIL 5 MG TABLET	10451
Y	LITHIUM CARBONATE 150 MG CAPSULE	4528
Y	LITHIUM CARBONATE 300 MG CAPSULE	4529
Y	LOPERAMIDE 1 MG/5 ML ORAL LIQUID	4561
Y	LOPERAMIDE 2 MG CAPSULE	4560
Y	LORATADINE 10 MG TABLET	10466
Y	LORAZEPAM 1 MG TABLET	4573
Y	LORAZEPAM 1 MG/ML INFUSION	1001312
Y	LORAZEPAM 2 MG/ML INJECTION SOLUTION	10467
Y	LORAZEPAM 2 MG/ML ORAL CONCENTRATE	82598
Y	LORAZEPAM INFUSION IMS TEMPLATE	1001294
Y	LORAZEPAM INJECTION IMS TEMPLATE	1000893
Y	LOSARTAN 25 MG TABLET	80886
Y	LOVASTATIN 20 MG TABLET	10470
Y	LUBRICATING EYE OINTMENT IMS TEMPLATE	1000885
Y	MAGNESIUM 64 MG (MAGNESIUM CHLORIDE) TABLET,DELAYED RELEASE	180455
Y	MAGNESIUM CITRATE ORAL SOLUTION	4711

Y	MAGNESIUM HYDROXIDE 400 MG/5 ML ORAL SUSPENSION	79944
Y	MAGNESIUM OXIDE 400 MG (241.3 MG MAGNESIUM) TABLET	10491
Y	MAGNESIUM REPLACEMENT REMINDER	301612
Y	MAGNESIUM SULFATE 2 GRAM/50 ML (4 %) IN WATER INTRAVENOUS PIGGYBACK	177444
Y	MAGNESIUM SULFATE 20 GRAM/500 ML (4 %) IN WATER INTRAVENOUS SOLUTION	177735
Y	MAGNESIUM SULFATE 4 GRAM/100 ML (4 %) IN WATER INTRAVENOUS PIGGYBACK	177669
Y	MAGNESIUM SULFATE 4 MEQ/ML (50 %) INJECTION SOLUTION	4720
Y	MAGNESIUM SULFATE IVPB IMS TEMPLATE	1000860
Y	MANNITOL 20 % INTRAVENOUS SOLUTION	4749
Y	MANNITOL 25 % INTRAVENOUS SOLUTION	4750
Y	MEASLES,MUMPS,RUBEL,VARICEL LIV(PF)10E3-4.3-3-3.99TCID50/0.5 ML SUBCUT	95003
Y	MEASLES,MUMPS,RUBELLA VACCINE LIVE(PF)1,000-12,500TCID50/0.5 ML SUBCUT	178633
Y	MECLIZINE 25 MG TABLET	12025
Y	MEDROXYPROGESTERONE 2.5 MG TABLET	4855
Y	MEGESTROL 20 MG TABLET	4870
Y	MEGESTROL 40 MG/ML ORAL SUSP IMS TEMPLATE	1000980
Y	MEGESTROL 400 MG/10 ML (40 MG/ML) ORAL SUSPENSION	10521
Y	MEMANTINE 10 MG TABLET	89652
Y	MENINGOC VAC A,C,Y,W-135 DIP(PF) 10 MCG-5 MCG/0.5 ML INTRAMUSCULAR KIT	184328
Y	MENINGOCOCCAL B VAC,4-CMP 50 MCG-50 MCG-50 MCG-25 MCG/0.5ML IM SYRINGE	212663
Y	MENINGOCOCCAL VACCINE A,C,Y,W-135 (PF) 50 MCG SUBCUTANEOUS SOLUTION	178574
Y	MEPERIDINE (PF) 25 MG/ML INJECTION SOLUTION	95099
Y	MEPERIDINE INJECTION IMS TEMPLATE	1000753
Y	MEPIVACAINE (PF) 15 MG/ML (1.5 %) INJECTION SOLUTION	178976
Y	MEPIVACAINE (PF) 20 MG/ML (2 %) INJECTION SOLUTION	178975
Y	MEPOLIZUMAB 100 MG SUBCUTANEOUS SOLUTION	216145
Y	MEPOLIZUMAB 100 MG/ML SUBCUTANEOUS AUTO-INJECTOR	230044
Y	MESALAMINE 1.2 GRAM TABLET,DELAYED RELEASE	167329
Y	MESALAMINE 4 GRAM/60 ML ENEMA	10535
Y	MESALAMINE 800 MG TABLET,DELAYED RELEASE	182121
Y	MESALAMINE RECTAL SUSP ENEMA WITH CLEANSING WIPES 4 GRAM/60 ML KIT	179652
Y	MESNA 100 MG/ML INTRAVENOUS SOLUTION	10537
Y	MESNA IVPB	169815
Y	METFORMIN 500 MG TABLET	10544
Y	METFORMIN 850 MG TABLET	14719
Y	METFORMIN ER 500 MG TABLET,EXTENDED RELEASE 24 HR	28995
Y	METHACHOLINE 0.0625 MG/ML SOLUTION FOR INHALATION	301443
Y	METHACHOLINE 0.25 MG/ML SOLUTION FOR INHALATION	300879
Y	METHACHOLINE 1 MG/ML SOLUTION FOR INHALATION	301442
Y	METHACHOLINE 4 MG/ML SOLUTION FOR INHALATION	301441
Y	METHADONE 10 MG TABLET	4953
Y	METHADONE 10 MG/5 ML ORAL SOLUTION	4951
Y	METHADONE 10 MG/ML INJECTION SOLUTION	10546
Y	METHIMAZOLE 10 MG TABLET	10552
Y	METHOCARBAMOL 500 MG TABLET	4971
Y	METHOTREXATE IV SYRINGE	169812
Y	METHOTREXATE IVPB	169818
Y	METHOTREXATE SODIUM (PF) 25 MG/ML INJECTION SOLUTION	87531
Y	METHOTREXATE SODIUM 2.5 MG TABLET	4973
Y	METHOTREXATE SODIUM 25 MG/ML INJECTION SOLUTION	4974



Y	METHYLDOPA 250 MG TABLET	4982
Y	METHYLENE BLUE (ANTIDOTE) 1 % (10 MG/ML) INTRAVENOUS SOLUTION	4985
Y	METHYLERGONOVINE 0.2 MG TABLET	78737
Y	METHYLERGONOVINE 0.2 MG/ML (1 ML) INJECTION SOLUTION	79633
Y	METHYLNALTREXONE 12 MG/0.6 ML SUBCUTANEOUS SOLUTION	178811
Y	METHYLPREDNISOLONE (PF) 500MG IVPB	1001036
Y	METHYLPREDNISOLONE 1000 MG IVPB	1000820
Y	METHYLPREDNISOLONE 4 MG TABLETS IN A DOSE PACK	14887
Y	METHYLPREDNISOLONE 500 MG IVPB	177296
Y	METHYLPREDNISOLONE ACETATE 40 MG/ML SUSPENSION FOR INJECTION	4995
Y	METHYLPREDNISOLONE ACETATE 80 MG/ML SUSPENSION FOR INJECTION	4996
Y	METHYLPREDNISOLONE INJECTION IMS TEMPLATE	1000856
Y	METHYLPREDNISOLONE SOD SUCC (PF) 1,000 MG/8 ML INTRAVENOUS SOLUTION	184032
Y	METHYLPREDNISOLONE SOD SUCC (PF) 125 MG/2 ML SOLUTION FOR INJECTION	184030
Y	METHYLPREDNISOLONE SOD SUCC (PF) 40 MG/ML SOLUTION FOR INJECTION	184029
Y	METHYLPREDNISOLONE SODIUM SUCCINATE 1,000 MG INTRAVENOUS SOLUTION	10577
Y	METHYLPREDNISOLONE SODIUM SUCCINATE 500 MG INTRAVENOUS SOLUTION	81820
Y	METOCLOPRAMIDE 10 MG TABLET	5005
Y	METOCLOPRAMIDE 5 MG/5 ML ORAL SOLUTION	5004
Y	METOCLOPRAMIDE 5 MG/ML INJECTION SOLUTION	5002
Y	METOCLOPRAMIDE INJECTION IMS TEMPLATE	1001663
Y	METOLAZONE 5 MG TABLET	10588
Y	METOPROLOL SUCCINATE ER 25 MG TABLET,EXTENDED RELEASE 24 HR	81866
Y	METOPROLOL TARTRATE 25 MG TABLET	37637
Y	METOPROLOL TARTRATE 5 MG/5 ML INTRAVENOUS SOLUTION	5007
Y	METOPROLOL TARTRATE 50 MG TABLET	5009
Y	METRONIDAZOLE 1000 MG IVPB	169237
Y	METRONIDAZOLE 500 MG TABLET	5016
Y	METRONIDAZOLE 500 MG/100 ML-SODIUM CHLORIDE(ISO) INTRAVENOUS PIGGYBACK	5018
Y	METRONIDAZOLE PEDIATRIC IVPB	1001472
Y	MICAFUNGIN 100 MG INTRAVENOUS SOLUTION	166990
Y	MICAFUNGIN 50 MG INTRAVENOUS SOLUTION	94343
Y	MICAFUNGIN DISPENSABLE (CUSTOM RX IVPB)	1000575
Y	MICAFUNGIN IVPB IMS TEMPLATE	5000319
Y	MICONAZOLE NITRATE 2 % TOPICAL CREAM	5039
Y	MICONAZOLE NITRATE 2 % TOPICAL POWDER	78532
Y	MICROFIBRILLAR COLLAGEN HEMOSTAT 70 MM X 35 MM SHEETS	182426
Y	MICROFIBRILLAR COLLAGEN HEMOSTAT POWDER	78008
Y	MIDAZOLAM (PF) 1 MG/ML INJECTION SOLUTION	207691
Y	MIDAZOLAM 1 MG/ML INJECTION IMS TEMPLATE	1001016
Y	MIDAZOLAM 1 MG/ML INJECTION SOLUTION	10607
Y	MIDAZOLAM 2 MG/ML ORAL SYRUP	24176
Y	MIDAZOLAM 5 MG/ML INFUSION IMS TEMPLATE	1001095
Y	MIDAZOLAM 5 MG/ML INJECTION IMS TEMPLATE	1001231
Y	MIDAZOLAM 5 MG/ML INJECTION SOLUTION	10608
Y	MIDAZOLAM 5 MG/ML INTRAVENOUS SOLUTION	301665
Y	MIDAZOLAM ORAL SOLUTION IMS TEMPLATE	301255
Y	MIDODRINE 2.5 MG TABLET	10609
Y	MILRINONE 1 MG/ML INTRAVENOUS SOLUTION	27327
Y	MINERAL OIL ENEMA	5087

Y	MINERAL OIL ORAL	5086
Y	MINERAL OIL	27386
Y	MINOCYCLINE 100 MG CAPSULE	5110
Y	MIRTAZAPINE 15 MG TABLET	17466
Y	MISOPROSTOL 100 MCG TABLET	10628
Y	MISOPROSTOL 200 MCG TABLET	10629
Y	MISOPROSTOL 25 MCG TAB	300001
Y	MITOMYCIN 0.2 MG/ML OPHTHALMIC SOLUTION	300624
Y	MITOMYCIN 0.5 MG/ML INJECTION SYRINGE	1001302
Y	MITOMYCIN 20 MG INTRAVENOUS SOLUTION	10630
Y	MITOMYCIN 40 MG INTRAVENOUS SOLUTION	10631
Y	MITOMYCIN 5 MG INTRAVENOUS SOLUTION	10632
Y	MITOXANTRONE 2 MG/ML CONCENTRATE,INTRAVENOUS	10634
Y	MODAFINIL 100 MG TABLET	83007
Y	MOEXIPRIL 7.5 MG TABLET	15025
Y	MOMETASONE 50 MCG/ACTUATION NASAL SPRAY	81311
Y	MONTELUKAST 10 MG TABLET	81627
Y	MONTELUKAST 4 MG CHEWABLE TABLET	78659
Y	MONTELUKAST 5 MG CHEWABLE TABLET	77102
Y	MORPHINE (PF) 0.5 MG/ML INJECTION SOLUTION	29464
Y	MORPHINE (PF) 1 MG/ML INJECTION SOLUTION	15852
Y	MORPHINE 10 MG/ML INTRAVENOUS CARTRIDGE	202017
Y	MORPHINE 10 MG/ML INTRAVENOUS SYRINGE	211626
Y	MORPHINE 2 MG/ML INJECTION SYRINGE	86478
Y	MORPHINE 2 MG/ML INTRAVENOUS SYRINGE	208733
Y	MORPHINE 25 MG/ML INTRAVENOUS SOLUTION	27392
Y	MORPHINE 4 MG/ML INTRAVENOUS CARTRIDGE	202016
Y	MORPHINE 4 MG/ML INTRAVENOUS SYRINGE	208734
Y	MORPHINE 5 MG/ML BOLUS FROM PCA SYRINGE	301208
Y	MORPHINE 5 MG/ML PCA ADULT HIGH TOLERANCE	301579
Y	MORPHINE 5 MG/ML PCA ADULT LOW TOLERANCE	301577
Y	MORPHINE 5 MG/ML PCA ADULT MODERATE TOLERANCE	301578
Y	MORPHINE 5 MG/ML PCA ADULT OPIOID NAIVE	301576
Y	MORPHINE CONCENTRATE 100 MG/5 ML (20 MG/ML) ORAL SOLUTION	10655
Y	MORPHINE ER 100 MG TABLET,EXTENDED RELEASE	20919
Y	MORPHINE ER 15 MG TABLET,EXTENDED RELEASE	20920
Y	MORPHINE ER 30 MG TABLET,EXTENDED RELEASE	20921
Y	MORPHINE IN NORMAL SALINE 250 MG/50 ML PCA SYRINGE	300431
Y	MORPHINE IN NS 5MG/ML INFUSION	301023
Y	MORPHINE INJECTION IMS TEMPLATE	1000640
Y	MORPHINE ORAL CONCENTRATE IMS TEMPLATE	1001592
Y	MULTIVIT AND MINERALS-FERROUS GLUCONATE 9 MG IRON/15 ML ORAL LIQUID	189648
Y	MULTIVITAMIN WITH MINERALS THERAPEUTIC TAB IMS TEMPLATE	1001105
Y	MULTIVITAMIN-IRON 9 MG-FOLIC ACID 400 MCG-CALCIUM AND MINERALS TABLET	181787
Y	MUPIROCIN 2 % TOPICAL OINTMENT	10674
Y	MVI,ADULT NO.4 WITH VIT K 3300 UNIT-150 MCG/10 ML INTRAVENOUS SOLUTION	202369
Y	MYCOPHENOLATE MOFETIL 500 MG TABLET	79491
Y	MYCOPHENOLATE SODIUM 360 MG TABLET,DELAYED RELEASE	89945
Y	NABUMETONE 500 MG TABLET	10676
Y	NADOLOL 20 MG TABLET	5330

Y	NAFCILLIN 1 GRAM SOLUTION FOR INJECTION	5333
Y	NAFCILLIN 1000 MG IN 50 ML DISPENSABLE (ADS)	5000167
Y	NAFCILLIN 1000 MG IN 50 ML DISPENSABLE (ADV ADS)	5000073
Y	NAFCILLIN 1000 MG IN 50 ML DISPENSABLE (MBP ADS)	5000165
Y	NAFCILLIN 1000 MG IN 50 ML SODIUM CHLORIDE 0.9% DISPENSABLE (ADV CMX)	5000252
Y	NAFCILLIN 1000 MG IN 50 ML SODIUM CHLORIDE 0.9% DISPENSABLE (CMX)	5000163
Y	NAFCILLIN 1000 MG IN 50 ML SODIUM CHLORIDE 0.9% DISPENSABLE (MBP CMX)	5000161
Y	NAFCILLIN 2 GRAM SOLUTION FOR INJECTION	5335
Y	NAFCILLIN 2000 MG IN 100 ML DISPENSABLE (ADV ADS)	5000074
Y	NAFCILLIN 2000 MG IN 50 ML DISPENSABLE (ADS)	5000168
Y	NAFCILLIN 2000 MG IN 50 ML DISPENSABLE (MBP ADS)	5000166
Y	NAFCILLIN 2000 MG IN 50 ML SODIUM CHLORIDE 0.9% DISPENSABLE (ADV CMX)	5000253
Y	NAFCILLIN 2000 MG IN 50 ML SODIUM CHLORIDE 0.9% DISPENSABLE (CMX)	5000164
Y	NAFCILLIN 2000 MG IN 50 ML SODIUM CHLORIDE 0.9% DISPENSABLE (MBP CMX)	5000162
Y	NAFCILLIN DISPENSABLE (CUSTOM RX IVPB)	5000169
Y	NAFCILLIN IVPB IMS TEMPLATE	5000042
Y	NALBUPHINE 10 MG/ML INJECTION SOLUTION	5339
Y	NALBUPHINE INJECTION IMS TEMPLATE	1000845
Y	NALOXONE 0.4 MG/ML INJECTION SOLUTION	5373
Y	NALOXONE 1 MG/ML INJECTION SYRINGE	5374
Y	NALOXONE INJECTION IMS TEMPLATE	1000892
Y	NALTREXONE 50 MG TABLET	10685
Y	NAPHAZOLINE 0.025 %-PHENIRAMINE 0.3 % EYE DROPS	82552
Y	NAPROXEN 500 MG TABLET	5393
Y	NAPROXEN SODIUM 220 MG TABLET	13135
Y	NATALIZUMAB 300 MG/15 ML INTRAVENOUS SOLUTION	93852
Y	NATALIZUMAB IVPB	1000351
Y	NEOMYCIN 3.5 MG/G-POLYMYXIN B 10,000 UNIT/G-DEXAMETH 0.1 % EYE OINT	19495
Y	NEOMYCIN-BACITRACIN ZN-POLYMYXIN 3.5 MG-400 UNIT-5,000 UNIT TOP OINT PKT	130017
Y	NEOMYCIN-BACITRACIN-POLYMYXIN TOPICAL OINT PACKET IMS TEMPLATE	1001188
Y	NEOMYCIN-BACITRACIN ZN-POLYMYX 3.5 MG-400 UNIT-5,000 UNIT/GRAM TOP OINT	854
Y	NEOMYCIN-POLYMYXIN-HYDROCORT 3.5 MG/ML-10,000 UNIT/ML-1 % EAR SOLUTION	34814
Y	NEOMYCIN-POLYMYXIN-HYDROCORT 3.5 MG-10,000 UNIT/ML-1 % EAR DROPS,SUSP	28810
Y	NEOSTIGMINE METHYLSULFATE 1 MG/ML INTRAVENOUS SOLUTION	206326
Y	NEOSTIGMINE METHYLSULFATE 3 MG/3 ML (1 MG/ML) INTRAVENOUS SYRINGE	216146
Y	NIACIN ER 500 MG TABLET,EXTENDED RELEASE 24 HR	5545
Y	NICARDIPINE 25 MG/10 ML INTRAVENOUS SOLUTION	79106
Y	NICARDIPINE INFUSION IMS TEMPLATE	1000852
Y	NICOTINE (POLACRILEX) 2 MG GUM	10717
Y	NICOTINE 14 MG/24 HR DAILY TRANSDERMAL PATCH	27862
Y	NICOTINE 21 MG/24 HR DAILY TRANSDERMAL PATCH	27863
Y	NICOTINE 7 MG/24 HR DAILY TRANSDERMAL PATCH	27860
Y	NIFEDIPINE 10 MG CAPSULE	5558
Y	NIFEDIPINE ER 30 MG TABLET,EXTENDED RELEASE 24 HR	28643
Y	NITROFURANTOIN MACROCRYSTAL 50 MG CAPSULE	5595
Y	NITROFURANTOIN MONOHYDRATE/MACROCRYSTALS 100 MG CAPSULE	10724
Y	NITROGLYCERIN 0.1 MG/HR TRANSDERMAL 24 HOUR PATCH	27471
Y	NITROGLYCERIN 0.4 MG SUBLINGUAL TABLET	5604
Y	NITROGLYCERIN 2 % TRANSDERMAL OINTMENT	81567
Y	NITROGLYCERIN 400 MCG/SPRAY TRANSLINGUAL	81111

Y	NITROGLYCERIN 50 MG/250 ML (200 MCG/ML) IN 5 % DEXTROSE INTRAVENOUS	15859
Y	NITROPRUSSIDE 50MG IN DEXTROSE 5% 250ML	168642
Y	NIVOLUMAB 100 MG/10 ML INTRAVENOUS SOLUTION	212306
Y	NIVOLUMAB 240 MG/24 ML INTRAVENOUS SOLUTION	224645
Y	NIVOLUMAB 40 MG/4 ML INTRAVENOUS SOLUTION	212305
Y	NIVOLUMAB IVPB	1001218
Y	NOREPINEPHRINE BITARTRATE 1 MG/ML INTRAVENOUS SOLUTION	10734
Y	NOREPINEPHRINE INFUSION IMS TEMPLATE	1001300
Y	NORETHINDRONE ACETATE 5 MG TABLET	10747
Y	NORFLURANE-PENTAFLUOROPROPANE TOPICAL SPRAY	93765
Y	NORTRIPTYLINE 10 MG CAPSULE	5674
Y	NORTRIPTYLINE 25 MG CAPSULE	5675
Y	NORTRIPTYLINE 75 MG CAPSULE	5677
Y	NS WITH POTASSIUM CHLORIDE 10 MEQ/L	168678
Y	NS WITH POTASSIUM CHLORIDE 30 MEQ/L	168692
Y	NS WITH POTASSIUM CL AND MAGNESIUM SULFATE	177298
Y	NYSTATIN 100,000 UNIT/GRAM TOPICAL CREAM	5749
Y	NYSTATIN 100,000 UNIT/GRAM TOPICAL OINTMENT	5750
Y	NYSTATIN 100,000 UNIT/GRAM TOPICAL POWDER	39136
Y	NYSTATIN 100,000 UNIT/ML ORAL SUSPENSION	5751
Y	NYSTATIN-LIDOCAINE VISCOUS-ANTACID ORAL SUSPENSION COMPOUND	1001477
Y	NYSTATIN-TRIAMCINOLONE 100,000 UNIT/G-0.1 % TOPICAL CREAM	5754
Y	OBINUTUZUMAB 1,000 MG/40 ML INTRAVENOUS SOLUTION	207710
Y	OBINUTUZUMAB IVPB	1001125
Y	OCRELIZUMAB 30 MG/ML INTRAVENOUS SOLUTION	221909
Y	OCRELIZUMAB IVPB	1001456
Y	OCTREOTIDE ACETATE 1,000 MCG/ML INJECTION SOLUTION	25125
Y	OCTREOTIDE ACETATE 100 MCG/ML INJECTION SOLUTION	25122
Y	OCTREOTIDE ACETATE 200 MCG/ML INJECTION SOLUTION	25123
Y	OCTREOTIDE ACETATE 50 MCG/ML INJECTION SOLUTION	25121
Y	OCTREOTIDE IV INFUSION	1000041
Y	OCTREOTIDE,MICROSPHERES ER 10 MG INTRAMUSCULAR SUSP, EXTENDED RELEASE	213470
Y	OCTREOTIDE,MICROSPHERES ER 20 MG INTRAMUSCULAR SUSP, EXTENDED RELEASE	213468
Y	OCTREOTIDE,MICROSPHERES ER 30 MG INTRAMUSCULAR SUSP, EXTENDED RELEASE	213469
Y	OFLOXACIN 0.3 % EYE DROPS	19746
Y	OLANZAPINE 10 MG DISINTEGRATING TABLET	81059
Y	OLANZAPINE 2.5 MG TABLET	79137
Y	OLARATUMAB 10 MG/ML INTRAVENOUS SOLUTION	220296
Y	OLMESARTAN 20 MG TABLET	84975
Y	OMEGA-3 ACID ETHYL ESTERS 1 GRAM CAPSULE	93947
Y	ONABOTULINUMTOXINA 100 UNIT SOLUTION FOR INJECTION	77983
Y	ONDANSETRON 4 MG DISINTEGRATING TABLET	82394
Y	ONDANSETRON 8 MG DISINTEGRATING TABLET	79332
Y	ONDANSETRON AND DEXAMETHASON IVPB	1000370
Y	ONDANSETRON HCL (PF) 4 MG/2 ML INJECTION SOLUTION	167013
Y	ONDANSETRON HCL 2 MG/ML INTRAVENOUS SOLUTION	78133
Y	ONDANSETRON HCL 4 MG/5 ML ORAL SOLUTION	79898
Y	ONDANSETRON INJECTION IMS TEMPLATE	1000907
Y	OPIUM TINCTURE 10 MG/ML (MORPHINE) ORAL	5828
Y	OSELTAMIVIR 6 MG/ML ORAL SUSPENSION	195456

Y	OSELTAMIVIR 75 MG CAPSULE	80482
Y	OTHER MEDICATION CONSULT TO PHARMACY	168289
Y	OXALIPLATIN 100 MG/20 ML INTRAVENOUS SOLUTION	94609
Y	OXALIPLATIN 50 MG/10 ML (5 MG/ML) INTRAVENOUS SOLUTION	94608
Y	OXALIPLATIN IVPB	169820
Y	OXCARBAZEPINE 600 MG TABLET	81436
Y	OXYBUTYNIN CHLORIDE 5 MG TABLET	5938
Y	OXYBUTYNIN CHLORIDE ER 5 MG TABLET,EXTENDED RELEASE 24 HR	81281
Y	OXYCODONE 5 MG TABLET	10814
Y	OXYCODONE 5 MG/5 ML ORAL SOLUTION	10813
Y	OXYCODONE ER 10 MG TABLET,CRUSH RESISTANT,EXTENDED RELEASE 12 HR	211843
Y	OXYCODONE ER 40 MG TABLET,CRUSH RESISTANT,EXTENDED RELEASE 12 HR	211847
Y	OXYCODONE-ACETAMINOPHEN 10 MG-325 MG TABLET	31864
Y	OXYCODONE-ACETAMINOPHEN 5 MG-325 MG TABLET	5940
Y	OXYMETAZOLINE 0.05 % NASAL SPRAY	5943
Y	OXYTOCIN 10 UNIT/ML INJECTION SOLUTION	5944
Y	OXYTOCIN 20 UNIT/1,000 ML INFUSION IMS TEMPLATE	1001582
Y	OXYTOCIN 30 UNIT/500 ML POSTPARTUM INFUSION (NOT FOR MERCY USE)	301872
Y	OXYTOCIN IN LACTATED RINGERS 30 UNIT/500 ML INTRAVENOUS SOLUTION	95363
Y	OXYTOCIN INDUCTION INFUSION IMS TEMPLATE	1001586
Y	PACLITAXEL 6 MG/ML CONCENTRATE,INTRAVENOUS	31025
Y	PACLITAXEL IV IN NS 500 ML (NON-PVC NON-GLASS) INFUSION	1000378
Y	PACLITAXEL-PROTEIN BOUND 100 MG INTRAVENOUS SUSPENSION	94097
Y	PALONOSETRON 0.25 MG/5 ML INTRAVENOUS SOLUTION	88501
Y	PANITUMUMAB 100 MG/5 ML (20 MG/ML) INTRAVENOUS SOLUTION	179913
Y	PANITUMUMAB 400 MG/20 ML (20 MG/ML) INTRAVENOUS SOLUTION	179915
Y	PANITUMUMAB IVPB	1000338
Y	PANTOPRAZOLE 40 MG INTRAVENOUS SOLUTION	78621
Y	PANTOPRAZOLE 40 MG TABLET,DELAYED RELEASE	80436
Y	PANTOPRAZOLE 80 MG IN 100 ML CONTINUOUS INFUSION	1000597
Y	PAPAVERINE 30 MG/ML INJECTION SOLUTION	6030
Y	PARENTERAL AMINO ACID 10 % COMBINATION NO.6 INTRAVENOUS SOLUTION	178027
Y	PAROXETINE 20 MG TABLET	10855
Y	PAROXETINE ER 12.5 MG TABLET,EXTENDED RELEASE 24 HR	83526
Y	PASTEURIZED DONOR HUMAN MILK	301470
Y	PATROMER CALCIUM SORBITEX 8.4 GRAM ORAL POWDER PACKET	216134
Y	PEG3350 100 GRAM-SOD SULF 7.5 GRAM-NACL-KCL-ASCORBATE-C ORAL PWDR PACK	130059
Y	PEGASPARGASE 750 UNIT/ML INJECTION SOLUTION	77053
Y	PEG-ELECTROLYTE SOLUTION 420 GRAM ORAL SOLUTION	79142
Y	PEGFILGRASTIM 6 MG/0.6 ML (DELIVERABLE) WEARABLE SUBCUTANEOUS INJECTOR	212539
Y	PEGFILGRASTIM-CBQV 6 MG/0.6 ML SUBCUTANEOUS SYRINGE	83055
Y	PEMBROLIZUMAB 25 MG/ML INTRAVENOUS SOLUTION	212708
Y	PEMBROLIZUMAB IVPB	1001190
Y	PEMETREXED 100 MG INTRAVENOUS SOLUTION	177754
Y	PEMETREXED 500 MG INTRAVENOUS SOLUTION	89864
Y	PEMETREXED IVPB	169809
Y	PENICILLIN G BENZATHINE 2,400,000 UNIT/4 ML INTRAMUSCULAR SYRINGE	86511
Y	PENICILLIN G POTASSIUM 20 MILLION UNIT SOLUTION FOR INJECTION	6085
Y	PENICILLIN G POTASSIUM 5 MILLION UNIT IN 100 ML DISPENSABLE (MBP ADS)	5000075
Y	PENICILLIN G POTASSIUM 5 MILLION UNIT SOLUTION FOR INJECTION	6086

Y	PENICILLIN G POTASSIUM DISPENSABLE (CUSTOM RX IVPB)	5000083
Y	PENICILLIN G POTASSIUM IVPB IMS TEMPLATE	5000044
Y	PENICILLIN V POTASSIUM 125 MG/5 ML ORAL SOLUTION	6090
Y	PENICILLIN V POTASSIUM 250 MG TABLET	6092
Y	PENICILLIN V POTASSIUM 250 MG/5 ML ORAL SOLUTION	6091
Y	PENICILLIN V POTASSIUM 500 MG TABLET	6093
Y	PENTAMIDINE 300 MG SOLUTION FOR INJECTION	27430
Y	PENTOSAN POLYSULFATE SODIUM 100 MG CAPSULE	77128
Y	PENTOXIFYLLINE ER 400 MG TABLET,EXTENDED RELEASE	21300
Y	PERFLUTREN LIPID MICROSOPHERES 1.1 MG/ML INTRAVENOUS SUSPENSION	79178
Y	PERTUZUMAB 420 MG/14 ML (30 MG/ML) INTRAVENOUS SOLUTION	200555
Y	PERTUZUMAB IVPB	1000945
Y	PHENAZOPYRIDINE 200 MG TABLET	6194
Y	PHENOBARBITAL 20 MG/5 ML (4 MG/ML) ORAL ELIXIR	6212
Y	PHENOBARBITAL 32.4 MG TABLET	6217
Y	PHENOBARBITAL IVPB	1001108
Y	PHENOBARBITAL SODIUM 65 MG/ML INJECTION SOLUTION	6224
Y	PHENTOLAMINE 5 MG INJECTION SOLUTION	10947
Y	PHENYLEPHRINE 0.25 % NASAL SPRAY	87930
Y	PHENYLEPHRINE 1 % NASAL SPRAY	80381
Y	PHENYLEPHRINE 1 MG/10 ML (100 MCG/ML) IN 0.9 % SOD.CHLORIDE IV SYRINGE	191000
Y	PHENYLEPHRINE 10 MG/ML INJECTION SOLUTION	6242
Y	PHENYLEPHRINE 2.5 % EYE DROPS	6246
Y	PHENYLEPHRINE INFUSION IMS TEMPLATE	1001299
Y	PHENYLEPHRINE INFUSION	1001317
Y	PHENYTOIN 125 MG/5 ML ORAL SUSPENSION	6255
Y	PHENYTOIN 5 MG/ML IVPB	1001187
Y	PHENYTOIN ORAL SUSPENSION IMS TEMPLATE	1001021
Y	PHENYTOIN SODIUM 50 MG/ML INTRAVENOUS SOLUTION	6256
Y	PHENYTOIN SODIUM EXTENDED 100 MG CAPSULE	78925
Y	PHOSPHORUS REPLACEMENT REMINDER	301613
Y	PHYSOSTIGMINE 1 MG/ML INJECTION SOLUTION	6270
Y	PHYTONADIONE (VITAMIN K1) 1 MG/0.5 ML INJECTION SOLUTION	34208
Y	PHYTONADIONE (VITAMIN K1) 10 MG/ML INJECTION SOLUTION	77693
Y	PHYTONADIONE (VITAMIN K1) 5 MG TABLET	82989
Y	PHYTONADIONE 1 MG INJECTION IMS TEMPLATE	1001216
Y	PHYTONADIONE 10 MG IVPB	1000073
Y	PILOCARPINE 2 % EYE DROPS	6280
Y	PILOCARPINE 5 MG TABLET	12803
Y	PIOGLITAZONE 30 MG TABLET	82256
Y	PIPERACILLIN-TAZOBACTAM 100 ML DISPENSABLE (CUSTOM RX IVPB)	5000214
Y	PIPERACILLIN-TAZOBACTAM 2.25 GRAM IN 50 ML DEXTROSE ISO-OSMOTIC IVPB (PREMIX)	80878
Y	PIPERACILLIN-TAZOBACTAM 2.25 GRAM IN 50 ML DISPENSABLE (ADS)	5000210
Y	PIPERACILLIN-TAZOBACTAM 2.25 GRAM IN 50 ML DISPENSABLE (ADV ADS)	5000076
Y	PIPERACILLIN-TAZOBACTAM 2.25 GRAM IN 50 ML DISPENSABLE (MBP ADS)	5000207
Y	PIPERACILLIN-TAZOBACTAM 2.25 GRAM IN 50 ML SODIUM CHLORIDE 0.9% DISPENSABLE (ADV)	5000249
Y	PIPERACILLIN-TAZOBACTAM 2.25 GRAM IN 50 ML SODIUM CHLORIDE 0.9% DISPENSABLE (CM)	5000204
Y	PIPERACILLIN-TAZOBACTAM 2.25 GRAM IN 50 ML SODIUM CHLORIDE 0.9% DISPENSABLE (MBF)	5000201
Y	PIPERACILLIN-TAZOBACTAM 2.25 GRAM INTRAVENOUS SOLUTION	82347
Y	PIPERACILLIN-TAZOBACTAM 3.375 GRAM IN 50 ML DEXTROSE ISO-OSMOTIC IVPB (PREMIX)	83455

Y	PIPERACILLIN-TAZOBACTAM 3.375 GRAM IN 50 ML DISPENSABLE (ADS)	5000211
Y	PIPERACILLIN-TAZOBACTAM 3.375 GRAM IN 50 ML DISPENSABLE (ADV ADS)	5000077
Y	PIPERACILLIN-TAZOBACTAM 3.375 GRAM IN 50 ML DISPENSABLE (MBP ADS)	5000208
Y	PIPERACILLIN-TAZOBACTAM 3.375 GRAM IN 50 ML SODIUM CHLORIDE 0.9% DISPENSABLE (AD	5000254
Y	PIPERACILLIN-TAZOBACTAM 3.375 GRAM IN 50 ML SODIUM CHLORIDE 0.9% DISPENSABLE (ME	5000202
Y	PIPERACILLIN-TAZOBACTAM 3.375 GRAM INTRAVENOUS SOLUTION	80250
Y	PIPERACILLIN-TAZOBACTAM 4.5 GRAM - PIPERACILLIN BASED DOSING	301682
Y	PIPERACILLIN-TAZOBACTAM 4.5 GRAM IN 100 ML DEXTROSE ISO-OSMOTIC IVPB (PREMIX)	83456
Y	PIPERACILLIN-TAZOBACTAM 4.5 GRAM IN 100 ML DISPENSABLE (ADS)	5000212
Y	PIPERACILLIN-TAZOBACTAM 4.5 GRAM IN 100 ML DISPENSABLE (MBP ADS)	5000209
Y	PIPERACILLIN-TAZOBACTAM 4.5 GRAM IN 100 ML SODIUM CHLORIDE 0.9% DISPENSABLE (ADV	5000255
Y	PIPERACILLIN-TAZOBACTAM 4.5 GRAM IN 100 ML SODIUM CHLORIDE 0.9% DISPENSABLE (CM)	5000206
Y	PIPERACILLIN-TAZOBACTAM 4.5 GRAM IN 100 ML SODIUM CHLORIDE 0.9% DISPENSABLE (MBF	5000203
Y	PIPERACILLIN-TAZOBACTAM 4.5 GRAM IN 50 ML DISPENSABLE (ADV ADS)	5000078
Y	PIPERACILLIN-TAZOBACTAM 4.5 GRAM INTRAVENOUS SOLUTION	80419
Y	PIPERACILLIN-TAZOBACTAM 40.5 GRAM INTRAVENOUS SOLUTION	77410
Y	PIPERACILLIN-TAZOBACTAM 50 ML DISPENSABLE (CUSTOM RX IVPB)	5000213
Y	PIPERACILLIN-TAZOBACTAM IVPB IMS TEMPLATE	5000046
Y	PIPERACILLIN-TAZOBACTAM PEDIATRIC IVPB	1001471
Y	PNEUMOCOCCAL 13-VAL CONJ VACCINE-DIP CRM (PF) 0.5 ML IM SYRINGE	300819
Y	PNEUMOCOCCAL 23 POLYVALENT VACCINE 25 MCG/0.5 ML INJECTION SOLUTION	82746
Y	PNEUMONIA 23 VACCINE IMS TEMPLATE	1001332
Y	POLYETHYLENE GLYCOL 3350 17 GRAM ORAL POWDER PACKET	25424
Y	POLYMYXIN B SULFATE 10,000 UNIT-TRIMETHOPRIM 1 MG/ML EYE DROPS	80790
Y	POLYMYXIN B SULFATE 500,000 UNIT SOLUTION FOR INJECTION	6393
Y	POTASSIUM ACETATE 2 MEQ/ML INTRAVENOUS SOLUTION	6420
Y	POTASSIUM BICARBONATE-CITRIC ACID 25 MEQ EFFERVESCENT TABLET	6423
Y	POTASSIUM CHLORIDE 2 MEQ/ML INTRAVENOUS SOLUTION	88387
Y	POTASSIUM CHLORIDE 20 MEQ IVPB IMS TEMPLATE	1001211
Y	POTASSIUM CHLORIDE 20 MEQ/100 ML INFUSION	301898
Y	POTASSIUM CHLORIDE 20 MEQ/100ML IN STERILE WATER INTRAVENOUS PIGGYBACK	11076
Y	POTASSIUM CHLORIDE 20 MEQ/15 ML ORAL LIQUID	6432
Y	POTASSIUM CHLORIDE 20 MEQ/L IN 0.45% SODIUM CHLORIDE IMS TEMPLATE	1001330
Y	POTASSIUM CHLORIDE 20 MEQ/L IN 0.9 % SODIUM CHLORIDE INTRAVENOUS	16426
Y	POTASSIUM CHLORIDE 20 MEQ/L IN D5-0.9 % SODIUM CHLORIDE INTRAVENOUS	14858
Y	POTASSIUM CHLORIDE 20 MEQ/L IN DEXTROSE 5 %-0.2 % SODIUM CHLORIDE IV	14862
Y	POTASSIUM CHLORIDE 20 MEQ/L IN DEXTROSE 5 %-0.45 % SODIUM CHLORIDE IV	14863
Y	POTASSIUM CHLORIDE 20 MEQ/L-LACTATED RINGERS-5 % DEXTROSE INTRAVENOUS	16014
Y	POTASSIUM CHLORIDE 40 MEQ IVPB IMS TEMPLATE	1001212
Y	POTASSIUM CHLORIDE 40 MEQ/100ML IN STERILE WATER INTRAVENOUS PIGGYBACK	11079
Y	POTASSIUM CHLORIDE 40 MEQ/L IN 0.9 % SODIUM CHLORIDE INTRAVENOUS	16427
Y	POTASSIUM CHLORIDE 40 MEQ/L IN DEXTROSE 5 %-0.45 % SODIUM CHLORIDE IV	14866
Y	POTASSIUM CHLORIDE CUSTOM IVPB	1000368
Y	POTASSIUM CHLORIDE ER 10 MEQ TABLET,EXTENDED RELEASE(PART/CRYST)	35942
Y	POTASSIUM CHLORIDE ER 20 MEQ TABLET,EXTENDED RELEASE(PART/CRYST)	35943
Y	POTASSIUM CITRATE ER 10 MEQ (1,080 MG) TABLET,EXTENDED RELEASE	80307
Y	POTASSIUM PHOSPHATE 15 MMOL IVPB	1000799
Y	POTASSIUM PHOSPHATE 20 MMOL IVPB	169228
Y	POTASSIUM PHOSPHATE 30 MMOL IVPB	1000800
Y	POTASSIUM PHOSPHATE 30 MMOL IVPB	169229

Y	POTASSIUM PHOSPHATE 40 MMOL IVPB	169230
Y	POTASSIUM PHOSPHATES-MBASIC AND DIBASIC 3 MMOL/ML INTRAVENOUS SOLUTION	6451
Y	POTASSIUM REPLACEMENT REMINDER	301610
Y	POVIDONE-IODINE 10 % TOPICAL OINTMENT	6455
Y	PRAMIPEXOLE 0.25 MG TABLET	81284
Y	PRAVASTATIN 20 MG TABLET	11111
Y	PRAZOSIN 1 MG CAPSULE	6468
Y	PREDNISOLONE ACETATE 1 % EYE DROPS,SUSPENSION	6487
Y	PREDNISOLONE SODIUM PHOSPATE 15MG/5ML ORAL SOLUTION IMS TEMPLATE	1000982
Y	PREDNISOLONE SODIUM PHOSPHATE 15 MG/5 ML (3 MG/ML) ORAL SOLUTION	29302
Y	PREDNISON 1 MG TABLET	6493
Y	PREDNISON 20 MG TABLET	6496
Y	PREDNISON 5 MG TABLET	6497
Y	PREGABALIN 25 MG CAPSULE	94902
Y	PREGABALIN 75 MG CAPSULE	94904
Y	PRENATAL VITAMIN IMS TEMPLATE	1000780
Y	PRENATAL VITAMIN-FERROUS FUMARATE 28 MG IRON-FOLIC ACID 800 MCG TABLET	80639
Y	PRIMIDONE 50 MG TABLET	11129
Y	PROBENECID 500 MG TABLET	6561
Y	PROCAINAMIDE 1000MG IN 250ML INFUSION	168653
Y	PROCAINAMIDE 500 MG/ML INJECTION SOLUTION	6563
Y	PROCHLORPERAZINE 25 MG RECTAL SUPPOSITORY	11138
Y	PROCHLORPERAZINE EDISYLATE 10 MG/2 ML (5 MG/ML) INJECTION SOLUTION	195710
Y	PROCHLORPERAZINE INJECTION IMS TEMPLATE	1000905
Y	PROCHLORPERAZINE MALEATE 5 MG TABLET	6583
Y	PROGESTERONE MICRONIZED 100 MG CAPSULE	82875
Y	PROMETHAZINE 12.5 MG RECTAL SUPPOSITORY	11143
Y	PROMETHAZINE 25 MG RECTAL SUPPOSITORY	11144
Y	PROMETHAZINE 25 MG TABLET	6622
Y	PROMETHAZINE 25 MG/ML INJECTION SOLUTION	6618
Y	PROMETHAZINE 6.25 MG/5 ML ORAL SYRUP	6620
Y	PROPAFENONE 150 MG TABLET	11146
Y	PROPARACAINE 0.5 % EYE DROPS	6644
Y	PROPOFOL 10 MG/ML INFUSION	300806
Y	PROPOFOL 10 MG/ML INTRAVENOUS EMULSION	11150
Y	PROPRANOLOL 20 MG TABLET	6657
Y	PROPRANOLOL ER 120 MG CAPSULE,24 HR,EXTENDED RELEASE	38226
Y	PROPRANOLOL ER 80 MG CAPSULE,24 HR,EXTENDED RELEASE	38225
Y	PROPYLTHIOURACIL 50 MG TABLET	6662
Y	PROTAMINE 10 MG/ML INTRAVENOUS SOLUTION	6677
Y	PSEUDOEPHEDRINE 30 MG TABLET	6714
Y	PSYLLIUM HUSK (ASPARTAME) 3.4 GRAM ORAL POWDER PACKET	183022
Y	PYRAZINAMIDE 500 MG TABLET	6738
Y	PYRIDOSTIGMINE BROMIDE 60 MG TABLET	11239
Y	PYRIDOXINE (VITAMIN B6) 100 MG/ML INJECTION SOLUTION	6744
Y	PYRIDOXINE (VITAMIN B6) 50 MG TABLET	6748
Y	QUETIAPINE 200 MG TABLET	78432
Y	QUETIAPINE 25 MG TABLET	76945
Y	QUINAPRIL 10 MG TABLET	11251
Y	QUINAPRIL 20 MG TABLET	11252



Y	QUINIDINE GLUCONATE 80 MG/ML INJECTION SOLUTION	6775
Y	QUINIDINE IVPB	1000473
Y	RABIES IMMUNE GLOBULIN (PF) 150 UNIT/ML INTRAMUSCULAR SOLUTION	79534
Y	RABIES VACCINE, PURIFIED CHICKEN EMBRYO CELL (PF) 2.5 UNIT IM SUSP	85758
Y	RABIES VACCINE,HUMAN DIPLOID (PF) 2.5 UNIT INTRAMUSCULAR SOLUTION	178575
Y	RACEPINEPHRINE 2.25 % SOLUTION FOR NEBULIZATION	93138
Y	RADIOPAQUE PVC MARKERS-BARIUM SULFATE 24 MARKERS CAPSULE	179764
Y	RALOXIFENE 60 MG TABLET	81433
Y	RAMIPRIL 2.5 MG CAPSULE	80700
Y	RAMIPRIL 5 MG CAPSULE	82694
Y	RAMUCIRUMAB 10 MG/ML INTRAVENOUS SOLUTION	209334
Y	RAMUCIRUMAB IN 0.9% SODIUM CHLORIDE INFUSION	1001140
Y	RASBURICASE 1.5 MG INTRAVENOUS SOLUTION	86699
Y	RASBURICASE 7.5 MG INTRAVENOUS SOLUTION	129536
Y	RASBURICASE IVPB	180534
Y	REGADENOSON 0.4 MG/5 ML INTRAVENOUS SYRINGE	178862
Y	RHO(D) IMMUNE GLOBULIN (300 MCG) 1500 UNIT IM IMS TEMPLATE	1001175
Y	RHO(D) IMMUNE GLOBULIN 1,500 UNIT (300 MCG)/2 ML INJECTION SYRINGE	89956
Y	RIFAMPIN 300 MG CAPSULE	11293
Y	RIFAXIMIN 550 MG TABLET	189801
Y	RISPERIDONE 1 MG TABLET	82540
Y	RITUXIMAB 10 MG/ML CONCENTRATE,INTRAVENOUS	82539
Y	RITUXIMAB IN NS 250 ML IVPB	1000328
Y	RITUXIMAB IVPB	169808
Y	RIVAROXABAN 10 MG TABLET	195410
Y	RIVAROXABAN 15 MG TABLET	196864
Y	RIZATRIPTAN 10 MG DISINTEGRATING TABLET	80330
Y	ROCURONIUM 10 MG/ML INTRAVENOUS SOLUTION	78847
Y	ROMIPLOSTIM 250 MCG SUBCUTANEOUS SOLUTION	179669
Y	ROPINIROLE 1 MG TABLET	77448
Y	ROPIVACAINE (PF) 0.2 %-0% NACL 745 ML INFILT,HI VAR RATE ELAST PUMP	301830
Y	ROPIVACAINE (PF) 2 MG/ML (0.2 %) INJECTION SOLUTION	79403
Y	ROPIVACAINE (PF) 5 MG/ML (0.5 %) INJECTION SOLUTION	195852
Y	ROPIVACAINE 0.2% BILATERAL VARIABLE RATE ON-Q PUMP	1001426
Y	ROPIVACAINE 0.2% UNILATERAL VARIABLE RATE ON-Q PUMP	1001423
Y	ROSUVASTATIN 10 MG TABLET	88503
Y	SACCHAROMYCES BOULARDII 250 MG CAPSULE	89615
Y	SACUBITRIL 24 MG-VALSARTAN 26 MG TABLET	214456
Y	SALMETEROL 50 MCG/DOSE BLISTER POWDER FOR INHALATION	81041
Y	SCOPOLAMINE 1 MG OVER 3 DAYS TRANSDERMAL PATCH	82141
Y	SENNOSIDES 8.6 MG-DOCUSATE SODIUM 50 MG TABLET	40926
Y	SENNOSIDES 8.8 MG/5 ML ORAL SYRUP	79026
Y	SEPSIS ANTIBIOTIC ALERT TO PHARMACY	301213
Y	SERTRALINE 50 MG TABLET	82509
Y	SILDENAFIL (PULMONARY HYPERTENSION) 20 MG TABLET	94671
Y	SILVER ER TOPICAL GEL,EXTENDED RELEASE	93183
Y	SILVER NITRATE APPLICATORS 75 %-25 % TOPICAL STICK	167324
Y	SILVER SULFADIAZINE 1 % TOPICAL CREAM	7224
Y	SIMETHICONE 40 MG/0.6 ML ORAL DROPS,SUSPENSION	7228
Y	SIMETHICONE 80 MG CHEWABLE TABLET	7227

Y	SIMVASTATIN 10 MG TABLET	78403
Y	SINCALIDE IVPB	168637
Y	SITAGLIPTIN 50 MG TABLET	166917
Y	SOD PHOS MONO-SOD PHOS DIBASIC 1.5 GRAM (1.102-0.398) TABLET	82404
Y	SODIUM ACETATE 2 MEQ/ML INTRAVENOUS SOLUTION	7301
Y	SODIUM BICARBONATE 1 MEQ/ML (8.4 %) INTRAVENOUS SOLUTION	7309
Y	SODIUM BICARBONATE 4.2 % (0.5 MEQ/ML) INTRAVENOUS SYRINGE	86434
Y	SODIUM BICARBONATE 650 MG TABLET	7313
Y	SODIUM BICARBONATE 8.4 % (1 MEQ/ML) INTRAVENOUS SYRINGE	86435
Y	SODIUM BICARBONATE INFUSION (NON-QS BASE)	1001040
Y	SODIUM CHLORIDE 0.45 % BOLUS IV	301317
Y	SODIUM CHLORIDE 0.45 % INTRAVENOUS SOLUTION	129269
Y	SODIUM CHLORIDE 0.65 % NASAL SPRAY AEROSOL	29676
Y	SODIUM CHLORIDE 0.9 % (FLUSH) INJECTION SYRINGE	86437
Y	SODIUM CHLORIDE 0.9 % FOR NEBULIZATION	7325
Y	SODIUM CHLORIDE 0.9 % INJECTION SOLUTION	7319
Y	SODIUM CHLORIDE 0.9 % INTRAVENOUS PIGGYBACK	95161
Y	SODIUM CHLORIDE 0.9 % INTRAVENOUS SOLUTION	27838
Y	SODIUM CHLORIDE 0.9 % IRRIGATION SOLUTION	11403
Y	SODIUM CHLORIDE 0.9 % IV PVC FREE	301251
Y	SODIUM CHLORIDE 0.9 %, BACTERIOSTATIC INJECTION SOLUTION	7028
Y	SODIUM CHLORIDE 0.9% BOLUS IV	168293
Y	SODIUM CHLORIDE 1 GRAM TABLET	7328
Y	SODIUM CHLORIDE 3 % FOR NEBULIZATION	7327
Y	SODIUM CHLORIDE 3 % INTRAVENOUS INJECTION SOLUTION	7321
Y	SODIUM CHLORIDE 4 MEQ/ML INTRAVENOUS SOLUTION	7322
Y	SODIUM CHLORIDE 5 % EYE DROPS	7332
Y	SODIUM CHLORIDE-ALOE VERA NASAL GEL	94168
Y	SODIUM CITRATE-CITRIC ACID 500 MG-334 MG/5 ML ORAL SOLUTION	15706
Y	SODIUM CL 0.45% WITH KCL 10 MEQ/L	168668
Y	SODIUM CL 0.45% WITH KCL 20 MEQ/L	168669
Y	SODIUM CL 0.45% WITH KCL 30 MEQ/L	168670
Y	SODIUM CL 0.45% WITH KCL 40 MEQ/L	168671
Y	SODIUM DI- AND MONOPHOSPHATE-POTASSIUM PHOS MONOBASIC 250 MG TABLET	81568
Y	SODIUM HYALURONATE-CHONDROITIN SULF 3%-4% AND SODIUM HYALURONATE 1% 0.35 ML	301700
Y	SODIUM HYALURONATE-CHONDROITIN SULFATE 3%-4% INTRAOCULAR SYRINGE	301703
Y	SODIUM HYPOCHLORITE 0.25 % SOLUTION	83485
Y	SODIUM NITRITE-SODIUM THIOSULFATE 300 MG/10 ML-12.5 GRAM/50 ML IV SOLN	193991
Y	SODIUM NITROPRUSSIDE 25 MG/ML INTRAVENOUS SOLUTION	18908
Y	SODIUM PHOSPHATE 15 MMOL IVPB	1000801
Y	SODIUM PHOSPHATE 20 MMOL IVPB	168657
Y	SODIUM PHOSPHATE 3 MMOL/ML INTRAVENOUS SOLUTION	7351
Y	SODIUM PHOSPHATE 30 MMOL IVPB	1000802
Y	SODIUM PHOSPHATES 19 GRAM-7 GRAM/118 ML ENEMA	81138
Y	SODIUM POLYSTYRENE SULFONATE 15 GRAM-SORBITOL 20 GRAM/60 ML ORAL SUSP	219546
Y	SODIUM POLYSTYRENE SULFONATE ORAL IMS TEMPLATE	1001421
Y	SODIUM THIOSULFATE 12.5 GRAM/50 ML (250 MG/ML) INTRAVENOUS SOLUTION	7364
Y	SOLIFENACIN 5 MG TABLET	93897
Y	SORBITOL 3 % IRRIGATION SOLUTION	7415
Y	SOTALOL 80 MG TABLET	11421

Y	SPIRONOLACTONE 100 MG TABLET	11425
Y	SPIRONOLACTONE 25 MG TABLET	7437
Y	SUCCINYLCHOLINE CHLORIDE 100 MG/5 ML (20 MG/ML) INTRAVENOUS SYRINGE	191001
Y	SUCCINYLCHOLINE CHLORIDE 20 MG/ML INJECTION SOLUTION	7536
Y	SUCCINYLCHOLINE INJECTION IMS TEMPLATE	1000909
Y	SUCRALFATE 1 GRAM TABLET	11442
Y	SUCROSE 24% ORAL SOLUTION	300015
Y	SULFACETAMIDE SODIUM 10 % EYE DROPS	7359
Y	SULFAMETHOXAZOLE 200 MG-TRIMETHOPRIM 40 MG/5 ML ORAL SUSPENSION	22560
Y	SULFAMETHOXAZOLE 400 MG-TRIMETHOPRIM 80 MG/5 ML INTRAVENOUS SOLUTION	7556
Y	SULFAMETHOXAZOLE 800 MG-TRIMETHOPRIM 160 MG TABLET	7555
Y	SULFANILAMIDE 15 % VAGINAL CREAM	78209
Y	SULFASALAZINE 500 MG TABLET	7562
Y	SUMATRIPTAN 50 MG TABLET	78652
Y	SUMATRIPTAN 6 MG/0.5 ML SUBCUTANEOUS SOLUTION	79781
Y	TACROLIMUS 1 MG CAPSULE	82570
Y	TAMOXIFEN 10 MG TABLET	7711
Y	TAMSULOSIN 0.4 MG CAPSULE	80077
Y	TELMISARTAN 80 MG TABLET	80810
Y	TEMAZEPAM 15 MG CAPSULE	7753
Y	TEMSIROLIMUS 30 MG/3 ML (10 MG/ML) (FIRST DILUTION) INTRAVENOUS SOLN	169141
Y	TEMSIROLIMUS IVPB	1000334
Y	TENECTEPLASE 50 MG INTRAVENOUS KIT	77985
Y	TERAZOSIN 1 MG CAPSULE	14550
Y	TERAZOSIN 5 MG CAPSULE	14553
Y	TERBINAFINE HCL 250 MG TABLET	79712
Y	TERBUTALINE 1 MG/ML SUBCUTANEOUS SOLUTION	11507
Y	TERBUTALINE 2.5 MG TABLET	11508
Y	TERCONAZOLE 0.4 % VAGINAL CREAM	11510
Y	TETANUS AND DIPHTHERIA TOX (PF) 5 LF UNIT-2 LF UNIT/0.5 ML IM SYRINGE	178321
Y	TETANUS DIPHTHERIA TOX (PF) VACCINE IMS TEMPLATE	1001304
Y	TETANUS IMMUNE GLOBULIN (PF) 250 UNIT INTRAMUSCULAR SYRINGE	178882
Y	TETRACAINE 0.5 % EYE DROPS	7795
Y	TETRACAINE HCL (PF) 0.5 % EYE DROPS	193379
Y	THIAMINE HCL (VITAMIN B1) 100 MG/ML INJECTION SOLUTION	7876
Y	THIAMINE IVPB	1000099
Y	THIAMINE MONONITRATE (VITAMIN B1) 100 MG TABLET	191409
Y	THIORIDAZINE 25 MG TABLET	7899
Y	THROMBIN (HUMAN)-FIBRINOGEN-APROTININ-CALCIUM 10 ML TOPICAL SYRINGE	168431
Y	THROMBIN (HUMAN)-FIBRINOGEN-APROTININ-CALCIUM 4 ML TOPICAL SYRINGE	168430
Y	THYROID (PORK) 65 MG TABLET	177738
Y	TICAGRELOR 60 MG TABLET	215074
Y	TICAGRELOR 90 MG TABLET	195747
Y	TIMOLOL MALEATE 0.5 % EYE DROPS	11562
Y	TIOTROPIUM BROMIDE 18 MCG CAPSULE WITH INHALATION DEVICE	92340
Y	TIZANIDINE 4 MG TABLET	14793
Y	TOBRAMYCIN 0.3 % EYE DROPS	7995
Y	TOBRAMYCIN 1.2 GRAM SOLUTION FOR INJECTION	11565
Y	TOBRAMYCIN 40 MG/ML INJECTION SOLUTION	7994
Y	TOBRAMYCIN CONSULT TO PHARMACY	168284

Y	TOBRAMYCIN EXTENDED INTERVAL IVPB	1000835
Y	TOBRAMYCIN IVPB	168659
Y	TOBRAMYCIN-DEXAMETHASONE 0.3 %-0.1 % EYE OINTMENT	78783
Y	TOCILIZUMAB 200 MG/10 ML (20 MG/ML) INTRAVENOUS SOLUTION	184016
Y	TOCILIZUMAB 400 MG/20 ML (20 MG/ML) INTRAVENOUS SOLUTION	184017
Y	TOCILIZUMAB 80 MG/4 ML (20 MG/ML) INTRAVENOUS SOLUTION	184015
Y	TOCILIZUMAB IVPB	1000610
Y	TOLTERODINE 2 MG TABLET	79866
Y	TOLTERODINE ER 2 MG CAPSULE,EXTENDED RELEASE 24 HR	76961
Y	TOLTERODINE ER 4 MG CAPSULE,EXTENDED RELEASE 24 HR	78012
Y	TOPIRAMATE 100 MG TABLET	82418
Y	TOPIRAMATE 25 MG TABLET	78823
Y	TOPOTECAN 4 MG INTRAVENOUS SOLUTION	79937
Y	TOPOTECAN IN NS 100 ML IV INFUSION	1000201
Y	TORSEMIDE 20 MG TABLET	18293
Y	TPN CONSULT TO PHARMACY	168286
Y	TRABECTEDIN 1 MG INTRAVENOUS SOLUTION	215484
Y	TRABECTEDIN INFUSION	1001331
Y	TRACE ELEMENTS CR-CU-MN-SE-ZN 10 MCG-1 MG-0.5 MG-60 MCG-5MG/ML IV SOLN	79384
Y	TRAMADOL 50 MG TABLET	14632
Y	TRANEXAMIC ACID 1,000 MG/10 ML (100 MG/ML) INTRAVENOUS SOLUTION	196970
Y	TRANEXAMIC ACID IVPB	1000924
Y	TRASTUZUMAB 150 MG INTRAVENOUS SOLUTION	222212
Y	TRASTUZUMAB IVPB	169806
Y	TRAZODONE 150 MG TABLET	8084
Y	TRAZODONE 50 MG TABLET	8085
Y	TRIAMCINOLONE ACETONIDE (PF) 40 MG/ML INTRAOCULAR SUSPENSION	178586
Y	TRIAMCINOLONE ACETONIDE 0.025 % TOPICAL CREAM	8112
Y	TRIAMCINOLONE ACETONIDE 0.1 % TOPICAL CREAM	8113
Y	TRIAMCINOLONE ACETONIDE 0.5 % TOPICAL CREAM	8114
Y	TRIAMCINOLONE ACETONIDE 10 MG/ML SUSPENSION FOR INJECTION	82054
Y	TRIAMCINOLONE ACETONIDE 40 MG/ML SUSPENSION FOR INJECTION	80370
Y	TRIAMTERENE 37.5 MG-HYDROCHLOROTHIAZIDE 25 MG TABLET	8132
Y	TRIHEXYPHENIDYL 5 MG TABLET	8167
Y	TRIMETHOPRIM-SULFAMETHOXAZOLE IVPB	1000067
Y	TROPICAMIDE 1 % EYE DROPS	8250
Y	TRYPAN BLUE 0.06 % INTRAOCULAR SYRINGE	95080
Y	URIDINE TRIACETATE 10 GRAM ORAL GRANULES IN PACKET	217529
Y	URSODIOL 300 MG CAPSULE	11624
Y	VALACYCLOVIR 500 MG TABLET	79112
Y	VALPROATE IVPB LOADING DOSE	169240
Y	VALPROATE IVPB ROUTINE	169241
Y	VALPROATE SODIUM 500 MG/5 ML (100 MG/ML) INTRAVENOUS SOLUTION	20887
Y	VALPROIC ACID (AS SODIUM SALT) 250 MG/5 ML (5 ML) ORAL SOLUTION	197584
Y	VALPROIC ACID 250 MG CAPSULE	8429
Y	VALSARTAN 80 MG TABLET	78747
Y	VANCOMYCIN 1,000 MG INTRAVENOUS INJECTION	8442
Y	VANCOMYCIN 1.25 GRAM INTRAVENOUS SOLUTION	228461
Y	VANCOMYCIN 1.5 GRAM INTRAVENOUS SOLUTION	228462
Y	VANCOMYCIN 10 GRAM INTRAVENOUS SOLUTION	11627

Y	VANCOMYCIN 1000 MG IN 100 ML DEXTROSE 5% IVPB (PREMIX)	189793
Y	VANCOMYCIN 1000 MG IN 100 ML SODIUM CHLORIDE 0.9% IVPB (PREMIX)	220585
Y	VANCOMYCIN 1000 MG IN 150 ML SODIUM CHLORIDE 0.9% IVPB (PREMIX)	191503
Y	VANCOMYCIN 1000 MG IN 200 ML DEXTROSE 5% IVPB (PREMIX)	93722
Y	VANCOMYCIN 1000 MG IN 200 ML SODIUM CHLORIDE 0.9% IVPB (PREMIX)	218355
Y	VANCOMYCIN 1000 MG IN 250 ML DEXTROSE 5% IVPB (PREMIX)	94029
Y	VANCOMYCIN 1000 MG IN 250 ML DISPENSABLE (ADS)	5000233
Y	VANCOMYCIN 1000 MG IN 250 ML DISPENSABLE (ADV ADS)	5000079
Y	VANCOMYCIN 1000 MG IN 250 ML SODIUM CHLORIDE 0.9% DISPENSABLE (ADV CMX)	5000248
Y	VANCOMYCIN 1000 MG IN 250 ML SODIUM CHLORIDE 0.9% DISPENSABLE (CMX)	5000230
Y	VANCOMYCIN 1000 MG IN 250 ML SODIUM CHLORIDE 0.9% IVPB (PREMIX)	94030
Y	VANCOMYCIN 125 MG CAPSULE	79303
Y	VANCOMYCIN 1250 MG IN 150 ML SODIUM CHLORIDE 0.9% IVPB (PREMIX)	184207
Y	VANCOMYCIN 1250 MG IN 250 ML DEXTROSE 5% IVPB (PREMIX)	184217
Y	VANCOMYCIN 1250 MG IN 250 ML DISPENSABLE (ADS)	5000349
Y	VANCOMYCIN 1250 MG IN 250 ML SODIUM CHLORIDE 0.9% IVPB (PREMIX)	190338
Y	VANCOMYCIN 1250 MG IN 262.5 ML SODIUM CHLORIDE 0.9% IVPB (PREMIX)	301164
Y	VANCOMYCIN 1500 MG IN 150 ML SODIUM CHLORIDE 0.9% IVPB (PREMIX)	184208
Y	VANCOMYCIN 1500 MG IN 250 ML DEXTROSE 5% IVPB (PREMIX)	193385
Y	VANCOMYCIN 1500 MG IN 250 ML SODIUM CHLORIDE 0.9% IVPB (PREMIX)	190339
Y	VANCOMYCIN 1500 MG IN 300 ML SODIUM CHLORIDE 0.9% IVPB (PREMIX)	301162
Y	VANCOMYCIN 1500 MG IN 500 ML DISPENSABLE (ADS)	5000351
Y	VANCOMYCIN 1500 MG IN 500 ML DISPENSABLE (CUSTOM RX IVPB)	5000235
Y	VANCOMYCIN 1500 MG IN 500 ML SODIUM CHLORIDE 0.9% IVPB (PREMIX)	218297
Y	VANCOMYCIN 1500 MG IN 515 ML SODIUM CHLORIDE 0.9% IVPB (PREMIX)	301536
Y	VANCOMYCIN 1750 MG IN 250 ML SODIUM CHLORIDE 0.9% IVPB (PREMIX)	219152
Y	VANCOMYCIN 1750 MG IN 350 ML SODIUM CHLORIDE 0.9% IVPB (PREMIX)	301231
Y	VANCOMYCIN 1750 MG IN 500 ML SODIUM CHLORIDE 0.9% IVPB (PREMIX)	190340
Y	VANCOMYCIN 2000 MG IN 250 ML SODIUM CHLORIDE 0.9% IVPB (PREMIX)	193892
Y	VANCOMYCIN 2000 MG IN 400 ML SODIUM CHLORIDE 0.9% IVPB (PREMIX)	301232
Y	VANCOMYCIN 2000 MG IN 500 ML SODIUM CHLORIDE 0.9% IVPB (PREMIX)	190341
Y	VANCOMYCIN 4 MG/0.4 ML OPHTHALMIC INJECTION	301801
Y	VANCOMYCIN 500 MG IN 100 ML DEXTROSE 5% IVPB (PREMIX)	82775
Y	VANCOMYCIN 500 MG IN 100 ML DISPENSABLE (ADS)	5000231
Y	VANCOMYCIN 500 MG IN 100 ML DISPENSABLE (CUSTOM RX IVPB)	5000258
Y	VANCOMYCIN 500 MG IN 100 ML DISPENSABLE (MBP ADS)	5000080
Y	VANCOMYCIN 500 MG IN 100 ML DISPENSABLE (MBP CMX)	5000227
Y	VANCOMYCIN 500 MG IN 100 ML SODIUM CHLORIDE 0.9% DISPENSABLE (CMX)	5000228
Y	VANCOMYCIN 500 MG IN 100 ML SODIUM CHLORIDE 0.9% IVPB (PREMIX)	218818
Y	VANCOMYCIN 500 MG INTRAVENOUS SOLUTION	8443
Y	VANCOMYCIN 750 MG IN 150 ML DEXTROSE 5% IVPB (PREMIX)	193807
Y	VANCOMYCIN 750 MG IN 150 ML SODIUM CHLORIDE 0.9% IVPB (PREMIX)	184209
Y	VANCOMYCIN 750 MG IN 150 ML SODIUM CHLORIDE 0.9% IVPB (PREMIX)	218813
Y	VANCOMYCIN 750 MG IN 250 ML DEXTROSE 5% IVPB (PREMIX)	218915
Y	VANCOMYCIN 750 MG IN 250 ML DISPENSABLE (ADS)	5000232
Y	VANCOMYCIN 750 MG IN 250 ML DISPENSABLE (ADV ADS)	5000081
Y	VANCOMYCIN 750 MG IN 250 ML SODIUM CHLORIDE 0.9% DISPENSABLE (CMX)	5000229
Y	VANCOMYCIN 750 MG IN 250 ML SODIUM CHLORIDE 0.9% IVPB (PREMIX)	216142
Y	VANCOMYCIN 750-1000 MG IN 250 ML DISPENSABLE (CUSTOM RX IVPB)	5000234
Y	VANCOMYCIN CONSULT TO PHARMACY	167991

Y	VANCOMYCIN CUSTOM DOSE IVPB (DO NOT USE)	168291
Y	VANCOMYCIN CUSTOM DOSE IVPB IN 500 ML (DO NOT USE)	1000857
Y	VANCOMYCIN IVPB IMS TEMPLATE	1000841
Y	VANCOMYCIN OVER 2000 MG IN 500 ML DISPENSABLE (CUSTOM RX IVPB)	5000420
Y	VARICELLA VIRUS VACCINE LIVE (PF) 1,350 UNIT/0.5 ML SUBCUTANEOUS SUSP	95938
Y	VASOPRESSIN 20 UNIT/ML INTRAVENOUS SOLUTION	211947
Y	VASOPRESSIN INFUSION IMS TEMPLATE	170289
Y	VASOPRESSIN INFUSION	1000568
Y	VECURONIUM BROMIDE 10 MG INTRAVENOUS SOLUTION	11634
Y	VECURONIUM IV INFUSION	177368
Y	VEDOLIZUMAB 300 MG INTRAVENOUS SOLUTION	209778
Y	VEDOLIZUMAB IVPB	1001153
Y	VENLAFAXINE 75 MG TABLET	77452
Y	VENLAFAXINE ER 37.5 MG CAPSULE,EXTENDED RELEASE 24 HR	77281
Y	VENLAFAXINE ER 75 MG CAPSULE,EXTENDED RELEASE 24 HR	77315
Y	VERAPAMIL 2.5 MG/ML INTRAVENOUS SOLUTION	8527
Y	VERAPAMIL 80 MG TABLET	8530
Y	VERAPAMIL ER (SR) 120 MG TABLET,EXTENDED RELEASE	13184
Y	VERAPAMIL ER (SR) 180 MG TABLET,EXTENDED RELEASE	14626
Y	VINBLASTINE 1 MG/ML INTRAVENOUS SOLUTION	8594
Y	VINCRIStINE 1 MG/ML INTRAVENOUS SOLUTION	8597
Y	VINCRIStINE 2 MG/2 ML INTRAVENOUS SOLUTION	179912
Y	VINORELBINE 10 MG/ML INTRAVENOUS SOLUTION	14203
Y	VINORELBINE 50 MG/5 ML INTRAVENOUS SOLUTION	179663
Y	VITAMIN A 10,000 UNIT CAPSULE	8639
Y	VITAMIN E (DL, ACETATE) 400 UNIT CAPSULE	180444
Y	VITAMINS A AND D-WHITE PETROLATUM-LANOLIN TOPICAL OINTMENT	180957
Y	VORICONAZOLE 200 MG INTRAVENOUS SOLUTION	85251
Y	VORICONAZOLE 200 MG TABLET	85250
Y	VORICONAZOLE 200 MG/5 ML (40 MG/ML) ORAL SUSPENSION	92274
Y	VORICONAZOLE IVPB	177301
Y	WARFARIN 1 MG TABLET	11664
Y	WARFARIN 2 MG TABLET	8749
Y	WARFARIN 2.5 MG TABLET	8750
Y	WARFARIN 3 MG TABLET	19433
Y	WARFARIN 4 MG TABLET	21372
Y	WARFARIN 5 MG TABLET	8751
Y	WARFARIN 7.5 MG TABLET	8752
Y	WARFARIN CONSULT TO PHARMACY	167990
Y	WATER FOR INJECTION, BACTERIOSTATIC INJECTION SOLUTION	864
Y	WATER FOR INJECTION, STERILE INJECTION SOLUTION	79513
Y	WATER FOR INJECTION, STERILE INTRAVENOUS SOLUTION	28400
Y	WATER FOR IRRIGATION, STERILE SOLUTION	7485
Y	WHITE PETROLATUM 43 % TOPICAL OINTMENT	181945
Y	WHITE PETROLATUM-MINERAL OIL 56.8 %-42.5 % EYE OINTMENT	177581
Y	WITCH HAZEL - GLYCERIN TOPICAL PADS IMS TEMPLATE	1000783
Y	WITCH HAZEL 50 % TOPICAL PADS	189222
Y	ZINC OXIDE 17 %-WHITE PETROLATUM 57 % TOPICAL PASTE	211120
Y	ZINC OXIDE 20 % TOPICAL OINTMENT	8874
Y	ZINC OXIDE-COD LIVER OIL 40 % TOPICAL PASTE	184248

Y	ZINC SULFATE 220 MG (50 MG) CAPSULE	129887
Y	ZIPRASIDONE 20 MG CAPSULE	79829
Y	ZIPRASIDONE 20 MG/ML (FINAL CONCENTRATION) INTRAMUSCULAR SOLUTION	86231
Y	ZIV-AFLIBERCEPT 100 MG/4 ML (25 MG/ML) IV	201472
Y	ZIV-AFLIBERCEPT IVPB	1000970
Y	ZOLEDRONIC ACID 4 MG IN 100 ML SODIUM CHLORIDE 0.9% (ADS)	5000435
Y	ZOLEDRONIC ACID 4 MG/100 ML INFUSION IMS TEMPLATE	1001176
Y	ZOLEDRONIC ACID 4 MG/5 ML INTRAVENOUS SOLUTION	87720
Y	ZOLEDRONIC ACID 5 MG/100 ML IN MANNITOL 5 %-WATER INTRAVENOUS PIGGYBCK	168190
Y	ZOLEDRONIC IVPB	1000070
Y	ZOLPIDEM 5 MG TABLET	81803
Y	ZOSTER VACCINE LIVE (PF) 19,400 UNIT/0.65 ML SUBCUTANEOUS SUSPENSION	95907



# TAHOE FOREST HEALTH SYSTEM

Origination Date:	N/A
Last Approved:	N/A
Last Revised:	N/A
Next Review:	N/A
Department:	<i>Health Information Management - DHIM</i>
Applicabilities:	<i>System</i>

## Scanning Advance Directives/POLSTS into the Electronic Health Record, DHIM-2001

### PURPOSE:

- A. To support the implementation of the Patient Self Determination Act within the framework of state and federal law advance directive laws.
- B. To ensure the advance directives documents and/or POLSTs are obtained from the patient/family and are secured by the responsible department and are accurately scanned into the electronic health record.

### POLICY:

- A. All Advance Directives and/or POLSTs (AD/P) will be maintained and secured in the electronic health record as soon as possible and the patient's storyboard is updated to indicate that the patient has an AD/P.
- B. A manual log to track receipt of an AD/P will be kept and filed in the G: drive, Public Folder and dept. for the following Departments:
  - 1. HIM
  - 2. Cancer Center
  - 3. Home Health/Hospice
  - 4. Palliative Care Team
- C. HIM Department, Cancer Center and Home Health staff are the only staff that can scan AD/P into the electronic health record.
- D. The electronic health record storyboard will automatically read "AD Received" when an AD/P is scanned into EPIC under Document Type: Advance Directive.
- E. All errors related to the quality of the scanned AD/P, scan location, document type or missing AD/P will be brought to the attention of the HIM Dept staff immediately.
- F. HIM, Cancer Center, Home Health/Hospice, Palliative Care Team will perform quality control/assurance of scanned documents to validate the accuracy of their scanned document/information.
- G. Scanned Advance Directives/POLSTs will be shredded after 30 days of retention in the respective department.



# PROCEDURE:

## A. Registration Staff

1. Registration staff will provide the TFH Acknowledgment of Advance Directive Form to: inpatients, observation patients, ambulatory surgery and emergency department patients to complete and authenticate.
2. The Registration staff will single scan the TFH Acknowledgement of AD Form into EPIC using Registration Documents Table and selecting Document Type: TFH Acknowledgement of AD Info, and type the Description: TFH Acknowledgement of AD Info.
3. If a patient presents with a valid Advance Directive or POLST, the Registration Staff will make a copy of the AD/P, and give the patient/family the original document to maintain.
4. Use the stamp labeled "COPY" and stamp the AD/P.
5. The copy of the AD/P will be scanned and saved as a PDF file. The PDF file will be emailed to HIM Dept at [HIMroi@tfhd.com](mailto:HIMroi@tfhd.com)
6. The HIM Staff will receive the email and immediately scan the AD/P into EPIC in Media Manager under Document Type Advance Directive, at the patient level.
7. The Registration staff will not scan Advance Directives or POLST into the electronic health record.

## B. Maintaining Inpatient Advance Directives/POLSTs

1. If a patient provides hospital staff with an Advance Directive or POLST, the Unit Clerk or the Case Manager, will provide a copy of the document to the HIM Dept Clerk to scan into the electronic record asap.
2. The Case Manager will review the AD/P as part of the Discharge Planning process and verify that the AD/P is filed accurately in EPIC.
  - a. The Case Management Department employee is able to scan AD/P, in addition to the HIM Dept employee, and will provide coverage when necessary.
3. In the event that there is an error in EPIC related to the quality, or misfile of an AD/P, contact the HIM Dept immediately.

## C. Maintaining Inpatient Advance Directives/POLSTs after regular business hours/weekends/holidays

1. If a patient provides hospital staff with an AD/P after regular business hours.
2. Make 2 copies of the AD/P and use the stamper labeled "COPY" and stamp the AD/P.
3. Place one copy in the "paper light chart" on the Inpatient Unit, and place a bright yellow "ADVANCE DIRECTIVE" square sticker on the front of the chart.
4. The Unit clerk will create a "Secure Chat" in EPIC to the treatment team to let them know the AD/P is in the "paper light chart".
5. Place the second copy of the AD/P in an inter-office envelope and mail to TFH HIM Dept.. The AD/P will be scanned into EPIC within the next business day by the HIM Dept Clerk.
6. Each shift, the inpatient Unit Clerk will check the inpatient "paper light charts" for AD/P.
7. On the next business day, the Unit Clerk will hand deliver the AD/P to the HIM Dept Clerk to be scanned into EPIC.

**D. Health Information Management Department workflow**

1. HIM Dept Clerk will receive AD/P in an interoffice envelope or via email (attached as a PDF file).
2. HIM staff will single scan at the Patient Level using Media Manager.
3. HIM Dept Clerk can also obtain AD/P from "paper light chart" for inpatients and single scan the document.
4. If an updated AD/P is received from the family/guardian/patient and an existing AD/P is in the electronic health record:
  - a. Single scan the most recent AD/P and edit the description to read "**UPDATED and DATE.**" at the patient level.
  - b. Both the updated and the previous AD/P will remain in the electronic record at the patient level.
5. Priority is given to scanning AD/P into the electronic health record.

**E. Cancer Center and Palliative Care Team**

1. Advance Directives/POLSTs will be scanned into the electronic health record at the patient level by Cancer Center staff.
2. If an updated AD/P is received from the family/guardian/patient and an existing AD/P is in the electronic health record
3. Single scan the most recent AD/P and edit the description to read "**UPDATED and DATE.**" at the patient level.
4. Both the updated and the previous AD/P will remain in the electronic record at the patient level.
5. A record of scanned AD/P is kept on the G Drive:-Public-Departments-CA Center-Advance Directive folder

**F. Home Health/Hospice Departments**

1. Advance Directives/POLSTs will be scanned into the electronic health record at the patient level by the Home Health Office staff.
2. If an updated AD/P is received from the family/guardian/patient and an existing AD/P is in the electronic health record
3. Single scan the most recent AD/P and edit the description to read "**UPDATED and DATE.**" at the patient level.
4. Both the updated and the previous AD/P will remain in the electronic record at the patient level.
5. A record of scanned AD/P is kept on the G Drive-Public-Departments-Home Health-Advance Directives folder

**G. Multi-Specialty Clinics workflow**

1. If a patient provides an authenticated TFH Acknowledgement of AD form, the Clinic Staff will single scan (at the encounter level) the document into EPIC using **DOCUMENT TYPE** : TFH Acknowledgement of AD. and **Description**: TFH Acknowledgement of AD.
2. If a patient presents a valid AD/P to the clinic staff, the staff will make a copy of the AD/P and save it as a PDF file.

3. The Clinic Staff will email the AD/P PDF file to [HIMroi@tfhd.com](mailto:HIMroi@tfhd.com).
4. The AD/P will be scanned into EPIC by HIM staff.
5. The Clinic Staff will not scan AD/P into EPIC.

#### H. Surgical Services Department workflow

1. During the first pre-admit telephone call, the Pre-admit office staff inquires if patient has an Advance Directive or POLST.
2. If patient does not have an AD/P, the Pre-admit Nurse advises patient that the AD/P forms are available at the Registration Desk at the hospital to pick up prior to surgery or day of surgery. **Forms are also on line.**
3. If the AD/P is to be completed on the day of surgery, patient arrives 30 minutes prior to check in time.
4. If the patient presents an AD/P once admitted to the Department, the form is given to Registration Staff to follow their workflow.
5. All patients are asked about an AD/P in the pre-procedure checklist.

#### I. Quality Control and retention of scanned documents:

1. One employee will scan the AD/P document and another employee will verify and validate the following information is correct:
2. Patient Name, medical record number, Document Type, Document Description, quality of documents, scanned at Patient Level, verify Storyboard is updated.
3. Each department will complete the information on their Department AD/P Log and track scan date, quality control and destruction date.
4. Once Quality Control is complete and accuracy validated, the AD/P should be held in the Dept for 30 days and then destroyed.
5. Each Dept will maintain a file of the hard copy AD/P and track the destruction date.

## Special Instructions / Definitions:

- A. **"SCANNED" Stamp** - stamp with red ink to be used to stamp the document and inform others the document was scanned.
- B. **POLST** - Physician Orders for Life-Sustaining Treatment
- C. **"COPY" Stamp** - stamp with red ink to be used to stamp the document and inform others that the document is a copy.
- D. **Advance Directive Stickers** - yellow stickers that will be placed on the Inpatient or ED paper light chart.

## Related Forms:

- A. 1California Hospital Association Advance Health Care Directive Form
- B. 2California POLST Form
- C. Tahoe Forest Hospital Acknowledgement of Advance Directives Form
- D. Department AD/Polst Log Excel Report

## References:

Patient Self Determination Act (PSDA) 42 U.S.C. Sections 1395i-3, 1395f, 1395cc, 1395mm, 1395bbb, 1396a, 1396b and 1396r;

**CALIFORNIA: Uniform Health Care Decisions Act California Prob Code §§ 4600-4806; Powers of Attorney for Health Care California Prob Code §§4680-4690; Advance Health Care Directive Forms California Prob Code §§4700 - 4701;**

Advance Health Care Directive Form Instructions - Attorney General

**NEVADA: (NRS) 449.535 to 449.720; Nevada Department of Health and Human Services; Written Information to Provide to Patients on NV Law Concerning Advance Directives; Guidance on Community Education Requirements; <http://www.unr.edu/>**

California Hospital Association Consent Manual

<https://capolst.org/>

## Related Policies/Forms:

Advance Directive Acknowledgment Form; CA Advance Directive Brochure; NV Advance Directive Brochure – *Contact Patient Registration for current brochures and form.*

Durable Power of Attorney ALG-1906 ; Advance Directive, DPTREG-1901

**Nursing :** Social Service Referrals ANS-103 ; DNAR- Withholding or Withdrawing Life Sustaining Procedures ANS-35 ; Admission to ECC from Acute ANS-139 ; DNAR – Surgical Patients DOR-12

**Skilled Nursing :** ECC Admission of Resident DECC-006

**Home Health :** Home Health Patient Bill of Rights – HH DHH-2001 ; Do Not Resuscitate/Do Not Intubate Orders, DHH-2047 ; Cardiopulmonary Resuscitation, DHH-2048 ; Withdrawal of Life-Sustaining Care, DHH-2049

**Hospice :** Advanced Directives DHOS-1004 ; Assessment / Reassessment, ANS-214 ; Social Service Referrals ANS-103

All revision dates:

## Attachments

AD DEPT LOG.xlsx

Advance Directive Acknowledgement English.pdf

Advance Health Care Directive 2019.pdf

CA POLST\_2017\_Final.pdf



# SPECIAL MEETING OF THE BOARD OF DIRECTORS **DRAFT** MINUTES

Thursday, April 23, 2020 at 2:30 p.m.

Pursuant to Section 3 of Executive Order N-29-20, issued by Governor Newsom on March 17, 2020, a Special Meeting of the Tahoe Forest Hospital District Board of Directors for April 23, 2020 will be conducted telephonically through Zoom. Please be advised that pursuant to the Executive Order, and to ensure the health and safety of the public by limiting human contact that could spread the COVID-19 virus, the Eskridge Conference Room will not be open for the meeting. Board Members will be participating telephonically and will not be physically present in the Eskridge Conference Room.

**If you would like to speak on an agenda item, you can access the meeting remotely:**

Please use this web link: <https://tfhd.zoom.us/j/91355795004>

**Or join by phone:**

If you prefer to use your phone, you may call in using the numbers below.

(346) 248 7799 or (301) 715 8592

Meeting ID: 913 5579 5004

Public comment will also be accepted by email to [mrochefort@tfhd.com](mailto:mrochefort@tfhd.com). Please list the item number you wish to comment on and submit your written comments 24 hours prior to the start of the meeting.

Oral public comments will be subject to the three minute time limitation (approximately 350 words). Written comments will be distributed to the board prior to the meeting but not read at the meeting.

## **1. CALL TO ORDER**

**Meeting was called to order at 2:33 p.m.**

## **2. ROLL CALL**

Board: Alyce Wong, Board Chair; Mary Brown, Vice Chair; Art King, Secretary; Dale Chamblin, Treasurer; Michael McGarry, Board Member

Staff in attendance: Harry Weis, Chief Executive Officer; Judy Newland, Chief Operating Officer; Crystal Betts, Chief Financial Officer; Karen Baffone, Chief Nursing Officer; Jake Dorst, Chief Information Innovation Officer; Alex MacLennan, Chief Human Resources Officer; Dr. Shawni Coll, Chief Medical Officer; Matt Mushet, In-House Counsel; Ted Owens, Executive Director of Governance; Janet Van Gelder, Director of Quality; Martina Rochefort, Clerk of the Board

Other: David Ruderman, Assistant General Counsel

## **3. DELETIONS/CORRECTIONS TO THE POSTED AGENDA**

No changes were made to the agenda.

## **4. INPUT AUDIENCE**

No public comment was received.

Open Session recessed at 2:35 p.m.

**5. CLOSED SESSION**

**5.1. Hearing (Health & Safety Code § 32155)**

*Subject Matter: Quality Assurance Report*

*Number of items: One (1)*

Discussion was held on a privileged item.

**6. OPEN SESSION**

Open Session reconvened at 4:01 p.m.

**7. REPORT OF ACTIONS TAKEN IN CLOSED SESSION, IF NECESSARY**

**8. ADJOURN**

Meeting adjourned at 4:02 p.m.

DRAFT



# REGULAR MEETING OF THE BOARD OF DIRECTORS **DRAFT** MINUTES

Thursday, April 23, 2020 at 4:00 p.m.

Pursuant to Section 3 of Executive Order N-29-20, issued by Governor Newsom on March 17, 2020, the Regular Meeting of the Tahoe Forest Hospital District Board of Directors for April 23, 2020 will be conducted telephonically through Zoom. Please be advised that pursuant to the Executive Order, and to ensure the health and safety of the public by limiting human contact that could spread the COVID-19 virus, the Eskridge Conference Room will not be open for the meeting. Board Members will be participating telephonically and will not be physically present in the Eskridge Conference Room.

If you would like to speak on an agenda item, you can access the meeting remotely:

Please use this web link: <https://zoom.us/j/91893367689>

**Or join by phone:**

If you prefer to use your phone, you may call in using the numbers below.

(346) 248 7799 or (301) 715 8592

Meeting ID: 918 9336 7689

Public comment will also be accepted by email to [mrochefort@tfhd.com](mailto:mrochefort@tfhd.com). Please list the item number you wish to comment on and submit your written comments 24 hours prior to the start of the meeting.

Oral public comments will be subject to the three minute time limitation (approximately 350 words). Written comments will be distributed to the board prior to the meeting but not read at the meeting.

## **1. CALL TO ORDER**

**Meeting was called to order at 4:03 p.m.**

## **2. ROLL CALL**

Board: Alyce Wong, Board Chair; Mary Brown, Vice Chair; Art King, Secretary; Dale Chamblin, Treasurer; Michael McGarry, Board Member

Staff in attendance: Harry Weis, Chief Executive Officer; Judy Newland, Chief Operating Officer; Matt Mushet, In-House Counsel; Martina Rochefort, Clerk of the Board

Other: David Ruderman, Assistant General Counsel

## **3. DELETIONS/CORRECTIONS TO THE POSTED AGENDA**

No changes were made to the agenda.

## **4. INPUT AUDIENCE**

No public comment was received.

**Open Session recessed at 4:09 p.m.**

**5. CLOSED SESSION**

**5.1. Hearing (Health & Safety Code § 32155)**

*Subject Matter: First Quarter 2020 Corporate Compliance Program Report*

*Number of items: One (1)*

Discussion was held on a privileged item.

**5.2. Conference with Legal Counsel; Anticipated Litigation (Gov. Code § 54956.9(d)(2) & (d)(3))**

*A point has been reached where, in the opinion of the District Board, on the advice of its legal counsel, based on the below-described existing facts and circumstances, there is a significant exposure to litigation against the District.*

*Statement made outside an open meeting of District (Gov. Code §54956.9(e)(5)) by Corrine Zack regarding access to medical records, and a written record of the statement was made prior to the meeting and is available for public inspection in the Clerk's office.*

Discussion was held on a privileged item.

**5.3. Hearing (Health & Safety Code § 32155)**

*Subject Matter: 2019 Annual Quality Report*

*Number of items: One (1)*

Discussion was held on a privileged item.

**5.4. Hearing (Health & Safety Code § 32155)**

*Subject Matter: Quality Assurance Report*

*Number of items: One (1)*

Discussion was held on a privileged item.

**5.5. Approval of Closed Session Minutes**

03/26/2020

Discussion was held on a privileged item.

**5.6. TIMED ITEM – 5:30PM - Hearing (Health & Safety Code § 32155)**

*Subject Matter: Medical Staff Credentials*

Discussion was held on a privileged item.

**6. DINNER BREAK**

**7. OPEN SESSION – CALL TO ORDER**

Open Session reconvened at 6:04 p.m.

**8. REPORT OF ACTIONS TAKEN IN CLOSED SESSION**

General Counsel noted there was no reportable action on item 5.1. through 5.4. Item 5.5. was approved on a 5-0 vote and item 5.6. was also approved on a 5-0 vote.

**9. DELETIONS/CORRECTIONS TO THE POSTED AGENDA**

No changes were made to the agenda.



**10. INPUT – AUDIENCE**

No public comment was received.

**11. INPUT FROM EMPLOYEE ASSOCIATIONS**

No public comment was received.

**12. ACKNOWLEDGMENTS**

**12.1.** Svieta Schopp was named April 2020 Employee of the Month.

**13. MEDICAL STAFF EXECUTIVE COMMITTEE**

**13.1.** Medical Executive Committee (MEC) Meeting Consent Agenda  
*MEC recommended the following for approval by the Board of Directors:*

With content changes

- *Bylaws*
- *Rules & Regulation*
- *Standardized Procedures for PA's and NP's*
- *Trauma Activation Algorithm*
- *AHP Guidelines*
- *NP-PA Privilege Form*

New Privilege Forms

- *Licensed Clinical Social Workers*
- *Licensed Marriage Family Therapist*
- *PA CA Practice Agreement*
- *Collaborative Practice Agreement NP*

Discussion was held.

No public comment was received.

**ACTION: Motion made by Director Brown to approve the Medical Executive Committee Meeting Consent Agenda as presented, seconded by Director McGarry. Roll call vote taken.**  
**McGarry – AYE**  
**Chamblin – AYE**  
**King – AYE**  
**Brown – AYE**  
**Wong – AYE**

**14. CONSENT CALENDAR**

**14.1. Approval of Minutes of Meetings**

**14.1.1.** 03/26/2020

**14.2. Financial Reports**

**14.2.1.** Financial Report – March 2020

**14.3. Approve Board Policies**

**14.3.1.** Financial Assistance Program Full Charity Care and Discount Partial Charity Care Policies, ABD-09

**14.3.2.** Emergency On-Call Policy, ABD-10

**14.4. Ratify new TFHS Foundation Board Member**

**14.4.1.** Alan Kern - Resume

**14.5. Accept Quarterly Compliance Report**

**14.5.1.** First Quarter 2020 Corporate Compliance Program Report

Discussion was held.

No public comment was received.

**ACTION:** Motion made by Director Chamblin to approve the Consent Calendar as presented, seconded by Director King. Roll call vote taken.

**McGarry – AYE**

**Chamblin – AYE**

**King – AYE**

**Brown – AYE**

**Wong – AYE**

**15. ITEMS FOR BOARD DISCUSSION**

**15.1. Annual Foundations Update**

Karli Epstein, Executive Director of Foundations, provided an annual update on the Tahoe Forest Health System Foundation and Incline Village Community Hospital Foundation.

**15.2. COVID-19 Update**

CEO provided an update on hospital and clinic operations related to COVID-19.

**16. ITEMS FOR BOARD ACTION**

**16.1. Resolution 2020-04 Declaration of Emergency**

The Board of Directors reviewed and considered approval of a resolution declaring and confirming a state of emergency due to spread and threatened spread of COVID-19.

Discussion was held.

No public comment was received.

**ACTION:** Motion made by Director Brown to approve Resolution 2020-04 as presented, seconded by Director McGarry. Roll call vote taken.

**McGarry – AYE**

**Chamblin – AYE**

**King – AYE**

**Brown – AYE**

**Wong – AYE**

**16.2. Moss Adams Engagement Letter**

*Director King recused himself from this item and disclosed the basis of his financial conflict. Clerk removed Director King from the meeting at 7:01 p.m.*

The Board of Directors reviewed and considered approval of a three-year engagement letter with Moss Adams for audit and nonattest services.

Discussion was held.

No public comment was received.

**ACTION: Motion made by Director Chamblin, seconded by Director McGarry, to approve the Moss Adams Engagement Letter subject to legal review. Roll call vote taken.**

**McGarry – AYE**

**Chamblin – AYE**

**Brown – AYE**

**Wong – AYE**

**Motion approved on a 4-0 vote.**

*Director King rejoined the meeting at 7:13 p.m.*

**17. DISCUSSION OF CONSENT CALENDAR ITEMS PULLED, IF NECESSARY**

Not applicable.

**18. BOARD COMMITTEE REPORTS**

None.

**19. BOARD MEMBERS REPORTS/CLOSING REMARKS**

Director McGarry attended the Foundation Board Meeting but update was covered by Executive Director of Foundations under item 15.1.

**20. CLOSED SESSION CONTINUED, IF NECESSARY**

Not applicable.

**21. OPEN SESSION**

**22. REPORT OF ACTIONS TAKEN IN CLOSED SESSION, IF NECESSARY**

**23. ADJOURN**

**Meeting adjourned at 7:15 p.m.**

**TAHOE FOREST HOSPITAL DISTRICT  
APRIL 2020 FINANCIAL REPORT  
INDEX**

<b>PAGE</b>	<b>DESCRIPTION</b>
2 - 3	FINANCIAL NARRATIVE
4	STATEMENT OF NET POSITION
5	NOTES TO STATEMENT OF NET POSITION
6	CASH INVESTMENT
7	TFHD STATEMENT OF REVENUES, EXPENSES, AND CHANGES IN NET POSITION
8 - 9	TFHD NOTES TO STATEMENT OF REVENUES, EXPENSES, AND CHANGES IN NET POSITION
10	IVCH STATEMENT OF REVENUE AND EXPENSE
11 - 12	IVCH NOTES TO STATEMENT OF REVENUE AND EXPENSE
13	STATEMENT OF CASH FLOW

**Board of Directors**  
*Of Tahoe Forest Hospital District*  
**APRIL 2020 FINANCIAL NARRATIVE**

The following is the financial narrative analyzing financial and statistical trends for the ten months ended April 30, 2020.

**Activity Statistics**

- ❑ TFH acute patient days were 352 for the current month compared to budget of 338. This equates to an average daily census of 11.7 compared to budget of 11.3.
- ❑ TFH Outpatient volumes were below budget in the following departments by at least 5%: Emergency Department visits, Clinic visits, Home Health and Hospice visits, Surgery cases, Pain consults, Diagnostic Imaging, Mammography, Nuclear Medicine, MRI, Ultrasounds, Cat Scans, PET CTs, Pharmacy units, Respiratory Therapy, Gastroenterology cases, Physical Therapy, Speech Therapy, and Occupational Therapy.

**Financial Indicators**

- ❑ Net Patient Revenue as a percentage of Gross Patient Revenue was 57.1% in the current month compared to budget of 50.3% and to last month's 53.0%. Current year's Net Patient Revenue as a percentage of Gross Patient Revenue was 50.7% compared to budget of 50.0% and prior year's 51.2%.
- ❑ EBIDA was \$(673,234) (-3.9%) for the current month compared to budget of \$129,919 (.5%), or \$(803,153) (-4.3%) below budget. Year-to-date EBIDA was \$18,312,944 (5.7%) compared to budget of \$11,191,178 (3.6%), or \$7,121,766 (2.2%) above budget.
- ❑ Net Income was \$(1,073,642) for the current month compared to budget of \$(283,118) or \$(790,524) below budget. Year-to-date Net Income was \$13,016,468 compared to budget of \$7,103,058 or \$5,913,410 above budget. Without the COVID-19 Emergency Funding received from HHS Net Income would have been \$(4,853,894) and Year-to-date Net Income would have been \$9,236,216.
- ❑ Cash Collections for the current month were \$13,402,946, which is 79% of targeted Net Patient Revenue.
- ❑ EPIC Gross Accounts Receivables were \$80,857,861 at the end of April compared to \$89,173,217 at the end of March.

**Balance Sheet**

- ❑ Working Capital is at 85.9 days (policy is 30 days). Days Cash on Hand (S&P calculation) is 227.4 days. Working Capital cash increased a net \$25,416,000. Accounts Payable decreased \$1,604,000 and Accrued Payroll & Related Costs decreased \$479,000. The District received \$4,126,000 from Centene for the FY19 Rate Range IGT and HQAF programs, \$3,780,000 from HHS for COVID-19 Emergency Funding, and \$20,381,000 in Medicare Accelerated payments. Cash collections were below budget 21%.
- ❑ Net Patient Accounts Receivable decreased approximately \$4,538,000 and Cash collections were 79% of target. EPIC Days in A/R were 83.0 compared to 77.1 at the close of March, a 5.90 days increase.
- ❑ Estimated Settlements, Medi-Cal & Medicare decreased a net \$3,071,000. The District recorded the estimated April FY20 receivable from the Rate Range IGT, Medi-Cal PRIME, and Quality Assurance Fee programs and remitted funds to the State of \$467,000 for participation in the DY15 Medi-Cal PRIME program. The District received and recorded \$4,126,000 from Centene for the FY19 Rate Range IGT and HQAF programs.
- ❑ Accounts Payable decreased \$1,604,000 as we witnessed a reduction in A/P with the decrease in operations.
- ❑ Accrued Payroll & Related Costs decreased a net \$479,000 due to an increase in accrued payroll days in April, which was offset by the semi-annual funding of the Employer's portion of Deferred Comp.
- ❑ Estimated Settlements, Medi-Cal & Medicare, increased \$21,195,000. The District recorded \$20,381,000 of Medicare Accelerated payments as a liability as these funds will have to be repaid to the Medicare program through claim withhold or direct remittance, along with recording a \$814,000 settlement from the Medicare program until we receive information from our intermediary as to the nature and validity of the funds.

**Operating Revenue**

- ❑ Current month’s Total Gross Revenue was \$17,439,796, compared to budget of \$27,454,967 or \$10,015,171 below budget.
- ❑ Current month’s Gross Inpatient Revenue was \$5,469,533, compared to budget of \$7,146,504 or \$1,676,971 below budget.
- ❑ Current month’s Gross Outpatient Revenue was \$11,970,263 compared to budget of \$20,308,463 or \$8,338,200 below budget.
- ❑ Current month’s Gross Revenue Mix was 36.3% Medicare, 18.0% Medi-Cal, .0% County, 6.6% Other, and 39.1% Insurance compared to budget of 37.9% Medicare, 16.3% Medi-Cal, .0% County, 3.1% Other, and 42.7% Insurance. Last month’s mix was 32.2% Medicare, 18.2% Medi-Cal, .0% County, 3.5% Other, and 46.1% Insurance. Year-to-date Gross Revenue Mix was 38.2% Medicare, 14.5% Medi-Cal, .0% County, 3.2% Other, and 44.1% Insurance compared to budget of 38.1% Medicare, 15.9% Medi-Cal, .0% County, 3.1% Other, and 42.9% Insurance.
- ❑ Current month’s Deductions from Revenue were \$7,473,816 compared to budget of \$13,644,702 or \$6,170,886 below budget. Variance is attributed to the following reasons: 1) Payor mix varied from budget with a 1.66% decrease in Medicare, a 1.70% increase to Medi-Cal, 0.05% increase to County, a 3.47% increase in Other, and Commercial was below budget 3.56% and 2) Revenues fell short of budget by 36.50%.

DESCRIPTION	April 2020 Actual	April 2020 Budget	Variance	BRIEF COMMENTS
Salaries & Wages	6,501,454	5,880,127	(621,327)	Negative variance in Salaries & Wages due to the addition of TTMG Physicians and Employees (unbudgeted) and increases in Technical and RN wages for testing and treating Coronavirus patients, as well as Shelter in Place and Federal Emergency Sick Time pay programs.
Employee Benefits	2,144,908	1,779,742	(365,166)	Negative variance in Employee Benefits related to increased use of Paid Leave for staff who chose to Shelter in Place and not remain available for the Labor Pool and Employer Related Payroll Taxes.
Benefits – Workers Compensation	40,727	78,105	37,378	
Benefits – Medical Insurance	830,025	1,177,057	347,032	
Medical Professional Fees	962,550	1,192,845	230,295	We saw positive variances in Multi-Specialty Clinic and Emergency Department physician fees and Therapy professional fees due to the temporary closure of services.
Other Professional Fees	223,338	200,062	(23,276)	Negative variance in Other Professional Fees related to consulting services provided to the Accounting department for the Cost Accounting/Decision Support implementation.
Supplies	1,720,251	2,005,589	285,338	Drugs Sold to Patients revenues fell short of budget by 26.13% and Implant costs were 19.19% of budgeted expenses due to cancellation of non-urgent/emergent surgeries.
Purchased Services	1,811,088	1,534,192	(276,896)	Snow removal, services provided to the COVID-19 Emergency Preparedness department, outsourced lab testing and JPA Housing Project services created a negative variance in Purchased Services.
Other Expenses	941,852	869,872	(71,980)	Oxygen tank rentals, Natural Gas/Propane, Water/Sewer, and physician recruitment and relocation expenses exceeded budget in the Other Expenses category.
Total Expenses	15,176,191	14,717,591	(458,600)	

TAHOE FOREST HOSPITAL DISTRICT  
STATEMENT OF NET POSITION  
APRIL 2020

	Apr-20	Mar-20	Apr-19	
<b>ASSETS</b>				
<b>CURRENT ASSETS</b>				
* CASH	\$ 45,131,066	\$ 29,708,096	\$ 10,440,139	1
PATIENT ACCOUNTS RECEIVABLE - NET	18,097,809	22,635,874	30,235,743	2
OTHER RECEIVABLES	8,419,160	7,949,356	8,539,698	
GO BOND RECEIVABLES	1,232,943	820,024	723,434	
ASSETS LIMITED OR RESTRICTED	8,272,953	8,503,673	8,031,404	
INVENTORIES	3,521,953	3,517,097	3,146,766	
PREPAID EXPENSES & DEPOSITS	2,561,315	2,564,000	2,291,552	
ESTIMATED SETTLEMENTS, M-CAL & M-CARE	11,253,262	14,324,603	9,079,043	3
<b>TOTAL CURRENT ASSETS</b>	<b>98,490,461</b>	<b>90,022,722</b>	<b>72,487,779</b>	
<b>NON CURRENT ASSETS</b>				
ASSETS LIMITED OR RESTRICTED:				
* CASH RESERVE FUND	74,384,022	64,390,780	64,209,805	1
MUNICIPAL LEASE 2018	2,350,316	2,350,316	5,149,709	
TOTAL BOND TRUSTEE 2017	20,520	20,520	20,182	
TOTAL BOND TRUSTEE 2015	1,035,909	898,812	1,021,676	
GO BOND PROJECT FUND	-	-	-	
GO BOND TAX REVENUE FUND	1,902,146	1,902,146	1,617,792	
DIAGNOSTIC IMAGING FUND	3,343	3,307	3,286	
DONOR RESTRICTED FUND	1,137,882	1,131,399	1,134,903	
WORKERS COMPENSATION FUND	23,474	39,696	17,880	
TOTAL	80,857,611	70,736,977	73,175,233	
LESS CURRENT PORTION	(8,272,953)	(8,503,673)	(8,031,404)	
TOTAL ASSETS LIMITED OR RESTRICTED - NET	72,584,658	62,233,304	65,143,829	
NONCURRENT ASSETS AND INVESTMENTS:				
INVESTMENT IN TSC, LLC	(381,754)	(381,754)	701,785	
PROPERTY HELD FOR FUTURE EXPANSION	904,927	892,545	927,633	
PROPERTY & EQUIPMENT NET	177,547,526	178,096,531	173,906,162	
GO BOND CIP, PROPERTY & EQUIPMENT NET	1,791,406	1,791,406	1,864,055	
<b>TOTAL ASSETS</b>	<b>350,937,224</b>	<b>332,654,754</b>	<b>315,031,244</b>	
DEFERRED OUTFLOW OF RESOURCES:				
DEFERRED LOSS ON DEFEASANCE	394,350	397,582	433,138	
ACCUMULATED DECREASE IN FAIR VALUE OF HEDGING DERIVATIVE	1,782,460	1,782,460	1,137,905	
DEFERRED OUTFLOW OF RESOURCES ON REFUNDING	5,461,584	5,485,289	5,746,040	
GO BOND DEFERRED FINANCING COSTS	425,527	427,462	448,742	
DEFERRED FINANCING COSTS	164,364	165,404	176,847	
<b>TOTAL DEFERRED OUTFLOW OF RESOURCES</b>	<b>\$ 8,228,285</b>	<b>\$ 8,258,197</b>	<b>\$ 7,942,673</b>	
<b>LIABILITIES</b>				
<b>CURRENT LIABILITIES</b>				
ACCOUNTS PAYABLE	\$ 5,861,850	\$ 7,465,590	\$ 7,877,510	4
ACCRUED PAYROLL & RELATED COSTS	15,262,965	15,742,376	11,324,427	5
INTEREST PAYABLE	353,623	271,246	357,198	
INTEREST PAYABLE GO BOND	967,964	687,475	1,028,356	
ESTIMATED SETTLEMENTS, M-CAL & M-CARE	23,690,397	2,495,860	1,514,689	6
HEALTH INSURANCE PLAN	2,166,758	2,166,758	1,463,491	
WORKERS COMPENSATION PLAN	2,396,860	2,396,860	1,888,143	
COMPREHENSIVE LIABILITY INSURANCE PLAN	1,172,232	1,172,232	1,184,419	
CURRENT MATURITIES OF GO BOND DEBT	1,330,000	1,330,000	1,330,000	
CURRENT MATURITIES OF OTHER LONG TERM DEBT	2,612,247	2,612,247	2,545,824	
<b>TOTAL CURRENT LIABILITIES</b>	<b>55,814,896</b>	<b>36,340,643</b>	<b>30,514,056</b>	
<b>NONCURRENT LIABILITIES</b>				
OTHER LONG TERM DEBT NET OF CURRENT MATURITIES	33,188,693	33,323,325	36,865,070	
GO BOND DEBT NET OF CURRENT MATURITIES	99,365,881	99,379,302	100,856,930	
DERIVATIVE INSTRUMENT LIABILITY	1,782,460	1,782,460	1,137,905	
<b>TOTAL LIABILITIES</b>	<b>190,151,931</b>	<b>170,825,730</b>	<b>169,373,961</b>	
<b>NET ASSETS</b>				
NET INVESTMENT IN CAPITAL ASSETS	167,875,697	168,955,821	152,465,053	
RESTRICTED	1,137,882	1,131,399	1,134,903	
<b>TOTAL NET POSITION</b>	<b>\$ 169,013,579</b>	<b>\$ 170,087,220</b>	<b>\$ 153,599,956</b>	

\* Amounts included for Days Cash on Hand calculation

TAHOE FOREST HOSPITAL DISTRICT  
NOTES TO STATEMENT OF NET POSITION  
APRIL 2020

1. Working Capital is at 85.9 days (policy is 30 days). Days Cash on Hand (S&P calculation) is 227.4 days. Working Capital cash increased a net \$25,416,000 and \$9,297,000 was transferred to our Cash Reserve Fund held with LAIF. Accounts Payable decreased \$1,604,000 (See Note 4) and Accrued Payroll & Related Costs decreased \$479,000 (See Note 5). The District received remittance from Centene for \$4,126,000 for the FY19 Rate Range IGT and HQAF programs (See Note 3), \$3,780,000 from HHS in Covid-19 Emergency funding, and \$20,381,000 in Medicare Accelerated Payments (See Note 6) and cash collections were below budget by 21%.
2. Net Patient Accounts Receivable decreased approximately \$4,538,000. Cash collections were 79% of target and the District reserved additional amounts against its Managed Care A/R based on conversations occurring with our Payors. EPIC Days in A/R were 83.0 compared to 77.1 at the close of March, a 5.90 days increase, driven by dramatically decreased revenues per day. Under normal operations, Days in A/R would have been 64.2.
3. Estimated Settlements, Medi-Cal & Medicare decreased a net \$3,071,000. The District recorded the estimated April FY20 receivable from the Rate Range IGT, Medi-Cal PRIME, and Quality Assurance Fee programs and remitted funds to the State of \$467,000 for participation in the Demonstration Year 15 Medi-Cal PRIME Program. The District received and recorded \$4,126,000 from Centene for the FY19 Rate Range IGT and HQAF programs.
4. Accounts Payable decreased \$1,604,000 as we witnessed a reduction in A/P with the decrease in operations.
5. Accrued Payroll & Related Costs decreased a net \$479,000. We saw an increase in month-end accrued payroll days, however, this increase was offset by the remittance of the District's semi-annual funding of the Employer's portion of deferred comp.
6. Estimated Settlements, Medi-Cal & Medicare increased \$21,195,000. The District recorded \$20,381,000 of Medicare Accelerated payments as a liability as these funds will have to be repaid to the Medicare program through claim withhold or direct remittance. The District also received \$814,000 as a settlement from Medicare and booked these funds as a liability until we receive information from our Intermediary as to the nature and validity of the settlement funds.



**Tahoe Forest Hospital District  
Cash Investment  
April 2020**

<b>WORKING CAPITAL</b>			
US Bank	\$ 44,103,962	0.01%	
US Bank/Kings Beach Thrift Store	7,233		
US Bank/Truckee Thrift Store	4,953		
US Bank/Payroll Clearing	-		
Umpqua Bank	<u>1,014,918</u>	0.05%	
<b>Total</b>			<b>\$ 45,131,066</b>
 <b>BOARD DESIGNATED FUNDS</b>			
US Bank Savings	\$ -	0.01%	
Capital Equipment Fund	<u>-</u>		
<b>Total</b>			<b>\$ -</b>
Building Fund	\$ -		
Cash Reserve Fund	<u>74,384,022</u>	1.65%	
Local Agency Investment Fund			<b>\$ 74,384,022</b>
Municipal Lease 2018			<b>\$ 2,350,316</b>
Bonds Cash 2017			<b>\$ 20,520</b>
Bonds Cash 2015			<b>\$ 1,035,909</b>
GO Bonds Cash 2008			<b>\$ 1,902,146</b>
DX Imaging Education	\$ 3,343		
Workers Comp Fund - B of A	23,474		
Insurance			
Health Insurance LAIF	-		
Comprehensive Liability Insurance LAIF	<u>-</u>		
<b>Total</b>			<b><u>\$ 26,817</u></b>
<b>TOTAL FUNDS</b>			<b>\$ 124,850,795</b>
 <b>RESTRICTED FUNDS</b>			
Gift Fund			
US Bank Money Market	\$ 8,360	0.01%	
Foundation Restricted Donations	27,309		
Local Agency Investment Fund	<u>1,102,212</u>	1.65%	
<b>TOTAL RESTRICTED FUNDS</b>			<b><u>\$ 1,137,882</u></b>
<b>TOTAL ALL FUNDS</b>			<b><u><u>\$ 125,988,677</u></u></b>

TAHOE FOREST HOSPITAL DISTRICT  
STATEMENT OF REVENUES, EXPENSES, AND CHANGES IN NET POSITION  
APRIL 2020

CURRENT MONTH				YEAR TO DATE				PRIOR YTD APR 2019	
ACTUAL	BUDGET	VAR\$	VAR%	ACTUAL	BUDGET	VAR\$	VAR%		
<b>OPERATING REVENUE</b>									
\$ 17,439,796	\$ 27,454,967	\$ (10,015,171)	-36.5%	\$ 319,038,801	\$ 313,298,460	\$ 5,740,341	1.8%	1 \$ 294,162,916	
Total Gross Revenue									
Gross Revenues - Inpatient									
\$ 2,566,086	\$ 2,119,371	\$ 446,715	21.1%	\$ 29,357,390	\$ 25,362,571	\$ 3,994,819	15.8%	\$ 29,354,773	
2,903,447	5,027,133	(2,123,686)	-42.2%	45,378,525	55,944,381	(10,565,856)	-18.9%	48,496,608	
5,469,533	7,146,504	(1,676,971)	-23.5%	74,735,915	81,306,952	(6,571,037)	-8.1%	77,851,381	
Total Gross Revenue - Inpatient									
11,970,263	20,308,463	(8,338,200)	-41.1%	244,302,886	231,991,508	12,311,378	5.3%	216,311,535	
11,970,263	20,308,463	(8,338,200)	-41.1%	244,302,886	231,991,508	12,311,378	5.3%	216,311,535	
Total Gross Revenue - Outpatient									
Deductions from Revenue:									
5,792,943	12,191,917	6,398,974	52.5%	139,966,560	139,906,156	(60,404)	0.0%	2 130,414,732	
-	-	-	0.0%	1,000,000	-	(1,000,000)	0.0%	2 1,200,000	
818,558	977,460	158,902	16.3%	12,050,273	11,264,500	(785,773)	-7.0%	2 11,004,927	
-	-	-	0.0%	-	-	-	0.0%	2 -	
862,316	475,325	(386,991)	-81.4%	5,759,899	5,528,519	(231,380)	-4.2%	2 3,021,165	
-	-	-	0.0%	(1,597,100)	-	1,597,100	0.0%	2 (2,003,985)	
7,473,816	13,644,702	6,170,886	45.2%	157,179,631	156,699,175	(480,456)	-0.3%	143,636,839	
Total Deductions from Revenue									
87,849	112,522	(24,673)	-21.9%	964,866	1,059,682	(94,816)	-8.9%	3 910,205	
3,780,252	-	3,780,252	100.0%	3,780,252	-	3,780,252	100.0%	3 -	
668,876	924,723	(255,847)	-27.7%	10,802,889	9,742,847	1,060,042	10.9%	3 8,768,078	
14,502,957	14,847,510	(344,553)	-2.3%	177,407,177	167,401,814	10,966,275	6.6%	160,204,360	
TOTAL OPERATING REVENUE									
<b>OPERATING EXPENSES</b>									
6,501,454	5,880,127	(621,327)	-10.6%	61,079,318	60,811,173	(268,145)	-0.4%	4 49,447,477	
2,144,908	1,779,742	(365,166)	-20.5%	20,225,770	18,410,440	(1,815,330)	-9.9%	4 15,764,658	
40,727	78,105	37,378	47.9%	761,053	781,050	19,997	2.6%	4 615,395	
830,025	1,177,057	347,032	29.5%	10,980,388	11,770,570	790,182	6.7%	4 8,197,537	
962,550	1,192,845	230,295	19.3%	14,934,771	14,537,398	(397,373)	-2.7%	5 20,228,355	
223,338	200,062	(23,276)	-11.6%	2,341,149	2,352,636	11,487	0.5%	5 1,843,321	
1,720,251	2,005,589	285,338	14.2%	24,551,150	22,621,539	(1,929,611)	-8.5%	6 21,090,930	
1,811,088	1,534,192	(276,896)	-18.0%	16,908,638	16,065,028	(843,610)	-5.3%	7 13,448,769	
941,852	869,872	(71,980)	-8.3%	7,311,996	8,860,802	1,548,806	17.5%	8 7,243,563	
15,176,191	14,717,591	(458,600)	-3.1%	159,094,233	156,210,636	(2,883,597)	-1.8%	137,880,006	
TOTAL OPERATING EXPENSE									
<b>(673,234)</b>	<b>129,919</b>	<b>(803,153)</b>	<b>-618.2%</b>	<b>NET OPERATING REVENUE (EXPENSE) EBIDA</b>	<b>18,312,944</b>	<b>11,191,178</b>	<b>7,121,766</b>	<b>63.6%</b>	<b>22,324,354</b>
<b>NON-OPERATING REVENUE/(EXPENSE)</b>									
521,735	497,062	24,673	5.0%	5,130,968	5,036,152	94,816	1.9%	9 5,561,137	
412,919	412,919	0	0.0%	4,129,194	4,129,194	0	0.0%	3,748,858	
131,993	159,794	(27,801)	-17.4%	1,603,556	1,600,294	3,262	0.2%	10 1,420,992	
-	-	-	0.0%	-	-	-	0.0%	-	
80,629	88,155	(7,526)	-8.5%	435,137	881,552	(446,415)	-50.6%	11 900,083	
-	-	-	0.0%	(833,539)	-	(833,539)	0.0%	12 -	
-	-	-	0.0%	-	-	-	0.0%	12 (538,384)	
-	-	-	0.0%	7,546	-	7,546	0.0%	13 5,850	
(1,154,497)	(1,154,615)	118	0.0%	(11,544,968)	(11,546,155)	1,187	0.0%	15 (11,067,202)	
(100,479)	(114,564)	14,085	12.3%	(1,184,316)	(1,167,699)	(16,617)	-1.4%	16 (1,033,101)	
(292,708)	(301,788)	9,080	3.0%	(3,040,054)	(3,021,458)	(18,596)	-0.6%	(3,291,173)	
(400,408)	(413,037)	12,629	3.1%	(5,296,476)	(4,088,120)	(1,208,356)	-29.6%	(4,292,940)	
TOTAL NON-OPERATING REVENUE/(EXPENSE)									
<b>\$ (1,073,642)</b>	<b>\$ (283,118)</b>	<b>\$ (790,524)</b>	<b>279.2%</b>	<b>INCREASE (DECREASE) IN NET POSITION</b>	<b>\$ 13,016,468</b>	<b>\$ 7,103,058</b>	<b>\$ 5,913,410</b>	<b>83.3%</b>	<b>\$ 18,031,413</b>
<b>NET POSITION - BEGINNING OF YEAR</b>				<b>155,997,111</b>					
<b>NET POSITION - AS OF APRIL 30, 2020</b>				<b>\$ 169,013,579</b>					
<b>-3.9%</b>	<b>0.5%</b>	<b>-4.3%</b>		<b>RETURN ON GROSS REVENUE EBIDA</b>	<b>5.7%</b>	<b>3.6%</b>	<b>2.2%</b>	<b>7.6%</b>	

**TAHOE FOREST HOSPITAL DISTRICT**  
**NOTES TO STATEMENT OF REVENUE, EXPENSES, AND CHANGES IN NET POSITION**  
**APRIL 2020**

		<u>Variance from Budget</u>	
		<u>Fav / &lt;Unfav&gt;</u>	
		<u>APR 2020</u>	<u>YTD 2020</u>
<b>1) Gross Revenues</b>			
<p>Acute Patient Days were above budget 4.14% or 14 days. Swing Bed days were below budget 45.46% or 10 days. Inpatient Ancillary revenues were below budget due to the cancellation of Inpatient Surgical cases due to COVID-19.</p> <p>Outpatient volumes were below budget in the following departments: Emergency Department visits, Clinic visits, Home Health and Hospice visits, Surgery cases, Pain Clinic consultations, Diagnostic Imaging, Mammography, Nuclear Medicine, MRI's, Ultrasounds, Cat Scans, PET CTs, Pharmacy units, Respiratory Therapy, GI cases, Physical Therapy, Speech Therapy, and Occupational Therapy.</p>	<p>Gross Revenue -- Inpatient</p> <p>Gross Revenue -- Outpatient</p> <p>Gross Revenue -- Total</p>	<p>\$ (1,676,971)</p> <p>\$ (8,338,200)</p> <p>\$ (10,015,171)</p>	<p>\$ (6,571,037)</p> <p>12,311,378</p> <p>\$ 5,740,341</p>
<b>2) Total Deductions from Revenue</b>			
<p>The payor mix for April shows a 1.66% decrease to Medicare, a 1.70% increase to Medi-Cal, 3.47% increase to Other, .05% increase to County, and a 3.56% decrease to Commercial when compared to budget. We saw a positive variance in Contractual Allowances due to revenues coming in below budget 36.50% along with a shift in our Payor Mix from Commercial to Other causing a negative variance in Bad Debt.</p>	<p>Contractual Allowances</p> <p>Managed Care</p> <p>Charity Care</p> <p>Charity Care - Catastrophic</p> <p>Bad Debt</p> <p>Prior Period Settlements</p> <p>Total</p>	<p>\$ 6,398,975</p> <p>\$ -</p> <p>158,902</p> <p>-</p> <p>(386,991)</p> <p>-</p> <p>\$ 6,170,886</p>	<p>\$ (60,403)</p> <p>\$ (1,000,000)</p> <p>(785,773)</p> <p>-</p> <p>(231,380)</p> <p>1,597,100</p> <p>\$ (480,456)</p>
<b>3) Other Operating Revenue</b>			
<p>Retail Pharmacy revenues exceeded budget by 11.95%.</p> <p>We witnessed negative variances in Thrift Store revenues, Fitness &amp; Wellness classes offered at The Center, Children's Center revenues, Cafeteria sales, and Community Wellness classes due to temporarily closing down retail services stemming from COVID-19 and Social Distancing requirements.</p> <p>The District received COVID-19 Emergency Funding from HHS causing a positive variance in Miscellaneous.</p>	<p>Retail Pharmacy</p> <p>Hospice Thrift Stores</p> <p>The Center (non-therapy)</p> <p>IVCH ER Physician Guarantee</p> <p>Children's Center</p> <p>Miscellaneous</p> <p>Oncology Drug Replacement</p> <p>Grants</p> <p>Total</p>	<p>\$ 27,260</p> <p>(97,718)</p> <p>(26,979)</p> <p>(2,845)</p> <p>(61,361)</p> <p>3,688,467</p> <p>-</p> <p>(2,418)</p> <p>\$ 3,524,406</p>	<p>\$ 702,743</p> <p>(286,745)</p> <p>727</p> <p>102,228</p> <p>(88,758)</p> <p>4,420,817</p> <p>-</p> <p>(10,718)</p> <p>\$ 4,840,294</p>
<b>4) Salaries and Wages</b>			
<p>Negative variance related to TTMG Physician and Staff salaries which were non budgeted items, increases in Technical &amp; RN salaries for treating and testing Coronavirus patients, as well as Shelter in Place and Federal Emergency Sick Time pay programs.</p>	<p>Total</p>	<p>\$ (621,327)</p>	<p>\$ (268,145)</p>
<b>Employee Benefits</b>			
<p>Negative variance in PL/SL related to greater usage of Paid Leave for staff who chose to Shelter in Place and not remain available for the Labor Pool.</p> <p>Negative variance in Other related to Employer Payroll Taxes.</p>	<p>PL/SL</p> <p>Nonproductive</p> <p>Pension/Deferred Comp</p> <p>Standby</p> <p>Other</p> <p>Total</p>	<p>\$ (328,159)</p> <p>(10,250)</p> <p>-</p> <p>(10,348)</p> <p>(16,409)</p> <p>\$ (365,166)</p>	<p>\$ (1,375,610)</p> <p>(216,621)</p> <p>(1,038)</p> <p>(27,451)</p> <p>(194,609)</p> <p>\$ (1,815,330)</p>
<b>Employee Benefits - Workers Compensation</b>			
	<p>Total</p>	<p>\$ 37,378</p>	<p>\$ 19,997</p>
<b>Employee Benefits - Medical Insurance</b>			
	<p>Total</p>	<p>\$ 347,032</p>	<p>\$ 790,182</p>
<b>5) Professional Fees</b>			
<p>Positive variance in Multi-Specialty Clinics related to budgeted physician fees that are now falling under Salaries &amp; Wages.</p> <p>Anesthesia Physician Guarantee and consulting services provided to Accounting for the Cost Accounting/Decision Support software implementations created a negative variance in Miscellaneous.</p> <p>Positive variance in TFH/IVCH Therapy Services due to temporary closure of face to face patient visits.</p>	<p>Multi-Specialty Clinics</p> <p>The Center (includes OP Therapy)</p> <p>Miscellaneous</p> <p>Human Resources</p> <p>Information Technology</p> <p>Home Health/Hospice</p> <p>Financial Administration</p> <p>Medical Staff Services</p> <p>Truckee Surgery Center</p> <p>Patient Accounting/Admitting</p> <p>Respiratory Therapy</p> <p>Multi-Specialty Clinics Administration</p> <p>IVCH ER Physicians</p> <p>Corporate Compliance</p> <p>TFH/IVCH Therapy Services</p>	<p>\$ 59,282</p> <p>35,669</p> <p>(110,920)</p> <p>(12,670)</p> <p>27,152</p> <p>(4,263)</p> <p>2,328</p> <p>914</p> <p>-</p> <p>-</p> <p>(1,222)</p> <p>5,679</p> <p>2,000</p> <p>85,062</p>	<p>\$ (725,322)</p> <p>(264,627)</p> <p>(263,739)</p> <p>(88,246)</p> <p>(42,213)</p> <p>(24,524)</p> <p>(13,647)</p> <p>(723)</p> <p>(146)</p> <p>-</p> <p>-</p> <p>6,477</p> <p>19,227</p> <p>20,000</p> <p>24,189</p>

**TAHOE FOREST HOSPITAL DISTRICT**  
**NOTES TO STATEMENT OF REVENUE, EXPENSES, AND CHANGES IN NET POSITION**  
**APRIL 2020**

		<b>Variance from Budget</b>	
		<b>Fav / &lt;Unfav&gt;</b>	
		<b>APR 2020</b>	<b>YTD 2020</b>
<b>5) Professional Fees (cont.)</b>			
Positive variance in TFH Locums associated with a decrease in Emergency Department visits.	Managed Care	8,500	37,352
	Sleep Clinic	7,118	55,993
	Marketing	5,733	59,975
	Administration	24,879	140,003
	Oncology	16,065	161,285
	TFH Locums	55,711	512,798
	<b>Total</b>	<b>\$ 207,019</b>	<b>\$ (385,886)</b>
<b>6) Supplies</b>			
Oncology Drugs Sold to Patients revenues were above budget by 21.47%, however, Drugs Sold to Patients revenues were below budget 26.13% minimizing the negative variance in Pharmacy Supplies.	Pharmacy Supplies	\$ (70,271)	\$ (1,652,638)
	Patient & Other Medical Supplies	367,269	(252,097)
	Minor Equipment	(85,573)	(162,406)
	Other Non-Medical Supplies	19,097	(84,675)
	Office Supplies	15,100	86,632
	Food	39,716	135,573
	<b>Total</b>	<b>\$ 285,338</b>	<b>\$ (1,929,611)</b>
Positive variance in Patient & Other Medical Supplies for Implants and patient chargeable supplies due to the decrease in patient services resulting from COVID-19.			
Purchase of required supplies for a potential COVID-19 surge created a negative variance in Minor Equipment.			
<b>7) Purchased Services</b>			
Snow removal and services provided to the Emergency Preparedness department and JPA Housing Project created a negative variance in Miscellaneous.	Miscellaneous	\$ (488,894)	\$ (893,187)
	Medical Records	21,479	(368,567)
	Patient Accounting	49,994	(38,729)
	Diagnostic Imaging Services - All	8,708	(32,348)
	Department Repairs	28,249	(29,993)
	The Center	12,456	(5,763)
	Community Development	(263)	1,919
	Pharmacy IP	8,474	28,906
	Home Health/Hospice	(3,130)	45,822
	Information Technology	14,590	50,883
	Laboratory	(16,494)	84,649
	Multi-Specialty Clinics	37,520	129,591
	Human Resources	50,416	183,206
	<b>Total</b>	<b>\$ (276,896)</b>	<b>\$ (843,610)</b>
Positive variance in Patient Accounting due to a decrease in use of our third party vendors due to fewer claims being generated and worked as a result of closure of non urgent/emergent services.			
Positive variance in Department Repairs related to a decrease in services which required fewer maintenance needs for our hospital buildings and equipment.			
Negative variance in Laboratory related to outsourced lab testing.			
Positive variance in Multi-Specialty Clinics associated with a true-up of prior period accruals and decrease in services due to the pandemic.			
Human Resources Pre-Employment and Employee Health screenings came in below budget, creating a positive variance in this category.			
<b>8) Other Expenses</b>			
An increase in Oxygen tank rentals created a negative variance in Equipment Rent.	Equipment Rent	\$ (44,431)	\$ (156,552)
	Physician Services	1,950	(8,052)
	Multi-Specialty Clinics Equip Rent	64	453
	Other Building Rent	3,492	15,170
	Multi-Specialty Clinics Bldg Rent	(14,754)	40,614
	Insurance	(3,704)	59,851
	Dues and Subscriptions	1,248	63,131
	Human Resources Recruitment	10,875	100,519
	Utilities	(11,303)	138,500
	Marketing	(82,689)	193,652
	Outside Training & Travel	86,654	471,925
	Miscellaneous	(19,382)	629,597
	<b>Total</b>	<b>\$ (71,980)</b>	<b>\$ 1,548,806</b>
Building rent on our new Primary Care/Urgent Care buildings created a negative variance in Multi-Specialty Clinics Building Rent.			
Natural Gas/Propane and Water/Sewer expenses exceeded budget creating a negative variance in Utilities.			
Advertisements for the Cancer Center, Multi-Specialty Clinics, and COVID-19 communications created a negative variance in Marketing.			
Negative variance in Miscellaneous associated with Physician Recruitment and Relocation costs.			
<b>9) District and County Taxes</b>			
	<b>Total</b>	<b>\$ 24,673</b>	<b>\$ 94,816</b>
<b>10) Interest Income</b>			
	<b>Total</b>	<b>\$ (27,801)</b>	<b>\$ 3,262</b>
<b>11) Donations</b>			
	IVCH	\$ (41,334)	\$ (399,680)
	Operational	33,808	(46,735)
	<b>Total</b>	<b>\$ (7,526)</b>	<b>\$ (446,415)</b>
<b>12) Gain/(Loss) on Joint Investment</b>			
	<b>Total</b>	<b>\$ -</b>	<b>\$ (833,539)</b>
<b>13) Gain/(Loss) on Sale or Disposal of Assets</b>			
	<b>Total</b>	<b>\$ -</b>	<b>\$ 7,546</b>
<b>15) Depreciation Expense</b>			
	<b>Total</b>	<b>\$ 118</b>	<b>\$ 1,187</b>
<b>16) Interest Expense</b>			
	<b>Total</b>	<b>\$ 14,085</b>	<b>\$ (16,617)</b>

INCLINE VILLAGE COMMUNITY HOSPITAL  
STATEMENT OF REVENUE AND EXPENSE  
APRIL 2020

CURRENT MONTH				YEAR TO DATE				PRIOR YTD		
ACTUAL	BUDGET	VAR\$	VAR%	ACTUAL	BUDGET	VAR\$	VAR%	APR 2019		
				<b>OPERATING REVENUE</b>						
\$ 682,860	\$ 2,045,322	\$ (1,362,462)	-66.6%	Total Gross Revenue	\$ 19,847,020	\$ 23,217,385	\$ (3,370,365)	-14.5%	1	\$ 19,958,261
				<b>Gross Revenues - Inpatient</b>						
\$ -	\$ 4,724	\$ (4,724)	-100.0%	Daily Hospital Service	\$ 16,423	\$ 103,702	\$ (87,279)	-84.2%		\$ 73,173
-	907	(907)	-100.0%	Ancillary Service - Inpatient	18,864	78,975	(60,112)	-76.1%		57,966
-	5,631	(5,631)	-100.0%	Total Gross Revenue - Inpatient	35,287	182,677	(147,391)	-80.7%	1	131,139
682,860	2,039,691	(1,356,831)	-66.5%	Gross Revenue - Outpatient	19,811,734	23,034,708	(3,222,974)	-14.0%		19,827,122
682,860	2,039,691	(1,356,831)	-66.5%	Total Gross Revenue - Outpatient	19,811,734	23,034,708	(3,222,974)	-14.0%	1	19,827,122
				<b>Deductions from Revenue:</b>						
168,736	831,452	662,716	79.7%	Contractual Allowances	8,527,248	9,354,847	827,599	8.8%	2	8,133,691
66,214	87,218	21,004	24.1%	Charity Care	1,022,408	1,104,065	81,657	7.4%	2	910,025
-	-	-	0.0%	Charity Care - Catastrophic Events	-	-	-	0.0%	2	-
107,462	87,218	(20,244)	-23.2%	Bad Debt	1,135,518	1,104,065	(31,453)	-2.8%	2	705,766
-	-	-	0.0%	Prior Period Settlements	(229,532)	-	229,532	0.0%	2	74,873
342,412	1,005,888	663,476	66.0%	Total Deductions from Revenue	10,455,643	11,562,977	1,107,334	9.6%	2	9,824,355
261,140	-	261,140	100.0%	COVID-19 Emergency Funding	261,140	-	261,140	100.0%	3	-
66,177	70,277	(4,100)	-5.8%	Other Operating Revenue	1,039,149	941,427	97,722	10.4%	3	944,917
667,765	1,109,711	(441,946)	-39.8%	<b>TOTAL OPERATING REVENUE</b>	10,691,667	12,595,835	(1,904,168)	-15.1%		11,078,823
				<b>OPERATING EXPENSES</b>						
335,562	323,216	(12,346)	-3.8%	Salaries and Wages	3,515,385	3,729,282	213,897	5.7%	4	3,011,607
161,224	110,738	(50,486)	-45.6%	Benefits	1,330,515	1,166,902	(163,613)	-14.0%	4	1,057,395
3,013	4,303	1,290	30.0%	Benefits Workers Compensation	55,594	43,030	(12,564)	-29.2%	4	36,411
47,522	67,391	19,869	29.5%	Benefits Medical Insurance	628,595	673,910	45,315	6.7%	4	541,742
188,658	217,586	28,929	13.3%	Medical Professional Fees	2,500,209	2,495,731	(4,478)	-0.2%	5	2,708,970
1,520	1,536	16	1.1%	Other Professional Fees	17,617	15,363	(2,254)	-14.7%	5	21,265
12,583	45,833	33,250	72.5%	Supplies	507,728	616,564	108,836	17.7%	6	546,417
102,459	47,201	(55,258)	-117.1%	Purchased Services	648,379	572,205	(76,174)	-13.3%	7	499,122
68,701	70,972	2,271	3.2%	Other	688,621	763,693	75,072	9.8%	8	719,779
921,241	888,776	(32,465)	-3.7%	<b>TOTAL OPERATING EXPENSE</b>	9,892,643	10,076,680	184,037	1.8%		9,142,708
<b>(253,476)</b>	<b>220,935</b>	<b>(474,411)</b>	<b>-214.7%</b>	<b>NET OPERATING REV(EXP) EBIDA</b>	<b>799,024</b>	<b>2,519,155</b>	<b>(1,720,131)</b>	<b>-68.3%</b>		<b>1,936,115</b>
				<b>NON-OPERATING REVENUE/(EXPENSE)</b>						
-	41,334	(41,334)	-100.0%	Donations-IVCH	13,656	413,336	(399,680)	-96.7%	9	200,534
-	-	-	0.0%	Gain/ (Loss) on Sale	-	-	-	0.0%	10	-
(65,676)	(65,043)	(633)	1.0%	Depreciation	(656,758)	(650,428)	(6,330)	-1.0%	11	(592,513)
(65,676)	(23,709)	(41,967)	-177.0%	<b>TOTAL NON-OPERATING REVENUE/(EXP)</b>	(643,103)	(237,092)	(406,011)	-171.2%		(391,979)
<b>\$ (319,152)</b>	<b>\$ 197,226</b>	<b>\$ (516,378)</b>	<b>-261.8%</b>	<b>EXCESS REVENUE(EXPENSE)</b>	<b>\$ 155,921</b>	<b>\$ 2,282,063</b>	<b>\$ (2,126,142)</b>	<b>-93.2%</b>		<b>\$ 1,544,136</b>
<b>-37.1%</b>	<b>10.8%</b>	<b>-47.9%</b>		<b>RETURN ON GROSS REVENUE EBIDA</b>	<b>4.0%</b>	<b>10.9%</b>	<b>-6.8%</b>			<b>9.7%</b>

**INCLINE VILLAGE COMMUNITY HOSPITAL  
NOTES TO STATEMENT OF REVENUE AND EXPENSE  
APRIL 2020**

		<u>Variance from Budget</u>	
		<u>Fav&lt;Unfav&gt;</u>	
		<u>APR 2020</u>	<u>YTD 2020</u>
<b>1) <u>Gross Revenues</u></b>			
Acute Patient Days were below budget by 1 at 0 and Observation Days were above budget by 1 at 1.	Gross Revenue -- Inpatient	\$ (5,631)	\$ (147,391)
	Gross Revenue -- Outpatient	(1,356,831)	(3,222,974)
		<u>\$ (1,362,462)</u>	<u>\$ (3,370,365)</u>
Outpatient volumes were below budget in Emergency Department visits, Clinic visits, Surgical cases, Lab testing, Diagnostic Imaging, Cat Scans, Pharmacy units, Physical Therapy and Speech Therapy.			
<b>2) <u>Total Deductions from Revenue</u></b>			
We saw a shift in our payor mix with a 10.59% increase in Medicare, a .58% increase in Medicaid, a 5.39% decrease in Commercial insurance, a 5.78% increase in Other, and County was below budget by .01%. We saw a positive variance in Contractuals due to revenues falling short of budget by 66.6% along with a shift to Bad Debt.	Contractual Allowances	\$ 662,716	\$ 827,599
	Charity Care	21,004	81,657
	Charity Care-Catastrophic Event	-	-
	Bad Debt	(20,244)	(31,453)
	Prior Period Settlement	-	229,532
	Total	<u>\$ 663,476</u>	<u>\$ 1,107,334</u>
<b>3) <u>Other Operating Revenue</u></b>			
COVID-19 Emergency Funding received from HHS created a positive variance in Miscellaneous.	IVCH ER Physician Guarantee	\$ (2,845)	\$ 102,228
	Miscellaneous	259,885	256,634
	Total	<u>\$ 257,040</u>	<u>\$ 358,862</u>
<b>4) <u>Salaries and Wages</u></b>			
	Total	<u>\$ (12,346)</u>	<u>\$ 213,897</u>
<b><u>Employee Benefits</u></b>			
Negative variance in PL/SL related to Long-Term Sick exceeding budget estimates.	PL/SL	\$ (46,634)	\$ (165,683)
	Standby	1,546	16,228
	Other	(5,397)	(11,987)
	Nonproductive	-	(1,179)
	Pension/Deferred Comp	-	(992)
	Total	<u>\$ (50,486)</u>	<u>\$ (163,613)</u>
<b><u>Employee Benefits - Workers Compensation</u></b>			
	Total	<u>\$ 1,290</u>	<u>\$ (12,564)</u>
<b><u>Employee Benefits - Medical Insurance</u></b>			
	Total	<u>\$ 19,869</u>	<u>\$ 45,315</u>
<b>5) <u>Professional Fees</u></b>			
Positive variance in Therapy Services associated with closure of face to face patient visits.	Multi-Specialty Clinics	\$ -	\$ (111,907)
	Foundation	17	(2,255)
	Administration	-	-
	Miscellaneous	(723)	268
COVID-19 closure of non urgent/emergency services created a positive variance in Sleep Clinic professional fees.	IVCH ER Physicians	5,679	19,227
	Therapy Services	16,854	31,942
	Sleep Clinic	7,118	55,993
	Total	<u>\$ 28,945</u>	<u>\$ (6,732)</u>
<b>6) <u>Supplies</u></b>			
Decrease in patient visits and procedures created positive variances in Patient & Other Medical Supplies and Pharmacy Supplies.	Food	\$ 129	\$ (1,259)
	Imaging Film	-	-
	Non-Medical Supplies	2,160	243
	Office Supplies	520	4,025
	Minor Equipment	(741)	5,587
	Patient & Other Medical Supplies	20,041	32,903
	Pharmacy Supplies	11,141	67,337
	Total	<u>\$ 33,250</u>	<u>\$ 108,836</u>

**INCLINE VILLAGE COMMUNITY HOSPITAL  
NOTES TO STATEMENT OF REVENUE AND EXPENSE  
APRIL 2020**

		<u>Variance from Budget</u>	
		<u>Fav&lt;Unfav&gt;</u>	
		<u>APR 2020</u>	<u>YTD 2020</u>
<b>7) <u>Purchased Services</u></b>			
Snow Removal and use of our Therapists in the COVID-19 Labor Pool created a negative variance in Miscellaneous.	Miscellaneous	\$ (69,594)	\$ (94,810)
	Diagnostic Imaging Services - All	1,120	(9,550)
	Multi-Specialty Clinics	92	(4,326)
	Pharmacy	-	(3,039)
Outsourced Lab testing created a negative variance in Laboratory.	Laboratory	(9,668)	(824)
	Surgical Services	-	-
Positive variance in Department Repairs related to a decrease in services which required fewer maintenance needs for our hospital building and equipment.	Foundation	1,136	638
	Department Repairs	14,870	3,825
	EVS/Laundry	2,908	12,455
	Engineering/Plant/Communications	3,879	19,457
	<b>Total</b>	<u>\$ (55,258)</u>	<u>\$ (76,174)</u>
<b>8) <u>Other Expenses</u></b>			
Natural Gas/Propane and Telephone expenses created a negative variance in Utilities.	Utilities	\$ (6,527)	\$ (17,695)
	Other Building Rent	(886)	(6,339)
	Equipment Rent	(4,247)	(3,220)
	Dues and Subscriptions	2,214	(2,047)
Negative variance in Equipment Rent related to oxygen tank rentals.	Physician Services	-	-
	Multi-Specialty Clinics Bldg Rent	-	-
	Marketing	(4,012)	5,658
	Insurance	1,366	10,984
	Outside Training & Travel	4,684	34,064
	Miscellaneous	9,679	53,667
	<b>Total</b>	<u>\$ 2,271</u>	<u>\$ 75,072</u>
<b>9) <u>Donations</u></b>	<b>Total</b>	<u>\$ (41,334)</u>	<u>\$ (399,680)</u>
<b>10) <u>Gain/(Loss) on Sale</u></b>	<b>Total</b>	<u>\$ -</u>	<u>\$ -</u>
<b>11) <u>Depreciation Expense</u></b>	<b>Total</b>	<u>\$ (633)</u>	<u>\$ (6,330)</u>

TAHOE FOREST HOSPITAL DISTRICT  
STATEMENT OF CASH FLOWS

	AUDITED FYE 2019		BUDGET FYE 2020	PROJECTED FYE 2020	ACTUAL APR 2020	PROJECTED APR 2020	DIFFERENCE	ACTUAL 1ST QTR	ACTUAL 2ND QTR	ACTUAL 3RD QTR	PROJECTED 4TH QTR
Net Operating Rev/(Exp) - EBIDA	\$ 25,310,161		\$ 12,072,919	\$ 24,284,785	\$ (673,234)	\$ (7,058,495)	\$ 6,385,261	\$ 9,856,557	\$ 6,757,769	\$ 2,354,328	\$ 5,316,131
Interest Income	1,322,573		1,854,579	1,624,277	329,016	481,114	(152,098)	414,192	423,396	387,673	399,016
Property Tax Revenue	7,435,543		7,125,000	7,846,475	-	-	-	496,314	96,653	4,303,508	2,950,000
Donations	968,991		1,060,000	502,863	-	80,000	(80,000)	75,072	69,371	198,420	160,000
Debt Service Payments	(3,938,422)		(5,031,900)	(5,523,716)	(284,787)	(285,588)	801	(1,522,582)	(1,060,089)	(1,291,601)	(1,649,443)
Property Purchase Agreement	(270,643)		(811,932)	(805,927)	-	-	-	(202,982)	(202,982)	(264,642)	(135,321)
2018 Municipal Lease	(1,148,646)		(1,717,332)	(1,574,217)	(143,111)	(143,111)	0	(286,221)	(429,332)	(429,332)	(429,333)
Copier	(24,163)		(64,560)	(63,714)	(4,579)	(5,380)	801	(16,235)	(16,139)	(16,001)	(15,339)
2017 VR Demand Bond	(853,995)		(792,912)	(1,448,714)	-	-	-	(620,221)	-	(170,334)	(658,159)
2015 Revenue Bond	(1,640,975)		(1,645,164)	(1,631,143)	(137,097)	(137,097)	(0)	(396,924)	(411,636)	(411,292)	(411,291)
Physician Recruitment	(145,863)		(180,000)	(293,670)	-	(15,000)	15,000	(152,500)	(111,170)	-	(30,000)
Investment in Capital											
Equipment	(3,296,438)		(5,320,498)	(4,354,629)	(225,351)	(511,318)	285,967	(688,769)	(983,613)	(1,382,675)	(1,299,572)
Municipal Lease Reimbursement	4,530,323		4,650,000	1,714,582	-	-	-	-	608,279	556,303	550,000
IT/EMR/Business Systems	(3,016,084)		(4,222,246)	(2,880,933)	(182,701)	(230,000)	47,299	(667,043)	(501,585)	(1,069,604)	(642,701)
Building Projects/Properties	(12,443,362)		(23,169,292)	(8,233,251)	(196,400)	(428,850)	232,450	(2,220,489)	(3,431,604)	(1,234,758)	(1,346,400)
Capital Investments	(916,898)		-	-	-	-	-	-	-	-	-
Change in Accounts Receivable	(2,492,148)	N1	2,451,297	4,295,659	4,538,065	2,685,465	1,852,600	(708,340)	1,165,101	3,075,661	763,237
Change in Settlement Accounts	265,612	N2	1,615,831	20,154,031	24,265,878	2,901,687	21,364,191	(4,680,479)	(410,433)	(805,682)	26,050,625
Change in Other Assets	(5,018,346)	N3	(2,400,000)	76,372	(153,500)	(500,000)	346,500	3,116,473	(479,352)	(1,407,249)	(1,153,500)
Change in Other Liabilities	7,647,518	N4	(695,000)	(566,057)	(2,000,774)	(375,000)	(1,625,774)	507,806	(5,762,386)	3,189,297	1,499,226
Change in Cash Balance	16,213,160		(10,189,310)	38,646,789	25,416,212	(3,255,985)	28,672,197	3,826,212	(3,619,663)	6,873,620	31,566,619
Beginning Unrestricted Cash	70,805,546		87,018,706	87,018,706	94,098,876	94,098,876	-	87,018,706	90,844,918	87,225,255	94,098,876
Ending Unrestricted Cash	87,018,706		76,829,396	105,284,958	99,134,550	90,842,890	8,291,660	90,844,918	87,225,255	94,098,876	105,284,958
Restricted Cash - Medicare Accelerated Pymts	-		-	20,380,537	20,380,537	-	-	-	-	-	20,380,537
Expense Per Day	486,737		516,504	524,927	525,503	520,093	5,411	519,036	509,924	518,350	524,927
Days Cash On Hand - Unrestricted	179		149	201	189	175	14	175	171	182	201
Days Cash On Hand - with Medicare Acc Pymts				239	227						239

Footnotes:

N1 - Change in Accounts Receivable reflects the 30 day delay in collections.

N2 - Change in Settlement Accounts reflect cash flows in and out related to prior year and current year Medicare and Medi-Cal settlement accounts.

N3 - Change in Other Assets reflect fluctuations in asset accounts on the Balance Sheet that effect cash. For example, an increase in prepaid expense immediately effects cash but not EBIDA.

N4 - Change in Other Liabilities reflect fluctuations in liability accounts on the Balance Sheet that effect cash. For example, an increase in accounts payable effects EBIDA but not cash.



## Tahoe Forest Health System – Job Description

Job Title:	President & CEO	Job Number:	0001001		
Department:	Administration	Reports To:	BOD		
Bargaining Unit:	Non-Represented	Benefit Group:	Chief		
Codes:	FLSA: Exempt	EEO:	0	Finance Code	0
Prepared by:	Director, Human Resources	Date:	06/05/2002		
Revised by:	Board Executive Compensation Committee	Date:	05/08/2019		
Approved by:	Board of Directors	Date:	05/23/2019		

**SUMMARY:**

Directs all functions of the hospital to achieve the mission and vision of the organization in accordance with the overall policies established by the Board of Directors, and in compliance with regulatory guidelines, in order that the strategic objectives of the hospital can be attained; provides leadership and direction in ensuring the efficient, economical, effective utilization of hospital resources to meet the identified needs of the service region through quality medical and health service programs.

**ESSENTIAL DUTIES AND RESPONSIBILITIES:** include the following:

Assists, counsels, and advises the Board of Directors on the establishment of hospital policies; acts as agent of the Board in carrying out such policies.

Recommends District policy positions regarding legislation, government, administrative operation and other matters of public policy as required.

Assists the Board of Directors in effectively fulfilling their responsibilities by keeping the Board informed, on a monthly basis, of the operating results of the hospital; compares monthly operations to Board approved plans and budgets explaining variances that may arise.

Assists and advises the Board with respect to public District authority and changes in state statutory guidelines and requirements.

Develops appropriate strategic and annual operating plans that document the long and short-term goals and objectives of the District.

Actively pursues and supports the appraisals and development of new programs which could benefit the long-range success and survival of the District.

Establishes concise reporting relationships for all positions and departments in the hospital. Establishes methods which will foster the achievement of hospital goals and objectives and support the efficiency and effectiveness of all operations through proper communication and coordination.

Coordinates all operations with the medical staff, its committee structure and its leadership; demonstrates a proactive and positive relationship with the medical staff.

Ensures a consistency of purpose and mutuality of interest between the operations and bylaws of the medical staff and the policies and bylaws of the District.

Develops and maintains Quality Improvement and Process Improvement programs designed to enhance quality and customer satisfaction.

Establishes operating policies and procedures for all departments, delegating specific responsibility for documentation, monitoring, compliance, and reporting or results to subordinates, as required.

## Tahoe Forest Health System – Job Description

Establishes and maintains a comprehensive budgeting program for the hospital. This program includes an appropriate consideration of operational, financial and statistical information needed to efficiently and effectively control all District operations.

Consistently generates sufficient net income to meet established financial goals.

Develops strong marketing and public relations programs.

Ensures the competitive viability and continuance of the hospital marketing plan in the marketplace.

Through various marketing techniques, encourages the development of services which promote District growth and expanded potential constituencies.

Ensures the coordination of Auxiliary and Foundation bylaws and operations with the bylaws and operations of the District.

Establishes a proper, consistent image of the District and its operations.

Personally represents the District to a variety of individuals, community groups, and health industry organizations.

Maintains active professional contacts through local, state and national associations in order to effectively network, as required.

Actively participates in outside programs and community affairs in order to represent the District, as appropriate.

Demonstrates the ability to effectively represent the District at national, state and local meetings, conferences and conventions, as required.

Remains current with national and local issues affecting District administration and their potential impact on the District; serves as a well-informed advisor to the Board of Directors.

Demonstrates System Values in performance and behavior.

Complies with System policies and procedures.

Other duties as may be assigned.

### **QUALIFICATIONS:**

To perform this job successfully, an individual must be able to perform each essential duty satisfactorily. The requirements listed below are representative of the knowledge, skill, and/or ability required. *Reasonable accommodations may be made to enable individuals with disabilities to perform the essential functions.*

### **SUPERVISORY RESPONSIBILITIES:**

Carries out supervisory responsibility in accordance with the organization's policies and applicable laws. Responsibilities include interviewing, hiring and training employees; planning, assigning and direction work; appraising performance, rewarding and disciplining employees; addressing complaints and resolving problems.

### **EDUCATION AND EXPERIENCE:**

Bachelor's degree required. Master's degree in Hospital Administration (MHA) or Business Administration (MBA) or related field or Doctoral degree (Ph.D.) preferred. Minimum of five years experience in Health Care Administration.

# Tahoe Forest Health System – Job Description

**LICENSES, CERTIFICATIONS:**

Required: Valid driver's license

Preferred: None

**OTHER EXPERIENCE/QUALIFICATIONS:**

Current membership in professional organization preferred (e.g. H.F.M.A., A.C.H.E.).

**COMPUTER/BUSINESS SKILLS:**

Ability to use office machines. Demonstrated ability to use word processing and other Microsoft Office programs.

**LANGUAGE SKILLS:**

Ability to read, analyze, and interpret the most complex documents. Ability to respond effectively to the most sensitive inquiries or complaints. Ability to write speeches and articles using original or innovative techniques or style. Ability to make effective and persuasive speeches and presentations on controversial or complex topics to top management, public groups, and/or boards of directors.

**MATHEMATICAL SKILLS:**

Ability to work with mathematical concepts such as probability and statistical inference, and fundamentals of plane and solid geometry and trigonometry. Ability to apply concepts such as fractions, percentages, ratios, and proportions to practical situations.

**PURPOSE OF CONTACTS:**

The purpose is to justify, defend, negotiate, or settle matters involving significant or controversial issues. Work at this level involves active participation in conferences, meetings, hearings or presentations involving problems or issues of considerable consequence or importance.

**REASONING SKILLS:**

Ability to define problems, collect data, establish facts, and draw valid conclusions. Ability to interpret an extensive variety of technical instructions in mathematical or diagram form and deal with several abstract and concrete variables.

Reference physical job description template 1

I have read and received a copy of this job description:

\_\_\_\_\_

Print Name

\_\_\_\_\_

Signature

\_\_\_\_\_

Date

## AGENDA ITEM COVER SHEET

<b>ITEM</b>	Exit and Security Doors & Central Supply Storage
<b>RESPONSIBLE PARTY</b>	Judy Newland, Chief Operating Officer Dylan Crosby, Director Construction and Facilities
<b>ACTION REQUESTED?</b>	For Board Action
<p><b>BACKGROUND:</b></p> <p><u>Exit and Security:</u> There are current required egress paths thru the Diagnostic Imaging department and Surgical Departments, it is for this reason we have not been able to provide security measures at these two critical locations. This project corrects these exiting issues and provides the security measures necessary to restrict the flow of traffic, allows employee badged access and the ability to lock down the Diagnostic Imaging and Surgical Service Departments.</p> <p><u>Central Supply Storage:</u> The Central Supply room for Tahoe Forest Hospital is in need of additional space to store and stock essential items. This project is a remodel of a vacant 181 square foot room directly adjacent to the existing central supply location to meet this need.</p>	
<p><b>SUMMARY/OBJECTIVES:</b> Bidding process has been completed.</p>	
<p><b>SUGGESTED DISCUSSION POINTS:</b> None</p>	
<p><b>SUGGESTED MOTION/ALTERNATIVES:</b> Motion #1: Move to award contract for the Exit and Security Doors and Central Supply Storage Project to J.M. Streamline, Inc. dba Streamline Construction for \$359,750.00 and authorize the CEO or his designee to sign the contract.</p>	
<p><b>LIST OF ATTACHMENTS:</b></p> <ul style="list-style-type: none"> <li>Exit and Security Doors &amp; Central Supply Storage – May 2020</li> </ul>	

**Tahoe Forest Hospital District**  
**Exit and Security Doors & Central Supply Storage**

**Staff Recommendations on Bids/Contracts**

**Action #1:** Staff recommends that the Board of Directors award the contract for the Exit and Security Doors & Central Supply Storage project at 10121 Pine Avenue Truckee, CA 96161 to the lowest bidder, J.M. Streamline, Inc. dba: Streamline Construction, for \$359,750.00 and authorize the CEO or his designee to sign the contract.

**TAHOE FOREST HOSPITAL DISTRICT  
RESOLUTION NO. 2020-05**

**RESOLUTION OF THE BOARD OF DIRECTORS OF THE TAHOE FOREST  
HOSPITAL DISTRICT DETERMINING TO CONSOLIDATE THE HOSPITAL  
DISTRICT GENERAL ELECTION WITH THE STATEWIDE GENERAL ELECTION  
AND AUTHORIZING THE CANVASS OF RETURNS BY THE RESPECTIVE BOARDS  
OF SUPERVISORS OF PLACER AND NEVADA COUNTIES, CALIFORNIA**

---

WHEREAS, Tahoe Forest Hospital District (“District”) is a Local Health Care District duly organized and existing under and by virtue of the laws of the State of California, and in particular, Division 23 of the California Health and Safety Code, and the District comprises, within its exterior boundaries, territory in the counties of Placer and Nevada; and

WHEREAS, pursuant to Section 32100.5 of the California Health and Safety Code, a General Election is to be held in the District on November 3, 2020 for the purpose of electing members of the Board of Directors of the District; and

WHEREAS, the General Election shall be to fill vacancies for the following Board Members whose terms will expire on Friday, December 4, 2020:

Alyce Wong	Regular Term
W. Arthur King	Regular Term
Michael McGarry	Short Term

WHEREAS, California Elections Code Section 10509 permits each candidate to prepare a candidate’s statement and the Board of Directors to require each candidate to pay for the publication of his/her statement and to limit the number of words in each statement; and

WHEREAS, California Elections Code Section 10400, et seq. authorizes the canvass of election returns by the Boards of Supervisors respectively of Placer and Nevada Counties;

NOW, THEREFORE, BE IT RESOLVED BY THE BOARD OF DIRECTORS OF TAHOE FOREST HOSPITAL DISTRICT AS FOLLOWS:

1. That the Tahoe Forest Hospital District General Election in November 2020 for the purpose of electing three (3) persons to the Board of Directors thereof be consolidated and held with the Statewide General Election on November 3, 2020.
2. That the three (3) positions to be filled at such election be designated as follows:  
Alyce Wong – At Large – 4 Year Term  
W. Arthur King – At Large – 4 Year Term  
Michael McGarry – At Large – 2 Year Term

That the candidate is to pay for the publication of the candidate’s statement, pursuant to Elections Code Section 13307. The limitation on the number of words that a candidate may use in his/her candidate’s statement is 200 words.

3. That the three (3) candidates for the Board of Directors, receiving the highest number of votes for their respective offices and who have filed the required disclosure statements, shall be declared

elected for their respective terms beginning when first administered the oath of office, and ending when their successors are elected and qualified.

4. That the Boards of Supervisors respectively of Placer and Nevada Counties are hereby requested and authorized to canvass the returns of said election of District officers as to the respective election precincts comprising Hospital District territory with each county.
5. That a copy of this Resolution shall be sent to the Boards of Supervisors of Placer and Nevada Counties respectively not later than July 1, 2020 for purposes, among others, of notice thereto of consolidation and authorization to canvass returns.
6. That the District does not request Measure(s) be decided at this election.
7. That the election be conducted by the County Clerk for each county and the county shall prorate the cost of the election back to the District.
8. That there have been no changes to the Tahoe Forest Hospital District boundaries since our last election.
9. In the case of a tie vote, the procedure to be followed is to decide by lot.

Passed and adopted this 28th day of May, 2020 at a meeting of the Board of Directors of Tahoe Forest Hospital District by the following vote:

AYES:

NOES:

ABSENT:

ABSTAIN:

TAHOE FOREST HOSPITAL DISTRICT

BY: \_\_\_\_\_  
Alyce Wong, Chair  
Board of Directors

ATTEST:

\_\_\_\_\_  
Art King, Secretary  
Board of Directors

**Tahoe Forest Hospital District  
Employment Agreement**

This Agreement is entered into on the ~~January-July 1, 2020~~<sup>2019</sup> by and between the Tahoe Forest Hospital District, (the "District") and Harry Weis (the "Employee"), with respect to the following facts:

A. The District is a public agency formed and operated pursuant to the Local Health Care District Law, California Health and Safety Code Sections 32000, et seq.

B. The District desires to **retain** Employee as its President and Chief Executive Officer and Employee desires to accept such employment, subject to the terms and conditions set forth herein.

WHEREFORE, the parties agree as follows:

1. DUTIES. Employee shall work full time for the District as its President and Chief Executive Officer and shall maintain a regular work schedule consistent with that approved for other executive employees of the District. Employee's duties may involve expenditures of time in excess of eight (8) hours per day and/or forty (40) hours per week, and may also include time outside normal office hours, for which Employee shall not be entitled to additional compensation. Subject to such restrictions as the District may impose, the Employee shall have full charge and control of and be responsible for the day-to-day operation of the District and shall be responsible for all of the functions assigned by the District including but not necessarily limited to the duties set forth on the job description attached hereto as Attachment 1 and incorporated here by this reference. The Employee shall perform all duties with due diligence and with the best interest of the District in mind. The Employee shall not engage in any other employment, business or profession in the Healthcare industry whether for pay or otherwise that would conflict with the performance of his duties pursuant to this Agreement.

2. RELATIONS WITH THE PUBLIC. Employee acknowledges that the position of President and Chief Executive Officer is a position of high visibility before the public. Employee shall conduct himself before the public, both during and outside of regular working hours, in a manner that reflects favorably upon the District.

3. TERM OF AGREEMENT. The term of this Agreement shall for a period of **4 (four) YEARS** beginning ~~January-July 1, 2019-2020~~<sup>2019</sup> and shall continue through ~~December-June 3130, 2022~~<sup>2024</sup>. This Agreement may be terminated by either party in accordance with the provisions of Section 6 below.



4. THIS AGREEMENT TAKES PRECEDENCE. Employee shall be entitled generally to the benefits accorded all other employees of the District and shall be subject to all of the rules, regulations, policies and procedures applicable to all other employees of the District. To the extent that the terms of this Agreement provide for benefits, rules, regulations, policies or procedures that differ from those of the District's general personnel policies and procedures, the terms of this Agreement shall take precedence.

5. COMPENSATION. During the term of this Agreement, Employee shall be entitled to the following compensation:

(a) Salary. The Employee's base salary during the term of this Agreement, beginning ~~January-July 1, 2019-2020~~ shall be ~~\$563,410.00~~\$580,312.32. The Employee shall receive this salary pro-rated on a bi-weekly basis less required and authorized deductions.

(b) Incentive Compensation Plan Participation. Employee shall participate in the District's Incentive Compensation Plan (the "Plan"). The Plan allows for additional compensation up to **15% (percent)** of Employee's base salary based on achievement of financial and other targets established by the District's Board of Directors. The District's Board of Directors shall determine whether the established financial targets have been achieved and the amount of Incentive Compensation, if any, due Employee.

(c) Split Dollar Plan. Should District enact a Split Dollar Plan, Employee shall be able to make an election to contribute a set amount of funds per year to District's Split Dollar Retirement Plan ("Plan") which will have the effect of reducing his annual base salary. This clause is irrevocable for at least five (5) years. District will not include this elected amount of compensation for purposes of other benefits, such as qualified retirement plan benefits, SERP benefits (e.g. a percentage of compensation that is the basis for a SERP), LTD coverage, or group term life insurance coverage.

If Employee's employment with District is terminated, no adjustments will be made to any severance payment or bonus to compensate for or replace the elected amount, and District would cease paying premiums for the elected amount under the Plan. If the Plan is terminated early while Employee remains employed with District, District will not repay or adjust the elected amount during the period of irrevocability, and Employee may incur negative tax consequences because of the early termination of the Plan.

For the purposes of incentive compensation, in addition to fifteen percent (15%) of Employee's new reduced base salary, Employee may also earn up to fifteen percent (15%) of the amount of contribution to District's Split Dollar Plan.

(de) Personal Leave. Employee's adjusted seniority date for personal leave accrual will be November 7, 2012. Employee will accrue thirty-three (33) days of Personal Leave annually. Said Personal Leave shall accrue each two-week pay period and may increase in accordance with District policies and practices based on length of service. Said leave shall continue to accrue during periods when employee is actively using said Personal Leave time. Employee's use of Personal Leave shall conform to the policy of the District regarding use of Personal Leave.

(ed) Long Term Sick Leave. Employee shall be entitled to 56.16 hours of Long Term Sick Leave each year to be used for long term illnesses or in the event of a work related injury. Said Long Term Sick Leave shall accrue at the rate of **2.16 HOURS** each two-week pay period and shall continue to accrue during periods when employee is actively using said Long Term Sick Leave or Personal Leave. Employee's use of Long Term Sick Leave shall conform to the policy of the District regarding use of Long Term Sick Leave.

(fe) Long Term Disability. The District shall maintain its standard long-term disability policy for Employee subject to acceptance of Employee by the Long Term Disability carrier.

(gf) Retirement Benefits. The Employee shall be entitled to the same retirement benefits as are provided to other employees of the District.

(hg) Medical and Life Insurance. Employee shall be entitled to term life insurance coverage in the amount of One Million Dollars (\$1,000,000.00), the premiums for said coverage to be paid for by the District during the term of this Agreement. Employee and his dependents shall be entitled to medical insurance benefits, the premiums for said coverage to be paid for by the District during the term of this Agreement. Employee will participate in Life Insurance benefits of two times base salary as available to other District management positions.

(ih) Automobile. In order to reimburse Employee for expenses related to the business use of Employee's automobile, and automobiles rented by Employee, and as part of Employee's compensation, the District shall pay to Employee the sum of Seven Thousand Five Hundred Dollars (\$7,500) per year prorated over two thousand eighty (2080) hours. This additional sum shall be paid on the same day that Employee's salary is paid. If the actual business related automobile expenses incurred by Employee in any one month are less than the sum herein agreed to be paid by the District, Employee shall be entitled to retain the excess. Further,

Employee shall be entitled to mileage reimbursement at the standard District rate for business travel outside of the service area of the Hospital District. Employee shall be responsible for all costs of maintenance and operation of his automobile. Employee shall at all times maintain automobile liability insurance on any vehicle he uses for District purposes. Such insurance shall have coverage limits acceptable in form and amounts to the District. Employee shall provide a certificate or evidence of such insurance to the District.

(j) Reimbursement of Expenses Other Than Auto. The District shall reimburse Employee for reasonable expenses necessarily incurred by Employee in the performance of his duties as Chief Executive Officer. Said expenses shall include but not be limited to payment of professional dues, participation in annual professional meetings and educational courses, community service organizations or other opportunities for community participation that the Board deems beneficial to the District to be reimbursed consistent with existing District policy regarding reimbursement of expenses.

(k) Travel Expenses. The District shall pay for reasonable and actual travel expenses to educational and District professional training, provided that Employee's expenses and reimbursements shall be subject to such additional limitations provided by District policy.

(l) Future Compensation Adjustment. Employee's base salary will be adjusted on an annual basis at the same time all District management employees' compensation is reviewed. Industry comparable statistics, as outlined by the Board of Directors, will be used as a basis to determine the market increase. Employee will receive either a three percent (3%) or market increase, whichever is greater.

## 6. TERMINATION OF AGREEMENT.

(a) Employment at will. The parties expressly acknowledge that Employee's employment with the District to be at will employment and that Employee may be terminated at any time with or without notice or cause at the sole discretion of the District's Board of Directors. The District recognizes that Employee may terminate his employment at any time with or without notice or cause to do so.

(b) Notwithstanding anything else contained in this Agreement, the terms and provisions of this Agreement shall terminate automatically and immediately upon the death of Employee. In the event of such occurrence, all benefits of this Agreement shall cease to accrue immediately upon the death of Employee.

(c) In the event the District elects to terminate this Agreement for cause, all benefits of this Agreement shall cease to accrue immediately upon written notice of the termination of the Agreement. Termination for cause shall be limited to the following:

1. Employee engages in or assists others in the commission of illegal acts in relation to the performance of his duties for the District; or
2. Employee is engaged in fraud, deceit, dishonesty, falsification of records, gross misconduct, willful misconduct, intentional misrepresentation, insubordination, embezzlement in connection with the performance of his duties for the District.
3. Employee's use of alcohol or drugs that impedes performance of duties.
4. Employee's conviction of a felony or misdemeanor involving moral turpitude (a plea or verdict of guilty or a conviction following a plea of nolo contendere is deemed a conviction for this purpose).
5. A proven claim of either sexual harassment or abuse of employees in violation of law or adopted District policy by Employee.
6. Employee's habitual neglect of duty in connection with the performance of his duties for the District.
7. Employee's failure to abide by or comply with the terms of this Agreement, DISTRICT'S bylaws or policies or directives, within (10) days of having received notice from the District's Board Chair that he has failed to abide by or comply with any of the foregoing and his failure or refusal to cure such failure or noncompliance within a reasonable period not to exceed seven (7) days.

(d) In the event that the District elects to terminate this Agreement for any reason other than a reason set forth in subparagraph (c), the District agrees to pay accrued leave and to pay a severance benefit of base salary and health insurance for Employee for a period of **18 calendar months** or an amount equal to his monthly salary multiplied by the number of months left on the unexpired term of this Agreement, subject to the limits of Government code section 53260. During this period Employee shall not be considered an employee of the District. For the period during which severance payments are being made, District shall pay all COBRA premiums for employee for the number of months remaining in the agreement until time of termination as authorized as pursuant to Government Code section 53261.

(e) In the event that Employee obtains employment at a salary which is equal to or greater than his base salary at the time of termination of this Agreement, Employee shall inform District of his employment and District's obligation to make severance payments shall

terminate, as of the date Employee's new employment begins. Any payment of salary to Employee attributable to new employment obtained by Employee shall be deducted from, and reduce, District's obligation to make said severance payments to Employee.

(f) Should Employee commence employment at a lower base salary, District's severance payment obligation shall be reduced to the difference between the amount of Employee's base salary at the time of termination of this Agreement and the lower base salary from the new employment.

(g) District's obligation to make payments toward health insurance on behalf of Employee shall terminate upon Employee's securing health insurance through new employment obtained prior to the expiration of the **18-month** post-termination period, or such other, shorter period as may be provided pursuant to Government Code section 53260 et seq. (e.g., the remaining term of this Agreement is less than 18 months).

(h) Should Employee at his discretion elect to terminate this Agreement for any reason, he shall endeavor to give the DISTRICT thirty (30) days written notice of his decision to terminate. At the end of those thirty (30) days, all rights, duties and obligations of both parties to this Agreement shall cease and District shall have no further obligation to provide payments and benefits, including severance benefits, upon the effective date of termination of employment, other than payment of accrued leave.

(i) However such obligation to continue to pay base salary and health insurance premiums shall cease if Employee files an administrative claim or lawsuit against the District based on or related to his employment with the District or the termination of his employment with the District or upon Employee's death.

(j) If by reason of any physical or mental incapacity, the Employee has been or will be prevented from properly performing his duties under this Agreement for more than ninety (90) consecutive days in any three hundred sixty-five (365) day period, and the Employee is not on an approved leave of absence including, without limitation, Family and/or Medical or disability leave or Workers' Compensation leave, if applicable, then to the extent permitted by law, the District's may terminate this Agreement upon eight (8) weeks advanced written notice to the Employee. The District shall pay the Employee all compensation and benefits set forth in this Agreement to which he is entitled up through the last day of the notice period, subject to the limits of Government code section 53260; thereafter, all obligations of the District under this Agreement shall cease, unless otherwise stated or reserved. Nothing in this Section shall affect the Employee's rights under any applicable District disability/or benefit plan/s. The District shall pay

all COBRA premiums for employee for the number of months remaining in the agreement until time of termination.

7. RELEASE Employee shall only be entitled to receive benefits as described in Section 6 above if he and the District have executed a severance agreement that is satisfactory to the District.

8. PERFORMANCE REVIEW. The District shall make reasonable efforts to provide Employee with a written performance review on an annual basis by December. Employee shall have the opportunity to discuss this review with the Board of Directors. If there are deficiencies in the performance of the Employee they shall be noted and suggestions for improvement provided to Employee. Performance review will take place only in closed session of Board meetings.

9. AGREEMENT. This Agreement contains the entire understanding between the parties, and the parties expressly acknowledge that there are no other agreements, oral or written, and no other understandings or representations made by either party to the other which have induced or caused the execution of this Agreement.

10. WAIVER OR MODIFICATIONS. No waiver or modification of this Agreement or any covenant, condition, or limitation herein contained shall be valid unless in writing and executed by both parties.

11. ARBITRATION. In the event that any dispute develops concerning the rights of either party regarding the terms of this Agreement, the parties may elect to submit that dispute to arbitration and may elect to accept as final and binding the decision of the duly selected arbitrator. Said arbitration of the dispute shall comply with the rules developed by the American Arbitration Association for employment arbitrations. The prevailing party in the arbitration shall be entitled to its reasonable attorney fees and costs.

12. BINDING EFFECT AND INTERPRETATION. This Agreement shall be binding on the respective parties and their legal representatives, successors, and heirs. This Agreement shall be construed in accordance with the laws of the State of California.

13. NOTICE. Any notice to the District pursuant to this Agreement shall be given in writing, either by personal service or by registered or certified mail, postage prepaid, addressed as follows:

Board of Directors Chair  
Tahoe Forest Hospital District  
10121 Pine Avenue  
P.O. Box 759  
Truckee, CA 96160

With a courtesy copy to:

Michael G. Colantuono, Esq.  
General Counsel  
420 Sierra College Drive, Suite 140  
Grass Valley, CA 95945

Any notice to Employee shall be given in a like manner, and, if mailed, shall be addressed to Employee at the address then shown in District's personnel records. For the purpose of determining compliance with any time limit stated in this Agreement, a notice shall be deemed to have duly given:

- a. on the date of delivery, if served personally, or
- b. on the second day after mailing, if mailed.

14. SEVERABILITY. If any provision or any portion of this Agreement is held to be unconstitutional, invalid or unenforceable, the remainder of the Agreement shall be deemed severable and shall not be affected and shall remain in full force and effect.

15. ATTORNEYS' FEES. If an action at law or in equity is necessary to enforce or interpret this Agreement, the prevailing party shall be entitled to reasonable and actual attorneys' fees and costs with respect to the prosecution or defense of the action.

16. COUNTERPARTS. This Agreement may be executed in counterparts which shall together constitute a single Agreement and signatures may be exchanged by facsimile, email or other electronic means with the same effect as original, wet signatures.

Tahoe Forest Hospital District

Employee

By: \_\_\_\_\_

By: \_\_\_\_\_

Dated: \_\_\_\_\_

Dated: \_\_\_\_\_